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Drugs frequently exert their action by the specific interaction with
some target protein. Only as a consequence of binding do the drugs
produce their biological effect. A complete understanding of
biological interactions can only be achieved at the molecular level.
This requires the use of techniques such as x-ray crystallography or
3-D NMR. Armed with a structural knowledge of these interactions it is
possible to exploit this information making a number of things
possible such as the development of novel compounds which interact
with more strength and the development of compounds that bind without
inducing biological effect. In this thesis, the determination of the
crystal structure of equine phospholipase A2 as outlined in Chapters 5
and 6 was performed with this ultimate aim in mind. It is hoped that
in the determination of this structure it would be possible to study
the interactions of this enzyme with existing inhibitors and suggest
novel or improved versions of these.
There are a number of approaches possible in the search for this
structural information. The approach taken in any investigation is
usually dictated by the material available to the investigator. The
best approach to the study of these interactions, but often the most
difficult to produce, is to determine the crystal structure of the
receptor and the drug in a complex. In this thesis an existing
inhibitor of equine PLA-2 was used in the attempted structural
determination of the enzyme-complex as described in Chapter 4 and 5.
If a complex is not available but rather the three dimensional
structure of both molecules are available, it is possible to "dock"
the two molecules together using molecular graphics and infer the
18
nature of their interactions. However if the structure of the receptor
is not available this is more difficult. Models for the receptor can
be obtained however if a homologous protein whose structure has been
determined is available. If no such homologous receptor structure is
available it is still possible to get information, such as the shape
of the binding site and spatial disposition of functional groups, by
the comparison of the crystallographic structures of compounds which
are known to bind to the receptor. This is the rationale behind the
investigation of the crystal structure of an adrenoreceptor antagonist
and it's comparison to similar compounds in Chapter 2. It is hoped
that structural features of these small ligands can be identified as
being important to their interaction with their receptor. The
attempted crystallisation of calcitonin and calcitonin analogues in
Chapter 4 is similarly with a view to understanding important
structural features involved in the interaction with its receptor. In
the absence of any material, providing the sequence is available, it
is still possible to produce some model of the receptor using
structure prediction methods and modelling techniques. These methods
are unlikely to produce useful results since our understanding of
protein architecture is not sufficiently advanced and the resulting
model will very likely be wrong.
1.1.1 Phospholipase A2 as a target for drug design
In a great many disease states, pain and disability are caused by
inflammation. The inflammatory process is mediated within the body by
the production of eicosanoids. The eicosanoids are a family of
molecules with diverse biological activities, but which are produced
from the same starting material. This starting compound is called
19
arachidonic acid (5,8,11,14-icosatetraenoic acid). Eicosanoid is the
term introduced by Corey et al. (1980) to cover all products of
arachidonate metabolism, whether by the cyclo-oxygenase pathway
(prostaglandins, endoperoxides, thromboxanes, etc.) or the
lipoxygenase pathway (hydroxyicosatetraenoic acids, leukotrienes,
etc.). At present, with the exception of steroidal compounds, anti¬
inflammatory compounds have been developed to inhibit only the cyclo-
oxygenase pathway. The most well known of these compounds, aspirin,
acts directly on the cyclooxygenase enzyme causing inhibition.
Eicosanoid production can therefore only be reduced with these
inhibitors and not obliterated, since alternate pathways remain
active. A more suitable target for the design of anti-inflammatory
compounds is another enzyme involved in the pathway of eicosanoid
production, phospholipase A2, which releases the starting material,
arachidonic acid, from phospholipids. Inhibition of this enzyme would
severely reduce the levels of arachidonate and consequently all
eicosanoids. It has been established that this enzyme plays an
important role in the inflammatory processes associated with
rheumatoid arthritis (Pruzanski & Vadas, 1988), osteoarthritis (Vignon
et al., 1989), adult respiratory distress syndrome (Vadas & Pruzanski,
1986), and gout (Bomolaski et al., 1990).
A wide variety of compounds has been shown to inhibit PLA-2, of which
the best characterised inhibitor is p-bromophenacylbromine, an
irreversible inhibitor that specifically modifies the active site
histidine residue (Roberts et al., 1977). Other covalent inhibitors
are the natural product monoalide (Glaser & Jacobs, 1986) and it's
synthetic analogue monoalogue (Reynolds et al., 1988) which have been
shown to modify covalently lysine residues. There are also a number of
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protein inhibitors of PLA-2. These produce their inhibitory effect
mainly through substrate depletion, consequently their physiological
significance is still in doubt (Davidson et al., 1987). These proteins
are very similar in both sequence and mechanism of inhibition and have
been classed together as the annexins and include the lipocortins and
calpactins (Klee, 1988). These are Ca^+ dependent membrane binding
proteins which can be phosphorylated by growth factor receptor
kinases. The anti-inflammatory action of glucocorticoids is known to
be through the inhibition of phospholipase A2 activity. The en2yme is
not inhibited directly, rather glucocorticoids are believed to induce
the synthesis of these annexins (Flower, 1989).
The vast majority of anti-PLA-2 compounds studied so far are non-
hydrolysable phospholipid analogues. These have provided valuable
information on the structural features of the phospholipid which are
important for binding. Since the hydrolysis of the phospholipids is a
stereospecific reaction, the D-isomer of the phospholipids is an
example of such a non-hydrolysable substrate. It has binding
characteristics similar to the natural substrate and is therefore of
no potential use as an inhibitor. A variety of these phospholipid
analogue inhibitors and their inhibitory activity are shown in
table 1.1.
There are difficulties in comparing the efficacy of these inhibitors
since it has been shown that PLA-2 activity is crucially dependent not
only on the nature of the substrate (de Haas et al., 1971), but also
on the physical state of the lipid (Lichtenberg et al., 1986). Also,
since there are many different methods available for the measurement
of enzyme activity, comparisons are not necessarily straightforward
(Dennis, 1991). Where more than one method has been used to measure
21
Table 1.1
Phospholipid analogue inhibitors of PLA-2 activity.
Inhibition is quoted as ICso values. These are the concentration
of inhibitor required to reduce enzyme activity by 50%.
Phosphatidylcholine and phosphatidylethanolamine are
represented by PC and PE respectively. R represents the
palmitoyl (CI 6) group.
Name
1. Ether Amide PC
Structure
2. Ester Amide PC
3. Thioether Amide PC
4. Thioether Amide PE









































inhibition by a particular inhibitor, quite different values have been
obtained (Davidson et al., 1986). Inhibition studies of water-soluble
lipolytic enzymes which act on water-insoluble substrates are
complicated. Thus lipolysis is an example of heterogeneous catalysis
and requires a slightly more complicated kinetic model to interpret
inhibition results (Verger & de Haas, 1976). This has frequently not
been applied in the interpretation of inhibitor studies.
One of the major problems in designing an inhibitor which is a non-
hydrolysable substrate analogue is that the inhibitor must be very
tightly bound in order to compete successfully against the natural
substrate which is vastly in excess. The other problem is that these
compounds are, by their nature, hydrophobic and therefore not water-
soluble. As is obvious from the IC50 values shown in table 1.1 these
types of inhibitors are far from being effective inhibitors for
clinical use. Further work using crystallographically determined
structures and inhibitor complexes may result in overcoming both of
these problems to produce some novel compounds with specific
phospholipase A2 inhibitory activity for clinical use.
1.1.2 Biochemistry of phospholipase A2.
The hydrolysis of various ester bonds in phospholipids is catalysed
by a number of different phospholipases (figure 1.1). Phospholipase A2
catalyses the hydrolysis of the acyl ester bond at the sn-2-position
of l,2-diacyl-sn-3-phosphoglycerides (L-isomer). This enzymic activity
is absolutely dependent on the presence of calcium ions. Since this 2-
acyl position is the position at which the bulk of arachidonate in
mammalian cells is esterified in the fatty acyl chains of
glycerophospholipids, the action of phospholipase A2 liberates
23
Figure 1.1 Classification of phospholipases according to the
site of hydrolysis. The phospholipid is shown here
in the sn-3 configuration. R1 represents an alkyl chain.
HEAD represents any of the naturally occuring substituents
(such as choline, serine, ethanolamine) or a proton. The





arachidonate. This has led to suggestions that phospholipase A2 may be
responsible for controlling free arachidonate levels (Vogt et al.,
1966; van den Bosch, 1980). However, it is far from clear that these
phospholipases are arachidonyl-specific. Phospholipases A2 (EC
3.1.1.4), both intracellular and extracellular, are widely found in
nature (Verheij et al., 1981; van den Bosch 1980). Although
intracellular phospholipases will be discussed, the work in this
thesis has been carried out on extracellular phospholipases of
pancreatic tissue. Other sources of extracellular phospholipases are
the venoms of snakes and arthropods. The primary function of the
extracellular pancreatic enzymes is in digestion. The snake venom
enzymes possess not only neurotoxic but other pharmacological effects
such as haemolytic action, anticoagulant properties and myonecrotic
properties (Karlsson, 1978; Howard & Gundersen, 1980). Intracellular
phospholipases are believed to participate in metabolic regulation of
phospholipids in membranes including eicosanoid biosynthesis (van den
Bosch 1980), the acylation-deacylation cycle (van den Bosch 1980), and
protection of membranes from lipid peroxidation damage (van Kuijk et
al., 1987). Recently intracellular phospholipases have been implicated
in receptor mediated signal transduction and as part of a G-protein-
regulated effector system generating arachidonic acid metabolites that
may serve as second messengers (Axelrod et al., 1988). However the
intracellular phospholipases have not been as extensively studied
structurally, due to their low concentrations, but appear to have the
same essential properties as the more abundant pancreatic and venom
enzymes (Crews et al., 1981; McGiveney et al., 1981). Consequently the
extracellular enzymes have been used as models for the general
structure and function of all phospholipases A2. Thus the design of
25
inhibitors and their action with the extracellular phospholipases are
also applicable to the intracellular enzymes.
1.1.3 Sequence properties of phospholipase A2
The extracellular enzymes are single chain polypeptides of between
120-130 residues. The chain contains 14 cysteines connected in 7
disulphide bridges. These bridges are believed to provide the
necessary structural stability to allow PLA-2 to act at the
hydrophobic/hydrophilic interface that is the membrane surface. This
structural stability has also enabled the ready purification of the
enzyme from a variety of sources: more than 40 complete amino acid
sequences and many more partial structures have been determined
(Verheij et al., 1981). Based upon this information, the
phospholipases have been separated into two groups (Heinrikson et al.,
1977). Group I enzymes are those from mammalian pancreatic juices and
the venoms of snake families Elapidae and Hydrophidae. These enzymes
possess a disulphide linkage between half cysteines 11 and 69
(numbering from Heinrikson et al., 1977) that is lacking in Group II
enzymes. The Group II enzymes are those from the venoms of the snake
families Crotalidae and Viperidae and possess a short extension at the
COOH terminus that terminates in a half-cysteine linked to a half-
cysteine near the active site at position 50 (numbering from
Heinrikson et al., 1977). The sequences of some pancreatic enzymes are
shown in figure 1.2. Overall, about one quarter of the residues are
absolutely conserved; and for another quarter, only conservative
changes have occurred (Verheij et al., 1981). It is clear that the
phospholipase A2's are homologous proteins which have probably
developed from a common ancestor. The venom enzymes unlike the
26
Figure 1.2 Sequence comparisons of some pancreatic PLA-2's. Residues
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pancreatic enzymes, are synthesised in their active forms. The
pancreatic enzymes are synthesised as zymogens. The prophospholipase
A2 contains an extra heptapeptide at the amino terminus which is
cleaved by trypsin to produce the active form. The high sequence
similarity of these phospholipases is thought to result in the
proteins having a similar fold. Even in the bee-venom phospholipases,
which have little sequence homology with other phospholipases, similar
"substructures" have been observed and a common catalytic mechanism
has been suggested (Scott et al., 1990).
1,1.4 Kinetic properties of phospholipase A2.
The most intriguing aspect of phospholipase kinetics is the
observation that although the enzyme can hydrolyse monomelic
substrates, the same substrate present as an organised lipid-water
interface is degraded at a much higher rate (de Haas et al., 1971). In
bulk studies, the influence of a changing lipid-water interface on
enzyme activity has been demonstrated using short chain lecithins as
substrates (Bonsen et al., 1972). This has been attributed to a
preferred conformation of the substrate at the lipid-water interface
of the micelle. Changes in monomer phospholipid conformation /
orientation as the phospholipid becomes packed in an interface have
been observed in and ^C-NMR studies (Roberts et al., 1978; Burns
and Roberts, 1980). Kinetic studies on the zymogen of the pancreatic
phospholipase indicated an identical activity to the active form with
monomelic substrates (Pieterson et al., 1974a). A similar activity for
aggregated substrates was not however observed with the zymogen. This
led to the idea of an "interface recognition site" (IRS) which is
absent in the zymogen.
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An absolute dependence for Ca^+ ions for enzyme activity has been
demonstrated in both the zymogen and the active enzyme (Pieterson et
al., 1974b). Although the related ions Sr^+ and Ba^+ can be bound,
the enzyme has no activity. However enzyme activity has been observed
with transition metal ions, such as Gd^+ (Hershberg et al., 1976). The
alkaline pH optimum of the enzyme activity (7-8) indicated the
involvement of a residue with a pK of 6-7 which was attributed to a
histidine (Volwerk et al., 1974). This was subsequently demonstrated
to be histidine-48 (numbering of residues as in active enzyme) by
chemical modification studies (Volwerk et al., 1974). Since Ca^+
protected the modification of this histidine it was concluded that the
Ca2+ binding site and His-48 were in close proximity at the active
site of the enzyme.
1.1.5 Catalytic Mechanism of phospholipase A2.
Although valuable information has been obtained from kinetic analysis,
such as the involvement of Ca^+ and His-48, the catalytic mechanism
has been proposed as a result of the high resolution crystal structure
of bovine phospholipase A2 (Dijkstra et al., 1981). The proposed
catalytic mechanism (Verheij et al., 1980) is shown in figure 1.3.
This model has been supported by a number of other lines of evidence;
combined molecular orbital and molecular mechanics calculations
(Waszkowycz et al., 1989), the x-ray crystal structure of bee-venom
enzyme in a complex with a transition-state analogue (Scott et al.,
1990), a similar complex for the cobra-venom enzyme (White et al.,
1990) and a substrate analogue complex with a porcine pancreatic
phospholipase (Thunnissen et al., 1990b).
The mechanism involves a hydrogen-bonded histidine-aspartate couple
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in the active site (His-48 and Asp-99 of bovine pancreatic PLA-2),
which is similar to other hydrolytic enzymes such as the serine
proteases. In PLA-2 there is no serine available locally and it has
been proposed that a water molecule in the active site becomes the
active nucleophile on proton transfer to histidine as shown in figure
1.3. The attack by water on the C-2 carbonyl of the phospholipid leads
to the formation of a tetrahedral oxyanion intermediate, which is
stabilised electrostatically by a calcium ion and by hydrogen bonding
to the backbone -NH of Gly-30. The oxyanion breaks down, on proton
transfer from His-48, to release the C-2 fatty acid.
1.1.6 X-ray Studies on phospholipase A2.
High resolution crystal structures of representatives ffom Group I
and II PLA-2's have been obtained as shown in table 1.2. There are
also structures which possess bound inhibitors and have provided
information on substrate binding and catalytic mechanism. Comparisons
of these structures have subsequently confirmed the earlier sequence
analysis predictions regarding the similarities between the group I
and II enzymes (Heinrikson et al., 1977). Similar folds have been
observed between members of the two different groups. This is most
noticeable with respect to the disposition of the active site residues
which are highly conserved (Scott et al., 1990).
The pancreatic enzymes are essentially kidney shaped, with dimensions
of approximately 22 x 30 x 42 A. In the bovine structure (Dijkstra et
al., 1981a), there is an appreciable content of secondary structure:
50% of the residues are in an a-helical conformation and 10% in an
antiparallel 2-stranded 8-structure. The core of the molecule consists
of two antiparallel a-helices, each having five full turns as shown in
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Table 1.2
Some existing crystal structures of PLA-2. The classification of the enzymes are indicated. Bee
venom PLA-2 which does not belong to class I or II is designated by the symbol ?.
Structure Resolution (A) Class Reference
Bovine PLA-2 1.7 I Dijkstra et al., 1981
Engineered Porcine PLA-2 2.1 I Thunnissen et al., 1990a
Crotalus Atrox (Dimeric) PLA-2 2.5 n Brunie el al., 1985
Recombinant human rheumatoid arthritic synovial
fluid PLA-2
2.2 n Wery et al., 1991
Engineered porcine PLA-2 in a complex with a
substrate derived inhibitor
2.4 i Thunnissen et al., 1990b
Cobra venom PLA-2 in a complex with
a transition-state analogue
2.0 i White et al„ 1990
Bee venom PLA-2 in a complex with a
transition-state analogue
2.0 ? Scott et al., 1990
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figure 1.4. The N-terminal region is also in an a-helical conformation
with the amino-terminal NH3 + 0f residue 1 buried in the interior of
the protein. There are two other helices (B and D in fig. 1.4) each of
about one turn. Two antiparallel 6-strands are present at the surface
of the molecule. The location of the seven disulphide bridges are also
shown in fig. 1.4.
The Ca^+ ion, essential for enzyme activity, is bound in the active
site which is located in a cavity at the molecular surface. It is
surrounded by seven oxygen ligands as shown in figure 1.5. Five
ligands are at the corners of an octahedron at an average distance of
2.39A from the Ca2 + . The sixth octahedral position is occupied jointly
o
by one of the Asp 49 carboxyl oxygen atoms (ODj at 2.69A) and a water
molecule at 2.66A from the Ca^+. The main chain oxygen ligands of the
Ca2+ belong to residues 28, 30, and 32. They are part of the calcium
binding loop that runs from residues 25-42. The calcium binding loop
is stabilised by two disulphide bonds, Cys 27-123 and Cys 29-45. This
stabilization of the calcium binding loop guarantees a precise
geometry of the Ca^+ with respect to the active site residues.
Despite these high resolution structures, an explanation for the
increased activity on aggregated substrates has not been proposed. A
few features of the face which is thought to interact with the
membrane have been identified. The area around the active site which
consists of essentially hydrophobic residues is believed to be
responsible for the interaction of the enzyme with the fatty-acyl
chains during catalysis. These residues are not absolutely conserved
but their character is usually maintained. Contact with the membrane
has been attributed to two areas at both ends of the molecule which
contains both hydrophobic and polar residues. There is always an
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Figure 1.4 Diagramatic representation of bovine PLA-2 (from
Dijkstra et al., 1981).
Figure 1.5 Diagramatic representation of the Ca2+ binding site













excess of basic over acidic residues in these areas, suggesting salt
bridge interactions with phosphate groups of the membrane
phospholipids. This preferred orientation has been proposed as partly
responsible for the high activity towards aggregated substrates
(Dijkstra et al., 1981b).
1.2 Calcitonin and related peptides as a target for drug design.
Small polypeptide hormones are ideal candidates for rational drug
design. The small sizes of these polypeptides are easily within the
realms of synthetic synthesis. Thus peptide hormone analogues can be
obtained in sufficient quantities and purity to be tested with a view
to determining quantitative structure-activity relationships. The
polypeptide hormone calcitonin is a suitable peptide for this type of
investigation. Since the receptor for calcitonin has not been
isolated, only studies of active and inactive analogues can be of use
to determine what groups or structural features are important in the
binding of calcitonin with it's receptor. Additionally, since
calcitonin has sequence and structural similarities to both calcitonin
gene-related peptide (CGRP) and amylin, it is possible that there are
also some general similarities in the nature of the interaction
between these peptides and their receptors. The role of an amphipathic
a-helix in the interaction of these peptides with their receptors has
been suggested (Moe & Kaiser, 1985). The similar nature of the
interaction of the peptides with their receptors has already been
demonstrated for two of these peptides, calcitonin and CGRP. These
have distinct receptors but have the ability to cross react at each
others receptors (Goltzman & Mitchell, 1985). It is therefore possible
that there is some general structure-activity relationship common to
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all three peptides. However, since the peptides themselves have such
widely differing biological activities, it would be highly unlikely
that their receptor interactions were too closely related. Structural
studies on calcitonins and analogues of calcitonins may therefore
provide some valuable information about the interaction of this
peptide with it's receptor and possibly lead to the development of
more active forms of the hormone.
1.2,1 Biochemistry of calcitonin.
Calcitonin is a polypeptide hormone consisting of 32 amino acids,
synthesised and secreted by the parafollicular, or C-cells, of the
thyroid in mammals. In submammalian vertebrates such as fish, birds
and reptiles, the secretion is from a discrete gland, called the
ultimobranchial body. The principal pharmacological action of
calcitonin in mammalian species is inhibition of bone resorption
(O'Riordan & Aurbach, 1968). Treatment with calcitonin over prolonged
periods also causes a decline in osteoclast numbers. This latter
effect is of great importance in the therapy of Paget's disease and,
more recently, of osteoporosis. However, the relevant receptor
characteristics for this reduction in osteoclast numbers is unknown.
Calcitonin also promotes urinary clearance of calcium and phosphate
(Cochran et al., 1970). Calcitonins have been chemically synthesised
from several species, porcine (pCT), human (hCT), and salmon (sCT)
(Guttmann, 1981) and are available for therapeutic use. Eel calcitonin
(eCT) is also available in the market but, unlike other CT's, is
produced as the amino-suberic acid derivative (ASU-eCT), since it's
natural form is highly unstable (Morikawa et al., 1976). The
hypocalcemizing effect of CT, usually measured by a rat bioassay,
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differs widely between the various hormone species. The estimated
potency of mammalian CT's is between 100-400 international units
(IU)/mg peptide, whereas nonmammalian CT's show higher potencies
ranging between 2000-6000 IU/mg peptide (Guttmann, 1981). One IU
corresponds to 1/100 of the amount of CT needed to induce a 10%
reduction of blood calcium 1 hour after intravenous injection into a
young fasting 150g rat. Also, the hypocalcemizing effect is more
prolonged for nonmammalian CT's (Galente et al., 1976;Genari et al.,
1981). Calcitonin receptor sites have been identified on whole bone
sections (Warshawsky et al., 1980) and on 'osteoclast rich' cultures
(Luben et al., 1976). Receptors have also been identified in non-bone
cells, such as kidney (Marx et al., 1972), brain (Tschopp et al.,
1985), testes (Chausmer et al., 1982), lymphoid cell lines (Marx et
al., 1974) and human cancer cell lines (Findlay et al., 1982). Binding
of Calcitonin to it's receptor is associated with stimulation of
adenylate cyclase (Nicholson et al., 1986).
1.2.2 Biochemistry of calcitonin gene-related peptide
With the advent of recombinant DNA technology the existence of a
related peptide, calcitonin gene-related peptide (CGRP) was predicted
in rats (Rosenfeld et al., 1983) and it's existence was subsequently
established in man (Morris et al., 1984). This gene, commonly referred
to as the a-gene, encodes a-CGRP. More recently, a second calcitonin
gene has been described (Hoppener et al., 1986), commonly referred to
as the B-gene. This gene encodes another CGRP molecule (Jonas et al.,
1985) and a second calcitonin-like peptide B-CGRP (Alevizaki et al.,
1986), although the latter peptide is not expressed either in the rat
or in humans. a-CGRP has subsequently been found to have a widespread
37
distribution in the body, being particularly prevalent in the central
nervous system and peripherally in nerves of the cardiovascular system
(Gibson et al., 1984). Calcitonin and CGRP are obtained from the same
gene by a process of alternate splicing at the mRNA level (Breimar et
al., 1988). The CGRP sequence consists of 37 amino acids with a
disulphide bridge between positions 2 and 7 and a C-terminal
phenylalanine amide residue. There is about 30% sequence identity
between the CGRP peptides and salmon calcitonin. CGRP has been shown
to have potent cardioexcitatory (Brain et al., 1986) and vasodilatory
(Tippins et al., 1986) effects and has also been shown to lower plasma
calcium (Tippins et al., 1984). More recently it has been demonstrated
to be a potent inhibitor of glycogen synthesis in rat skeletal muscle
in vitro (Leighton & Cooper, 1988). Discrete receptor sites for CGRP
have been identified in the nervous system and peripheral tissues. It
has also been shown that sCT and CGRP can cross react at each others
receptors. CGRP has been shown to be 1000-fold less potent than human
calcitonin on interaction with CT receptors in an osteoclastic bone
resorption assay (Zaidi et al., 1987). Also, in contrast to CT
receptors, neural CGRP receptors are not linked to adenylate cyclase
(Goltzman & Mitchell, 1985). The cardiovascular CGRP receptors are
slightly different to the neural receptors in that they do not cross
react with sCT and these are linked to adenylate cyclase (Kubota et
al., 1985).
1.2.3 Biochemistry of amylin
Amylin is a 37-amino-acid peptide which is the major component of
amyloid deposits in the islets of Langerhans (Cooper et al., 1987).
These amyloids are a common feature in human type 2 diabetic subjects
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and have been described in a variety of diabetic animals such as the
domestic cat (Johnson & Stevens, 1973) and the monkey Macaca niagra
(Howard, 1986). Amyloid is the term used for a group of pathological
extracellular proteinaceous substances that share common morphological
characteristics and appear in a diverse number of clinical settings as
shown in table 1.3. The main constituents of amyloid are protein
fibrils whose protein subunits vary in the different forms of the
disease and the chemical nature of which form the basis of
classification. Amyloid may be localised or systemic in distribution.
Amyloid is generally identified by it's green birefringence after
staining with Congo Red (Glenner, 1980).
Amylin has 46% identity to the rat and human calcitonin gene-related
peptides. Like CGRP, the peptide contains a disulphide linkage between
amino acids at positions 2 and 7 and possesses a C-terminal amide (in
this case, Tyr-NH2). Like a-CGRP, human pancreatic amylin has been
shown in vitro to inhibit both basal and insulin stimulated rates of
glycogen synthesis. It has been suggested that amylin may be a newly
recognised hormone with an opposing role to insulin in the homeostasis
of glucose metabolism (Leighton & Cooper, 1988). No receptor has yet
been identified for amylin and there is no evidence that amylin can
bind to either calcitonin or CGRP receptors.
1.3 Sequence comparisons of calcitonin and related peptides.
Sequence comparisons can be very useful between related molecules
since residues that are important for biological activity and
structure are highly conserved. Thus it is possible to identify
conserved regions of molecules and suggest possible roles for these
regions. This is particularily useful information in the design of new
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Table 1.3 Clinical amyloidosis syndromes. Adapted from Pepys, (1988).
Distribution
of deposits
Clinical syndromes Fibril proteins and precursors
Systemic
amyloidosis
Associated with immunocyte dyscrasiaimyeloma, monoclonal
gammopathy, ocult dyscrasia
AL fibrils derived from monoclonal
immunoglobulin light chains
Associated with chronic active diseases: reactive systemic
amyloidosis
AA fibrils derived from serum amyloid A
protein (SAA)
Hereditary symptoms:
Predominantly neuropathic forms (several types)
Predominantly nephrotic forms include that associated with
familial Mediterranean fever (autosomal recessive), typical
AA amyloidosis
Predominantly cardiomyopathic forms include
Senile systemic amyloidosis (formerly called senile cardiac
amyloidosis
Associated with chronic haemodialysis
Prealbumin fibrils, genetic variant of
plasma prealbumin
AA fibrils derived from serum amyloid A
protein (SAA)
Prealbumin fibrils, genetic variant of
plasma prealbumin




Senile amyloidosis (heart, brain, joints, seminal vesicles)
Cerebral amyloid angiopathy and cortical plaques in
Alzheimer's disease, senile dementia, and Down's syndrome
Periarticular, bony, and renal amyloid in chronic
haemodialysis patients
Endocrine amyloidosis
Atrial naturetic peptide related fibrils in
isolated atrial amyloid, otherwise not known;
different in different organs
^-protein fibrils, precursor encoded on
chromsome 21
[^-microglobulin derived from high
plasma levels
Precalcitonin-related fibrils in medullary
carcinoma of thyroid; calcitonin gene-realted
peptide fibrils in islets of Langerhans; ? other
peptide hormones
Isolated massive nodular deposits (skin, lung, urogenital tract)
Primary localised cutaneous amyloid (macular, papular)
Hereditary syndromes:
Hereditary cerebral haemorrhage with amyloidosis
Icelandic type
Dutch type
Cutaneous deposits (bulllous, papular, poikilodennal)
Ocular deposits (corneal, conjunctival)
AL fibrils derived from monoclonal
immunoglobulin light chains
? Keratin-derived
Cystatin C (y-trace) fibrils, Glu 58







Several mammalian and submammalian calcitonins have been isolated,
sequenced and synthesised: porcine (Baghdiantz et al., 1964); human
(Riniker et al., 1968); bovine (Brewer & Ronan, 1969); ovine (Potts et
al., 1970); salmon (O'Dor et al., 1968); eel (Otani et al., 1976); rat
(Raulias et al., 1976). The sequences of calcitonin from seven species
are given in Figure 1.6. These display considerable differences in
amino acid composition. Salmon has three forms of calcitonin, the
major component sCT I (from here on referred to as sCT) and two minor
components sCT II and sCT III as shown in Figure 1.6. For all the
calcitonins, the sequence is closely conserved through the first nine
residues. There is considerable variation in the remaining positions
particularly in the middle of the molecule. However, much of the
variation is more apparent than real in that the hydrophobic or
hydrophilic properties of the positions are retained.
1.3.2 Calcitonin gene-related peptide
Only the primary structure of human a-CGRP has been determined
unequivocally by fast atom bombardment mass spectrometry (Morris et
al., 1984). The sequence of the rat a- and 8-CGRP and the human B-CGRP
have been predicted from the nucleotide sequence (Rosenfeld et al.,
1983; Hoppener et al., 1985; Steenbergh et al., 1985). These known
sequences are highly conserved, as shown in Figure 1.7. Human a-CGRP
differs from the B-form by three amino acids (positions 3, 22 and
25). The predicted rat a-CGRP differs from the human sequence by four
amino acids (positions 1, 3, 25 and 35; three of these involve charge
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Figure 1.6 Sequence alignment of calcitonins from different species.
Residues common to sCT I are enclosed in shaded boxes. The
single letter code is used to describe the amino acids. The
(NH2) group represents the C-terminal amide.
10 20
Porcine C S N L S T C V L S A Y W R N L N N F H
Bovine C S N L S T C V L S A Y W K D L N N Y H
Ovine C SN L S T C V L s A Y W K D L N N Y H
Human C G N L ST C M L G T Y T Q D F N K F H
Salmon I C S N L S T C V L G K L S Q E L H K L Q
Salmon II C S N L S T C V L G K L S Q D L H K L Q
Salmon III C S N L S T C M L L K L S Q D L H K L Q
30
Porcine R F S G M G F G P E
Bovine R F S G M G F G P E
Ovine R F s G M G Y G P E
Human T F p Q T A I G V G
Salmon I T Y p R T N T G s G
Salmon II T F p R T N T G A G

















Sequence alignment of four CGRP molecules with salmon calcitonin
(sCT). A gap of five amino acids, denoted by (-), has been introduced to
maximise alignment. Boxed residues show sequence identity to sCT.
The asterisks show amino acid substitution differences between
human alpha CGRP and the other CGRP molecules. Human CGRP alpha
and beta, h(a) and h(p);rat CGRP alpha and beta, r(a) and r(|3).
h(a) A C D T A T C V T H R L A G L L S R S G
h(p) A c N* T A T C V T H R L A G L L S R S G
r(a) S* c N* T A T c V T H R L A G L L s R S G
r(P) S* c N* T A T c V T H R I A G L L s R S G
sCT C s N L S T c V L G K S Q E I H K - -
30 37
NH2h(a) G V V K N N F V P T N V G S K A F
h(p) G M* V K S* N F V P T N V G S K A F NH2
r(a) G V V K D* N F V P T N V G s m * > F NH2
r(P) G V V K N N F V P T N V G s E* A F NH2
sCT - - - L Q T Y p R T N T G s G T P NH2
43
changes). A gap of five amino acids has to be introduced between Lysl8
and Leu 19 of sCT to maximise sequence alignment with CGRP.
1.3.3 Amylin
Amylin from pancreatic amyloid of human (Clark et al., 1987), cat
(Westermark et al., 1987) and rat (Leffert et al., 1989) has been
purified and sequenced. The cat sequence has only been partly assigned
but indicates similarity to the human form as shown in figure 1.8. The
sequences of human and rat differ at only six residues (84% identity)
as shown in Figure 1.8. However, three proline residues have been
introduced towards the C-terminal region of rat amylin which may have
a profound effect on the structure at the C-terminal region. Like
CGRP, a gap of five amino acids has to be introduced into sCT to
maximise sequence alignment with amylin.
1.4 Structure of calcitonin and related peptides.
In the absence of any crystallographically determined structure most
of the structural information available on the three peptides has come
from spectroscopic methods. In particular, circular dichroism (CD)
spectroscopy and nuclear magnetic resonance (NMR) spectroscopy have
provided the most valuable structural information.
1,4.1 Calcitonin
There are several structural features common to all calcitonins. All
are 32 amino acids in length, contain a disulphide bridge between
positions 1 and 7 and have a carboxyl terminal amide. A structural
feature of calcitonins common to several other polypeptide hormones
(Epand et al., 1983) is that the primary sequence has regularly
44
Figure 1.8
Sequence alignment of three different Amylins with sCT,
human a and human p CGRP. A gap of five amino acids has been
introduced to maximise the alignment of sCT with the others.
Salmon calcitonin (sCT);humanCGRP a and p, h(a) and h(p);human
amylin,rat amylin and cat amylin, are h(A), r(A) and c(A)
respectively. Boxed residues show sequence identity to the
Amylins. Undetermined residues in the partial sequence of cat
amylin are denoted with (?).
10 20
h(A) K C N T A T C A T Q
r(A) K c N T A T C A T Q
c(A) K ? N T A T ? A T Q
h(a) A c D T A T c V T H
h(P) A c N T A T c V T H
sCT C s N L S T c V L G
R L A N F L V H S s
R L A N F L V R s s
R L A N F L V R s s
R L A G L L s R s G
R U A. G L L s R _s. G







N N F G AI I L s S T
N N L G P V L p p T
N N L G A|l W ? ? ?
G V V K N N F V P T
G M V K S N F V P T
- - - L Q T Y p R T
30
N V G S N T Y
N V G S N T Y
? ? ? ? ? ? ?
N V G S K A F
N _v G s K A F








spaced hydrophobic amino acids at every third, or fourth, position in
the central region of the chain. This regular spacing of hydrophobic
amino acids can allow the polypeptide chain to fold into an
amphipathic helix in which one face is hydrophobic and the other
hydrophilic. This type of helix has been implicated in the interaction
of proteins with lipids. For example, the apolipoproteins are believed
to interact with phospholipid through the formation of an amphipathic
helix (Segrest et al., 1974). Other polypeptides that form amphipathic
helices include glucagon (Jones et al., 1978) and mellitin
(Terwilliger et al., 1982a) and it may be this property that enables
these polypeptides to solubilise phospholipids. Phospholipids may be
directly involved in the binding of many drugs and hormones to
specific cell-surface receptor sites.
Early circular dichroism (CD) experiments proved the existence of the
amphipathic helix in the presence of the acidic phospholipid
dimyristoylphosphatidylglycerol (DMPG) (Epand et al., 1983).
Subsequent work showed that this helicity could also be induced by
sodium-dodecylsulphate (SDS) (Epand et al., 1985), methanol (Orlowski
et al., 1987) and tri-flouroethanol(Epand et al., 1985). It has been
assumed that this a-helix was the predicted amphipathic helix
extending from Val8-Pro23. Early NMR experiments (Wiithrich, 1976) with
human calcitonin in aqueous and in DMSO solutions suggested a random-
coil conformation. Further NMR work on human calcitonin in DMSO and
cryoprotective DMSO-water mixtures (Motta et al., 1991) also did not
find a helical conformation. This cryoprotective mixture has
properties at low temperature similar to those of water at room
temperature. In DMSO, the data indicated a highly flexible and
extended conformation with both proline residues, Pro23 and Pro32,
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exhibiting cis-trans isomerism. The structure was more ordered in the
cryoprotective mixture and the data indicated an anti-parallel 15-sheet
between Phel6 and Thr21. Only Pro23 exhibited cis-trans isomerism with
25 % of the population containing the cis peptide bond at this residue.
Similar NMR work has been carried out with salmon calcitonin (Motta,
1989). Data from cryoprotective mixtures of calcitonin in DMSO-water
indicated an extended conformation with a short double stranded 15-
sheet from Leul2-Lysl8. This 15-sheet had an amphipathic distribution
of residues which was postulated as the "seed" of the amphipathic a-
helix responsible for the interaction with lipids, similar to the
folding mechanism of signal peptide-lipid interactions (Briggs et al.,
1986). Once again there was cis-trans isomerism at Pro23. The proposed
a-helix was finally observed in an NMR study of salmon calcitonin in
90% methanol-10% water (Meadows et al., 1991). This helix extended
from Val8-Tyr22 and was broken by Pro23 which exhibited cis-trans
isomerism. However this was not a classic helix and an amphipathic
distribution of residues in the helix was not observed (Meadows,
personal communication). Additionally, the C-terminal segment was
found to exhibit conformational heterogeneity. Another NMR study
(Meyer, J.-P. et al., 1991) performed in the presence of the helix
inducing solvent trifluoroethanol identified the existence of an ot-
helix. Circular dichroism measurements showed that the helix was also
present in aqueous solutions containing as little as 15% of TFE.
Solutions containing any less TFE than this resulted in a loss of
structure. This helix started at Leu4 of the N-terminal ring and had
the hydrophobic face predicted by helical wheel projections (Meyer,
J.-P., personal communication) as shown in plates 1.1 and 1.2. As
shown in plate 1.2 this helix had an amphipathic distribution of amino
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Plate 1.1
Ribbon diagram of sCT from NMR structure of Meyer et al.,
(1991). The helix starts at Leu 4 and terminates at Tyr 22. Proline
23 is in the trans conformation in this structure. Diagram
produced on an ESV workstation using SYBYL.
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Plate 1.2
Space filling model of NMR structure from Meyer et al., (1991).
In this orientation the helix axis is vertical. Hydrophobic residues
are shown in orange, basic in royal blue, and acidic in red. The
amphipathic nature of the helix is clearly illustrated. Proline 23 is
in die trans conformation. Diagram produced on an ESV
workstation using SYBYL.














acid sidechains. The C-terminal residues were less well assigned but a
loop in the last 10 residues was identified which resulted in the
interaction of the C-terminus with the helix. While it was clear that
the residues in the C-terminal region were more mobile, they did
possess a degree of structure that interacted with the helix. A major
finding of this work was that the addition of water caused cis-trans
isomerism at Pro23.
It is clear from all this NMR work that while secondary structural
elements can exist, the extent and form of these are highly dependent
on the conditions of the experiment. Both a-helix and 8-sheet are
observed but have widely differing structures. All contain areas,
primarily around the C-terminus, that are more dynamic and adopt
multiple conformations.
1.4.2 Calcitonin gene-related peptide.
When the high sequence homology of CGRP with calcitonin was
determined (Jonas et al., 1985), subsequent work demonstrated that
CGRP and sCT-I cross react with each other's receptors (Goltzmann &
Mitchell, 1985). From the amino acid sequence it was suggested that
CGRP, like calcitonin, had the potential to form an amphipathic a-
helix between residues 8 and 25 (Lynch & Kaiser, 1988). However in
aqueous solution, circular dichroism (CD) experiments have suggested
that CGRP is largely unstructured with only 20% helix. This solution
structure was also shown to be unaffected by pH in the range 3.5-9.0
(Hubbard et al., 1991). Increased helical content has been shown to
occur with 1:1 (v/v) TFE/1water. Early CD work (Manning, 1989)
estimated 60% helix in this TFE/water mixture whereas NMR work (Breeze
et al., 1991) suggested only 27%. Subsequent CD experiments (Hubbard
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et al., 1991) confirmed a high helical content (45-70%) in this
TFE/water mixture, and indicated a concentration dependent decrease in
helicity as a possible explanation for the differences between the NMR
and the earlier CD results. The NMR work (Breeze et al., 1991)
confirmed that an a-helix existed, which stretched from residue 8 to
18. It was also confirmed that the helix possessed an amphipathic
distribution of hydrophobic and hydrophilic amino acids. The rest of
the molecule was essentially disordered although there were
suggestions of a turn-type conformation between residues 19 and 21.
This work also indicated that the a and B forms of CGRP were
structurally very similar.
1.4.3 Amylin
As well as possessing sequence similarity with CGRP, amylin also has
a structural similarity. CD experiments (Hubbard et al., 1991) have
suggested that amylin, like CGRP, possesses a small a-helical content
(13%) in aqueous solution but this can be increased by addition of 50%
v/v TFE (20%) or 0.4% SDS (62%). However unlike CGRP, amylin helix
content was shown to be temperature sensitive, decreasing with
increasing temperature.
X-ray diffraction studies on amyloid isolated from humans with
primary and secondary systemic amyloidoses has revealed that the
protein adopts a cross-B pleated sheet conformation (Eanes & Glenner,
1968; Bonar et al., 1969). It is believed that this conformation is
the structural basis for both the staining properties and the
fibrillar structure of the amyloids.
1.5 Structure-activity relationships of calcitonin and related
peptides.
By measuring the biological activity of a series of related molecules
it is possible to correlate increased or decreased activity with some
structural feature of the molecule itself. This is the concept of the
structure-activity relationship. This provides information on the
nature of the interaction between a molecule and it's receptor.
1.5.1 Calcitonin
Although CT's from many species have been sequenced and characterised
biologically, few correlations have been made between structure and
biological activity. It has been shown that ultimobranchial
calcitonins were approximately 30-fold more potent than calcitonins of
thyroidal origin both in vitro and in vivo (Galente et al., 1971).
Analogue studies on sCT (Orlowski et al., 1987) have suggested that
the N-terminal disulphide-bridged ring structure is not required for
biological activity. However, similar work on hCT (Rittel et al.,
1976), showed that hypocalcaemic activity was drastically reduced by
opening of this disulphide ring. Replacement of the disulphide bridge
by a carba-type analogue in the amino-suberic acid derivative of eel
[ASU 1,7] calcitonin resulted in full retention of biological activity
(Morikawa et al., 1976). These results suggest there is not a direct
relationship between the ring structure and biological activity.
However it may be that the role of the N-terminal ring is to promote
the formation of a helical structure in other regions of the peptide
when bound to lipids. This is supported by the finding that sCT-(12-
32)-peptide amide, which lacks the N-terminal ring structure, attains
little helical structure even in the presence of lipid or detergent
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(Epand et al., 1986).
The biological activity of sCT is drastically reduced by a number of
modifications at the C-terminus. The C-terminal prolinamide is
absolutely required for activity. This residue is completely conserved
in all the species studied so far. The position of the C-terminal
amide is important as was shown in two hCT analogues, hCT-(l-31)-NH2
and [Pro29]-hCT-(l-29)-NH2, possessing no biological activity. Any
shortening at this C-terminal end results in a loss or depletion of
biological activity (Rittel et al, 1976). However, C-terminal
fragments of eel calcitonin (eCT) have been shown to possess receptor
binding activity (Yamamoto et al., 1981). It has been proposed that
receptor binding is a function the C-terminus which does not lead to
adenylate cyclase activity. Activation of adenylate cyclase has been
attributed to the N-terminus between residues 1 to 18 (Yamamoto et
al., 1981).
The majority of the structure activity work on calcitonins has
focused on the central region (position 8-23) which has the potential
to form an amphipathic helix. Attempts have been made to correlate
this amphipathic helix with biological activity. However, neither the
hydrophobic moment of the helix (Epand et al., 1986) nor optimisation
of the amphipathic helix (Moe et al., 1985) result in increased
biological activity. The structural requirements of this helix are not
very specific and active analogues of calcitonins have been prepared
with a number of substitutions in the region expected to fold into an
amphipathic helix. The production of sCT analogues with increased
biological activity and reduced helical content (Epand et al., 1986)
has reduced the significance of the amphipathic helix. Also, some
analogues have been shown to retain biological activity without the
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ability to form an amphipathic helix (Epand et al., 1988). Thus, the
structure-activity results are far from clear and in some cases appear
contradictory. A knowledge of the three dimensional structure of
calcitonin, or a calcitonin analogue, will greatly help the
interpretation of these results.
1.5.2 Calcitonin gene-related peptide.
Existing information concerning the relationship between the
structure and activity for CGRP largely hinges upon the effects of
residue deletions/substitutions and of chemical modifications on
biological activity. In a comprehensive study (Zaidi et al., 1990)
involving three different biological assays, it was shown that, as
with calcitonin, the intact peptide was required for full biological
activity. Even the molecule hCGRP-(Alal-Lys35), which had lost two
residues at the C terminus, resulted in a marked decrease in activity.
Tryptic and chymotryptic fragments were also without activity.
However, unlike calcitonin (Orlowski et al., 1987), the destruction of
the disulphide bridge between Cys2 and Cys7 abolished biological
activity suggesting an important role for the N-terminus in the
interaction of CGRP with its receptor. However, the lack of activity
shown by N-terminal fragments (Alal-Argl8) of CGRP rather suggested
that the rest of the peptide was probably necessary for the peptide to
assume the correct conformation for interaction with it's receptor.
Also, the fact that minor modifications such as the acetylation of the
lysine residues Lys24 and Lys35 or substitutions at the C-terminus,
which occur naturally in B-CGRP, do not cause significant changes in
biological activity suggest an important role for the C-terminus. This
was further supported by the finding that hCGRP-(Va!8-Phe37) (Chiba et
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al., 1989) possessed receptor antagonist activity. However, without
the N-terminal disulphide bridge and ring structure, this C-terminal
fragment was unable to induce the subsequent intracellular signal
transduction event. Like calcitonin, the role of the proposed
amphipathic a-helix has been investigated (Lynch & Kaiser, 1988) in
CGRP. Two analogues of CGRP with differing lengths of idealised
amphipathic a-helix were investigated. The first analogue, which
possessed approximately five turns of helix between residue 8 and 25,
had no receptor antagonist activity. The second analogue, which
possessed approximately three turns of an helix between residues 8 and
18, possessed agonist activity. It was concluded that residue 18
represented the termination point for the amphipathic a-helix. This
was also the finding of the NMR study carried out on CGRP (Breeze et
al., 1991). It is therefore highly likely that this amphipathic a-
helix plays an important role in the interaction of CGRP with it's
receptor.
1.5.3 Amylin
Since amylin's role is still not fully understood little work has
been carried out on structure activity relationships. Molecular
modelling of amylin (Saldanha & Mahadevan, 1991) using a combination
of knowledge sources, has suggested an a-helix/B-sheet motif similar
to that found in the insulin B-chain. This work has suggested a
possible explanation for the aggregation properties of amylin.
Hydrophobic patches which are at residues 13, 15, 16, 17 in the ex-
helix and residues 23, 25, 26, 27 in the B-strand are thought to be
important in fibrillogenesis and polymerisation of amylin. The
hypothesis that hydrophobic patches are important in the
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fibrillogenesis is that in the rat (Leffert et al., 1989) amylin does
not form amyloid. This has been shown to be related to a changed
sequence motif in this species (Betsholtz et al., 1989). In the
modelled rat amylin the C-terminal 8-strand sequence suggested a
polyproline-like helix sequence and was modelled as such rather than a
6-strand.
1.6 Overall Similarities between calcitonin and related peptides.
It is clear that these polypeptides are each capable of carrying out
a wide variety of biological activities. However, it is also clear
that they have certain biological activities in common. For example,
CT and CGRP can cross react at each other's receptors ultimately
affecting calcium levels. Both CGRP and amylin can inhibit in vitro
glycogen synthesis. These functional similarities are presumably a
result of some structural similarity. This biochemical evidence is
supported by the sequence similarities shown in figures 1.7 and 1.8.
The possibility that all three peptides are related structurally has
never before been proposed. Structure prediction and structural work
on all three peptides has indicated an important role for an
amphipathic a-helix/turn structure and this may be a common motif for
all three of these peptides. It is highly likely that this structure
is responsible for the interaction of both calcitonin and CGRP with
their respective receptors. This idea is further supported by the
observation that calcitonin and CGRP can cross react at each others
receptors while possessing amphipathic helices of approximately the
same length. Thus a structural understanding of one of these,
calcitonin, will aid in understanding the structure/activity
similarities of all three. In an attempt to use x-ray crystallography
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to provide this structural information, Chapter 4 outlines the first
step in this process - the attempted crystallisation of sCT and two
derivatives. Having determined the crystal structure of calcitonin it
may subsequently be possible to rationally design more active
analogues or simpler analogues which possess the necessary biological
activities.
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The purpose of this Chapter is to give a brief introduction to the
theory of the methods used in the structural determination of a small
biologically active molecule. Most of this information forms the basis
for similar work in protein crystallography. For a fuller description
the reader is directed to Stout & Jensen (1968) and Woolfson (1970).
The structure of this molecule is compared to the structures of
previously determined structures of similar biological activity. It is
hoped that important structural features of these molecules can be
identified.
2.1.1 Diffraction of X-rays.
Diffraction is the phenomenon which occurs whenever a wave motion
interacts with an obstacle. The first diffraction of X-rays by a
crystal in 1912 led to the final proof of the wave nature of X-rays.
However it was not until Bragg noted the similarity of diffraction
from a crystal to ordinary reflection and derived a simple equation
treating diffraction as "reflection" from planes of atoms, that X-ray
crystallography became tractable.
If we consider two parallel planes Pj and P2 with interplanar spacing
d, illuminated by an x-ray beam at an angle 9 as shown in Figure 2.1
then the parallel incident rays 1 and 2 will cause electrons (assumed
at O and C) to vibrate by the oscillating field of the incident beam
and, as vibrating charges, will radiate in all directions.
Constructive interference between rays scattered from successive
planes in the crystal will only take place if the path difference
between the rays is equivalent to an integral number of wavelengths
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= BC = dsin 9
2.1 Construction showing the conditions for diffraction from a
pair of parallel planes PI and P2 with interplanar spacing d.
The parallel rays 1 and 2 are incident on these planes with
an angle 0.
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Thus the derived equation for diffraction to occur is
n A = 2 d sin 9 (1)
With reference to Figure 2.1 drawing perpendiculars from O to A and B,
respectively, it is clear that <AOC = < BOC = 9. Therefore AC - BC and
waves in 2' will be in phase with 1' if the path difference AC + BC (=
2AC ) is an integral number of wavelengths, A. It can also be shown
that what holds for points O and C can be shown to hold for any points
in planes 1 and 2. Therefore any ray parallel to 1' but from another
point in plane Pj, will differ in phase by n A not only from ray 2'
emergent from C but also from any other parallel ray from any other
point on plane P2.
In the derivation of Bragg's law electron density is described as a
plane. In crystal structures, the electron density is distributed
throughout what is called the unit cell. Bragg's law is still valid in
the crystal, since waves scattered from electron density not lying in
the plane P may be added to give a resultant as if reflected from the
plane. Variation in these resultants accounts for the differing
intensities of reflection observed for various planes. Diffraction
maxima from the crystal are sharp and occur only at clearly defined
values of 20 because of the fact that hundreds or thousands of planes
make up each of the mosaic blocks.
2.2 Crystal Systematics.
2.2.1 The Unit Cell.
Since the seventeenth century, it has been realised that crystals
contain a high degree of internal order. A detailed study of crystals
led to the realisation that regularity of form of different crystals
must result from an ordered packing within the crystal (Burke, 1966).
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This led von Laue to suggest that crystals could be treated as a
three-dimensional diffraction grating when radiation of a comparable
wavelength to the interatomic distances within the crystal was used.
Thus any crystal can be regarded as being built from blocks of a unit
structure regularly repeated in three dimensions. The unit structure
may be one or more atoms, a molecule, or a complex assembly of
molecules. This unit structure is termed the Unit Cell and is defined
as the basic parallelipiped shaped block from which the whole volume
of the crystal may be built by regular assembly of these blocks. Unit
Cells are chosen, by convenience, to have the shortest edges possible
and at the same time be in accord with the highest possible symmetry
of the crystal. The edges are defined by three vectors, which are
conventionally given the symbols a, b and c and the angle between
these defined as a, 6 and X as shown in Figure 2.2.







The axial lengths are a, b and c. Any point in the unit cell can be
specified with respect to a given origin by parameters x, y and z
measured parallel to the axes and expressed as fractions of the cell
edges.
2.2.2 The Space Lattice.
If each unit cell is represented by a point at some defined position,
then the array of cells can be defined by a lattice of points. Each
point is in exactly the same environment and orientation as every
other point. This is the space lattice. The concept of the lattice is
important when diffraction by a crystal is considered. Only 14
distinct kinds of lattices - the Bravais lattices - may be
geometrically constructed which satisfy the condition that the
environment and orientation of each lattice point is the same. These
lattices have one of seven different unit cell shapes with different
symmetry properties, corresponding to the seven crystal systems. The
arrangement of structures on these lattices must be consistent with
one of the 230 different combinations of symmetry elements that are
possible for arranging objects in a regularly repeating manner in
three dimensions. These are the 230 space groups. All 230 space groups
and the systematically absent reflections that they imply are listed
in International Tables, Vol.A (1983). Therefore before any crystal
structure can be determined it is necessary to determine the
underlying symmetry of the crystal - its space group. The symmetry of
the crystal will be manifest in the symmetry of the diffraction
pattern leaving only the asymmetric portion of the unit cell, the
asymmetric unit, to be determined. Although representatives of most,
but not all, of the 230 space groups have been found, about
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60% of the organic compounds studied crystallise in one of six space
groups.
In the explanation of Bragg's Law, diffraction was described as
reflection from planes. Sets of parallel planes can be constructed for
the lattice, so that for any given set of planes every lattice point
lies on some member of the set. These sets of planes are identified by
three indices, one corresponding to each axis. The intercept of the
plane with the cell axes are expressed as fractions of the unit cell
edge, their reciprocals are just the desired indices. Thus the set of
planes defined by h,k,l intercept the unit cell axes at a/h, b/k, c/1
where h,k,l are three integers. The h, k, I are also the orders of
diffraction with respect to each axis.
2.2.3 The Reciprocal Lattice.
The reciprocal lattice is a necessary extension of the space lattice
from which it is derived. Considering Bragg's law in the form
sin 0 = nA (2)
2d
sin 0 is inversely proportional to d, the interplanar spacing. To make
this relationship a direct one and allow easy interpretation of
diffraction patterns a reciprocal lattice is constructed, based on 1/d
which varies directly as sin 0. The reciprocal lattice can be defined
by considering normals to all possible direct lattice planes (h, k, 1)
to radiate from some lattice point taken as the origin. Each normal is
terminated at a point a distance l/d^kl from this origin, where djjkl
is the perpendicular distance between the set of planes (hkl). The set
of points so generated constitutes the reciprocal lattice. As before,
sets of parallel planes can be constructed so that for any given set,
64
every reciprocal lattice point lies on some member of it. The planes
of these reciprocal lattice points are now directly related to the
space lattice axes. Reciprocal cell lengths are designated by a*,b*,c*
and the angles /. For lattices that are either orthorhombic,
tetragonal or cubic the algebraic expressions relating a parameter of
the reciprocal unit cell to the real unit cell are simple, for example
a*=l/a. For the other lattice types the algebraic relationships are
more complex. The most important property of the reciprocal lattice is
that it allows easier understanding of Bragg's law in the diffraction
experiment. For a more comprehensive treatment of the reciprocal
lattice the reader is directed to Woolfson (1970).
2.2.4 Crystallisation.
These concepts of planes and lattices are the imaginary constructs
that are useful for describing diffraction from crystals. However,
obtaining a suitable crystal for study and the collection of data
represent the practical considerations. Protein crystals and the
crystallisation of proteins will be discussed separately in Chapter 4.
The theory of crystallisation is applicable to all molecules, only the
practical aspects differ between protein and small molecule
crystallisation. Briefly the crystallisation of a molecule represents
the dynamic equilibrium between the molecule in the fluid phase and in
the solid phase. The crystal is highly ordered with the molecules in
regular positions. The loss of the entropic energy of the molecules is
compensated for by the various types of bonding energies formed by the
ordering process. The growth of most organic and inorganic crystals is
achieved by producing a supersaturated solution of the compound in a
suitable solvent. A supersaturated solution can be obtained in a
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number of ways namely by slow evaporation, slow cooling and diffusion.
The crystallisation of small molecules is relatively simple compared
to protein crystallisation. For small molecules, crystallisation
generally occurs very rapidly resulting in microcrystalline material
which is not suitable for analysis. Thus the main problem for small
molecule crystallisation is controlling the process to produce large
single crystals. Slow evaporation can be used when the solvent of the
saturated solution is slowly allowed to evaporate. This method
requires the use of volatile solvents, evaporation rates can be
controlled and best results occur when the rate is slow. Slow cooling
requires that a solution of the compound is made at an elevated
temperature which on cooling becomes supersaturated. The compound must
be stable at the elevated temperature if this approach is to be used.
Here also the rate of cooling can be controlled and best results are
normally when the rate of cooling is slow. If difficulty is
experienced in growing suitable crystals from single solvents,
mixtures of two or more solvents can be used. The properties of the
solvent, such as density, dielectric constant, viscosity, solvation
and solubility can have a pronounced effect on crystal growth. These
can be varied in a controlled way over wide ranges and adjusted to
fit the particular circumstances.
2.2.5 Choice of Crystal.
If a crystal is to be of any use for collecting x-ray diffraction
data it has to fulfil two main requirements:(1) it must possess
uniform internal structure and (2) it must be of proper size and
shape. Crystals with any physical defects such as being twinned or
cracked are of no use. It is not necessary for the crystal to possess
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uniform or well defined external faces. The ability of a crystal to
polarise light under a polarising microscope can be used to screen
suitable crystals. In order that all parts of the crystal are exposed
to the same intensity of radiation the crystal should not be too
large. If the crystal exceeds about 0.5mm x 0.5 mm it may need to be
cut or shaped. However, some crystals are too soft, fragile, or
sensitive for cutting that they must be used as they are grown. Since
the intensities of diffracted rays are proportional to the amount of
material that is scattering them, crystals that are too small are
generally not suitable. The absorption of x-rays is an important
factor concerning the shape of the crystal. If the crystal is
particularly thick in one dimension then the opportunity for
absorption of diffracted rays will be increased relative to other
reflections. As a result a systematic error will be introduced into
the observed intensities. It is possible to make a calculated
correction for this effect, but the corrections are not very accurate
and it is therefore better to try and avoid the problem by proper
choice of the crystal.
2.3 Intensity data collection.
There are two general methods for measuring intensities of diffracted
rays. Either the ray can be detected by a quantum counting device
measuring the photons directly (diffractometers), or else the degree
of blackening of photographic emulsion may be measured and taken as
directly proportional to the intensity of the diffracted ray.
Automated diffiractometers are the more recent development and have
been used in the data collection for the work described in this
thesis. Photographic methods will not be discussed. However, the
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corrections and the production of integrated intensities are
essentially the same for both types of data collection.
Integrated intensities are a measure of the total number of photons
of the characteristic wavelength diffracted when the Bragg condition
is satisfied. However the actual measurements made are only close to
these values. Certain corrections have to be made to produce these
integrated intensities. Difficulties of intensity measurement arise
from three sources:
1. Scattering of radiation by processes other than Bragg
reflection.
2. The spectral impurity of the beam.
3. Diffraction spot size and shape variation.
For true intensities the background radiation must be removed. There
are two sources of background radiation, the first from diffuse
scattering of x-rays by the crystal itself and by air, the second
arises from spectral impurities and can be removed by selective
filtering. Two reflections of the same integrated intensity can have
widely differing spot shapes and sizes and also different intensities
at some defined point within each spot. The reasons for this are
partly due to apparent changes in the illuminated area of the crystal
surface as the crystal rotates and also to geometric factors. There is
a general tendency for reflections to be larger and more diffuse at
high values of sin 0 than at low values.
The most common instrument for automatic intensity data collection is
the four-circle diffractometer as shown in Figure 2.3. The four
circles of rotation allow the crystal to be oriented in such a way as
to bring the normal of any desired plane (i.e. the scattering vector)
into the equatorial plane where it can be detected by the counter
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which is moved to the Bragg position by the circle. The entire
instrument is controlled by a computer and the angular settings of the
crystal and the detector can be calculated from the unit cell
dimensions and the orientation of the crystal on the instrument. Thus
the whole data collection can be done automatically.
Figure 2.3 The Four circle diffractometer. The crystal is randomly mounted on the spindle
which can be rotated around the cj>-axis. This spindle assembly can be rotated
about a perpendicular axis, the % axis, by rotation of ring B inside the stationary
ring A. This x-"n<3 together with the spindle assembly and the crystal can be
rotated about a vertical axis, the ro-axis. The detector D is mounted on an arm
which enables it to be rotated about a vertical axis, designated the 20-axis,
coincident with the u-axis. C represents the collimator.
Standard reflections are measured regularly so that crystal slippage
and radiation damage (which would result in weaker diffracted
intensities) can be observed.
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2.4 Data reduction.
The result of the collection of X-ray diffraction data is a relative
intensity, I, for each reflection with indices, h, k, 1, together with
the scattering angle, 20, for that reflection and some estimate in the
error in the measurement of the reflection (standard deviation).
Intensities are not the most suitable form in which the measured data
can be expressed. The required quantity, which can be derived from
intensity, is the structure factor modulus | Fhkl | • This is related to
the observed intensity by
| F | al1* (3)
The structure factor has both magnitude (amplitude) and phase
(relative to the origin of the unit cell). Once the approximate
positions of the atoms in the cell are known these structure factors
can be theoretically calculated. Structure factors are also used in
the calculation of electron density maps from which the position of
atoms may be determined. Thus it is essential to convert these
intensities into observed structure amplitudes | F0 | for use in
subsequent calculations.
2,4.1 Lorentz and polarisation corrections.
As described previously, certain corrections, primarily geometric,
have necessarily to be applied to | F0 | . The first correction is the
Lorentz factor Ljjd, which corrects for the different geometries of
intersection of a lattice point with the Ewald sphere when it
satisfies the Bragg condition. This is described for a four circle
difffactometer, with the geometry as shown in figure 2.3, by the
factor
L = 1/sin 20 (4)
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however other geometries have different expressions for the Lorentz
factor and can be found in Vol.IV of The International Tables for X-
ray Crystallography (1974). The second correction is a polarisation
correction (p) which corrects for the partial polarisation of the
diffracted beam. This is also an angle dependent term described by
p = 1 + cos-^26 (5)
2
and is independent of the method used for data collection. Thus the
result of these data reduction corrections are | Freiayve | 's ( | Frei | )
defined by
I Frei I =(Ihkl/Lp)'A (6)
The output data after data reduction therefore contains hkl, | Frei | ,
(sin0)/A and some measure of the probable error in the | Frej | .
2.4.2 Atomic scattering factors.
The scattering power of a given atom for a given reflection is known
as its scattering factor (f0) and is expressed in terms of the
scattering power of an equivalent number of electrons located at the
position of the atomic nucleus. The scattering factor is always equal
to the total number of electrons in the atom at sin 0/A = 0 and
decreases as sin 0/A increases. Scattering factor curves have been
calculated for a large number of atomic species using theoretical
electron distributions. The results are available in the International
Tables for X-ray Crystallography Vol.IV (1974).
2.4.3 Temperature factors and absolute scaling.
In the solution of the crystal structure the atoms are assumed to
exist at discrete positions within the unit cell. This does not take
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account of the vibrational motion of atoms at non absolute zero
temperatures. Thermal energy causes the atoms to oscillate about their
equilibrium positions. The effect of this is to reduce the effective
scattering power of an atom. The change in scattering power has been
theoretically shown to be given by
e-B[(sin20)/A2] (7)
where B is related to the mean-square amplitude (u2) of atomic
vibration by
B= 8X2U2 (8)
Thus the true scattering factor for an atom becomes
f = f0e-B[(sin2e)/A2] (9)
This assumes the amplitudes of vibration are radially symmetric.
However the most realistic model for atoms in a crystal is to treat
the vibrations as ellipsoidal rather than as a sphere. There are six
parameters for the ellipse which define the lengths of the axes and
their orientation relative to the crystal axes.
An estimate of the overall temperature factor can be determined from
the data by means of the Wilson plot. This plot also gives scaling
information relating the average observed intensity to the theoretical
value predicted knowing the number and type of atoms in the unit cell.
This absolute value of intensity is calculated in small shells of
(sin20/A2) and compared to the observed. The thermal motion is
calculated by
labs = E fo 2 e-2B(sin20)/A2 (10)
where B remains to be determined. The assumption which is
necessary is that the average intensity of diffraction at a certain 20
value depends only on the contents of the unit cell and not their
positions. Thus a straight line plot of ln(Irei /Ef2) against
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sin29/ A2 allows B to be derived from the slope and the scale to be
derived from the intercept when sin20/ A2 =o. The resulting scale
factor can be applied to the data to put the values of | F | on an
approximately absolute scale for all reflections measured.
2.5 The Fourier syntheses and diffraction.
2.5.1.The structure factor.
As previously mentioned, the calculation of the structure factor is
an important step in the determination of any structure. The Structure
Factor, F^kl, is the resultant of j waves scattered in the direction
of the reflection hkl by the j atoms of the unit cell. It is measured
relative to the scattering of a single electron at the origin and is
the Fourier transform of the scattering density sampled at reciprocal
point hkl. The structure factor can be represented in either of two
mathematical ways which describe a wave, namely exponentially or as an
ordinary complex number.
In the exponential form,
Fhkl = £j fje 27ri(hxj + kyj + lzj) (11)
I F I or I Fhkl I ' Amplitude of the scattered wave.
In the complex number form,
F(hkl) = A(hkl) + iB(hkl) (12)
A(hkl) = E fj cos 2ir( hxj + kyj + lzj )
B(hkl) = E fj sin 2ir( hxj + kyj + lzj )
Where x,y,z are expressed as fractions of the unit cell lengths a,b
and c.
i= -11//z "imaginary number"
fj = atomic scattering factor amplitude
The phase, a, of the scattered wave can be determined by
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a = tan-!(B/A) (13)
and
| F | = (A2 + B2)!/2 (14)
2.5.2. Fourier syntheses.
Fourier's theorem states that a continuous, single-valued, periodic
function can be represented by the summation of cosine and sine terms.
Since crystals represent the periodic distribution of scattering
matter the Fourier Series can be used. Just as the diffraction pattern
is a Fourier summation of the electron density (in the calculation of
structure factors), the electron density is a Fourier summation of the
structure factors. The required series to describe the electron
density of a point (x,y,z) in the crystal is of the form,
p(x,y,z)= l/V Eh £k S1 I Fhkl I cos27r(hx+ky+lz - a'hkl) (15)
where V - the volume of the unit cell
p(xyz) - the electron density at a point x,y,z
a'hid - the phase angle
2.6 The Phase problem (the direct methods approach).
If | F | is known and a (for each h,k,l) can be calculated, then the
electron density for all values of x, y and z can be determined.
However, while | F | can be measured (from the diffraction intensities),
the phase angle a is lost during the diffraction experiment. This is
the essence of what is termed "The Phase Problem". Therefore values of
a must be derived by some other technique. There are a number of
techniques that can be used to determine the phase information.
However only the Direct Methods approach will be discussed in detail
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since it was used in the work for this thesis. This is a method that
is still only generally applicable to small molecule structure
determination. Details of the other methods of phase determination are
discussed in Stout & Jensen (1969).
The Direct methods approach is so called since it derives a set of
phases by consideration solely of the structure factor amplitudes. The
intensity data, or the structure factors | F(hkl) | are converted to
normalised structure factors | E(hkl) | . The normalised structure
factors are produced as E^Oikl) = F^fhkl)/< F^> where <F^> is the mean
of F^ for ranges of sinG. The method relies on three general
conditions (i) the electron density is everywhere positive, (ii) the
atoms are assumed to be spherically symmetrical and have the same
shape, (iii) the structure consists of identical atoms fully resolved
from each other (approximately true for organic crystals). Such
conditions, apart from any knowledge of the relative positions of the
atoms, are sufficient to place some limitations on the phases of the
reflections. There are important probability relationships that apply
between groups of structure factors. The most important of these is
the 12 relationship: fir large values of | E | , say | Ej | , | E2 | and | E3 |
all >1.5,
if: hi+h2+h3 =k}+k2+k3 = 11 +12+13 =0 then: 1+^2 +<l>3~0
Direct methods are generally applicable to all small molecule
structure solutions and these probabilistic equations have been
included in a number computer programmes for structure determination.
It has been particularly useful for centrosymmetric space groups,
where the phase of each reflection is either 0 or 180°, although more
recently non centrosymmetric space groups can be solved by direct
methods. The result of this method is a starting structure which can
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be used for the refinement process.
2.7 Refinement.
The refinement method that will be discussed here is that of Least
Squares. It is a method of great power and generality and it was the
method used in the refinement of both the small molecule and the
protein equine PLA-2 in this thesis. It is a technique for adjusting a
set of variables (called the parameters) in such a way that they give
the best fit between the measured experimental observations and those
calculated from some assumed model. The best parameters for the
assumed model are obtained by minimising the sum of the squares of the
differences between the experimental quantities and the values of the
same quantities calculated with the derived parameters. Thus the
function to be minimised is
R — "i Wi(y0-yc)i 2 (16)
where y0 and yc are the measured and calculated values for a set of n
observations of weight w, with i running from 1 to m. If the
calculated values are defined in terms of a set of m parameters, pj,
this minimum occurs when:
dR/dpj = Ej -2wi(y0 - yc)idyc/dpj = 0 (17)
for all m values of j. These equations are called the Normal
equations for the refinement. The method is only valid if the
observations are independent of one another and that there are at
least five times as many observations as parameters (n> > m).
2.7.1 Refinement of cell parameters.
A solution to these equations can be found if the relationship
between the observations and the parameters is linear. This is the
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method that is used in the refinement of the cell parameters. A set of
accurately measured values of sin 9 are measured for between 20 and 30
strong reflections. These form the basis for the observational
equations of the form:
4sin20A2= h2a*2+1^5*2+i2c*2
+2klb*c*cosa!*+2hla*c*cos6*+2hka*b*cosy* (18)
The equations are linear in terms of the six parameters a*2, b*2, c*2,
b*c*coso!, a*c*cos6 and a*b*cosy*. Unit weights are used and the
resulting six linear equations in six unknowns are solved by matrix
methods. The use of matrix methods allows the calculation of errors in
the parameters. These are obtained from the diagonal terms of the
inverse matrix which are directly proportional to the required errors.
Also the off-diagonal terms provide information about the correlation
between the parameters. The correlation between two parameters pj and
pk will be Ijk/(Ijj Ikk)1//2- If the parameters are genuinely
independent, this will be 0.
2.7.2. Structure refinement.
The quantity to be minimised in structure refinement is:
D = Ehk] whkl ( I F0 | - | Fc | )2 (19)
where wj^i is the weight of the observation and Shy indicates
summation over all reflections. If the relationship between the
observations and the parameters is not linear, as is the case here,
least squares cannot be used directly to refine the structure. However
it can be used in the refinement by making use of the approximate
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relationship, neglecting the higher order terms in the Taylor
expansion:
for y = f (pl,p2,p3 ) 5y ~ Ej <5pj.dy/dpj (20)
Thus, providing reasonably approximate values are known, there is
an approximate linear relationship for shifts in parameters. Since the
results of the calculation are only approximate a cyclical
arrangement is needed such that the new parameters serve as the
starting point for the next calculation. The cycles continue until the
shifts in the parameters are less than the errors associated with the
parameters themselves.
A measure of the correctness of the model structure is the fit of the
observed structure factor amplitudes to those calculated from the
model. This is called the conventional residual, R, which is
calculated over all reflections:
R = S| | Fn [ - | F£ | | (21)
S | F0 |
Values for R below 0.06 (6%) are regarded as reliably determined
structures. However sensible stereochemistry in the model is essential
as well as a low R value.
2.8 Introduction to Drug 212-842.
This compound, 4-[4-{2-(3,4-dimethoxyphenyl)ethyl}-l-piperazinyl]-lH-
indole-2-carboxylic acid methyl ester, here termed 212-842, is a small
biologically active molecule. The compound has blood pressure lowering
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activity by acting as an antagonist to both a- and B-adrenoreceptors.
These receptors are classified into al, a2, 61, B2, distinguishable on
the basis of their affinities for different agonists and antagonists
and have different tissue specific effects. Stimulation of a-
adrenoreceptors by adrenalin, the natural agonist, causes arteriole
contraction. Stimulation of B-adrenoreceptors by adrenalin or
noradrenalin causes increased rate of contraction in heart cells. In
addition to this the compound has partial activity, by acting as an
agonist, at 5HT receptors. Like the adrenoceptors there are multiple
populations of 5HT receptors and these have been identified as 5HT1,
5HT2 and 5HT3. Stimulation of these 5HT receptors causes
vasoconstriction and smooth muscle contraction. It has also been shown
(Glennon, R.A. 1987) that there is heterogeneity at the 5HT1 receptor
(i.e., 5HTia, 5HTjb, 5HTjc and 5HTid sites). The compound 212-842 has
specificity for 5HT^ receptors. Thus 212-842 has a wide range of
activities which are of potential clinical application.
2.8.1 Experimental.
Large rectangular crystals were obtained from a supersaturated
solution of the drug 212-842 in malonic acid at 297K. A suitable
single crystal of dimensions 0.7 x0.65x0.4 mm was selected for data
collection. The crystal was mounted with its longest edge along the
axis of the spindle. A unit cell was determined and refined using 25
strong reflections. The space group was monoclinic, P2j/a, with unit
cell dimensions a = 15.9531(6), b = 9.9683(7), c = 16.9717(9) A, B =
91.4517(5)° ( the numbers in the brackets refer to the estimated
standard deviations in the last place quoted). Thus the unit cell
volume is 2698.9 A3 and contains 4 molecules giving the crystal a
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calculated density (Dx) of 1.299 gcmrA
The data set was collected on a Enraf-Nonius CAD-4 using Nickel
filtered Cu Ka radiation (A = 1.4518 A). The range of indices
collected was -17 < h < 17, 0 < k < 11, -1 < 1 < 19, ©max was 60°- The
standard reflections chosen to monitor crystal decay and slippage were
0 4 0 and 10 0 0. No significant variation in intensity was observed
during data collection and no absorption corrections were applied to
the data. During data collection 4429 reflections were measured. The
data for the refinement were sorted and merged to produce 3993 unique
reflections, once all the systematically absent reflections were
removed. The E-statistics as a function of sin 9 were close to unity
indicating a centrosymmetric structure. The number of reflections used
in the further refinement were reduced to 3663 after 330 reflections
with I < 2a were suppressed.
The location of non hydrogen atoms was achieved using direct methods
with SHELXS86 (Sheldrick,1986). Two molecules, namely the drug and the
malonic acid in which the drug was crystallised, were located. The
coordinates of these were used in the subsequent refinement process
which was carried out using SHELXS-76. The R factor at this stage was
0.212 and after 4 cycles of least squares including all the non
hydrogen atoms with isotropic temperature factors the R factor dropped
to 0.146. At this stage hydrogens were added to their calculated
positions and allowed to ride on the atoms to which they were
attached, with fixed isotropic temperature factors and site
occupancies. No hydrogens were placed on the carboxyl groups of the
malonic acid. Finally all the non hydrogen atoms were refined with
anisotropic temperature factors. The R factor dropped to 0.053. At
this stage the difference map contained two additional peaks, each of
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a size equivalent to an electron, that were not accounted for by the
structure. These were in approximately correct positions to be assumed
to be hydrogen atoms. The first of these was within 0.98 A from the
piperazine nitrogen N(6). The other was within 1.02 A from the
carboxyl 0(37) of the malonic acid. These were included as hydrogens
with fixed occupancies and isotropic temperature factors before a
further 4 cycles of refinement. However after this refinement the
solvent hydrogen H(37 O) - 0(37) distance was 0.79 A. This bond was
therefore constrained to be a distance of 1.0 A in subsequent
refinements. After a further 4 cycles of refinement the R factor was
0.0493. It was at this stage that unit weights were dropped in favour
of those based on ct(F). The scheme in SHELX-76 uses
weight - K / ( a2 (F) + gF2 ) (22)
(K and g are constants which are redetermined after each structure
factor calculation) the value chosen initially for g was -0.0001 but
both K and the absolute value of g are refined when g is given as a
negative quantity. The weighting scheme was refined for six cycles.
The atomic parameters were not refined. The refinement proved to be no
better than unit weights. The initial value of g was reduced to -
0.000001 and the values refined for another six cycles as before.
While there was a very slight improvement R = 0.0492 this weighting
scheme was finally dropped in favour of unit weights. Ten reflections
with 8/a > 6.0 were suppressed and the coordinates refined for 2
cycles. The R factor was now 0.0488. While the structure was now
solved the difference map contained a trough twice the size of the
largest peak suggesting more than random noise. A further 3
reflections with 8/a > 6.0 were suppressed and 4 cycles of refinement
did not remove the trough. It was necessary to determine the
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explanation for this trough in the difference map. Thus a difference
map was produced from SHELX-76 which was converted to a format
suitable for FRODO. Both the map and the structure were viewed on an
Evans & Sutherland PS300. The map was contoured so that this negative
density could be viewed. From this it was easily seen that the holes
in the map were associated with the hydrogen atoms of three methyl
groups. Thus the methyl groups of C (1), C (27) and C (30) were
subsequently refined as rigid groups for a further 4 cycles. The
maximum shift (5/a) in the final run was 0.07. The final R factor was
0.0479. During refinement there were 343 reflections with I < 2a,
these were treated as unobserved. The total number of parameters
refined was 355, the number of observations used was 3663. The final
difference map had maximum and minimum values of + 0.19 and - 0.298
eA~3 respectively and the maximum sin 9A was 0.623 A"A
The program CALC (Gould and Taylor, 1983) was used to provide the
molecular geometry data presented in table 2.2a-c and also to provide
interplanar angles and centre of gravity values in table 2.5. Diagrams
were prepared using PLUTO (Motherwell, 1972) and an interactive
version of ORTEP (Johnson, 1965:Mallinson & Muir, 1985). Atomic
scattering factors were from International Tables for X-ray
Crystallography Vol.IV (1974). The final atomic parameters are given
in table 2.1a-b. A connectivity search was carried out on the
Cambridge Structural Database (Allen et. al., 1979) for related
structures. The fragment chosen for the search was a benzyl ring
bonded to a piperazine ring through the nitrogen atom. This search
retrieved 33 compounds from the database of which 2 compounds were
selected which possessed similar activity to 212-842. These two
compounds together with 212-842 are shown in figure 2.6. The first
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compound QUEST88 REFCODE = COKTAX possess 8 blocking activity, the
second QUEST88 REFCODE -= CAGXIR has a-adrenoreceptor antagonist
activity and is a tranquiliser. Molecular superposition and graphics
visualisation was carried out using FRODO (Jones, 1978) on an Evans &
Sutherland PS300.
2,9 Discussion.
The crystal structure of 212-842 is shown in Figure 2.4, the
coordinates of which are shown in table 2.1a-b. Table 2.2 a-c lists
bond lengths, bond angles and torsion angles. Figure 2.5 shows a
stereodiagram of the molecular packing. The associated bond distances
and angles are in good agreement with tabulated values (Allen,
Kennard, Watson, Orpen & Taylor, 1987). While the structure has
acceptably low temperature factors the three methoxy groups on C(3),
C(26) and C(28) show some of the largest vibrational motions. This may
be due to the fact that they are not involved in any bonding
interactions. The malonic acid is a planar structure. The charge of
the deprotonated carboxyl group C(33) is delocalised, both C-0 bond
lengths being almost equivalent. The other carboxyl group of C(36) is
not delocalised, retaining it's hydroxyl hydrogen. The nitrogen N(17)
is protonated probably as a result of the pH at which the crystal was
grown in malonic acid and thus the drug has crystallised as an acid
salt. Protonation of N(17) has not affected the chair conformation of
the ring. The protonation of this nitrogen occurs in one other of the
structures found in the database search, oxypertine (QUEST88 REFCODE =
CAGXIR). This compound is an a-adrenoreceptor antagonist. The
interaction of a-ligands with their receptor are believed to involve
the quaternary Nitrogen (Pullman, Coubeils, Courriere & Gervois, 1972)
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so the capacity of 212-842 to become protonated might be very
important in its activity.
Figjre 2.4. 212-842 crystal structure. Non-H atoms are shown as 50%
probability thermal ellipsoides. The counterion derived from
malonic acid is also shown.
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Table 2.1(a). Fractional Coordinates of 212-842 non-H Atoms with Standard
Deviations.
X y z Ueq
C (1) 0.41890 22) 0 . 7057 ( 3) 0.21466 21) 0.0872 23)
0(2) 0.47039 12) 0.58603(19) 0 .21420 11) 0.0700 12)
c (3) 0.48796 18) 0.5375( 3) 0.14376 16) 0.0609 17)
0(4) 0.46035 16) 0.58525(23) 0.08348 12) 0.0967 16)
C (5) 0.54527 16) 0 .42339(25) 0.14833 14) 0.0527 15)
N(6) 0.57831 14) 0.37430(22) 0.08010 12) 0.0608 14)
C (7) 0.63299 17) 0.2725( 3) 0.09936 14) 0.0567 16)
C (8) 0.63240 15) 0.25507(23) 0.18212 13) 0.0464 14)
C (9) 0.57664 15) 0.35347(23) 0 .21177 14) 0.0468 14)
C(10) 0.68388 19) 0.1970 ( 3) 0.05046 16) 0.0714 19)
C(ll) 0.73504 20) 0.1050 ( 3) 0.08685 17) 0.0739 20)
C (12) 0.73554 17) 0.0832 ( 3) 0.16912 15) 0.0609 17)
C (13) 0 . 68405 14) 0.15535(23) 0.21758 14) 0.0467 14)
N (14) 0.68094 11) 0.13706(19) 0.30040 11) 0.0437 11)
C (15) 0.59838 14) 0.0960 ( 3) 0.32774 14) 0.0493 14)
C (16) 0.59411 14) 0.11314(25) 0.41530 14) 0.0488 14)
N (17) 0.65961 10) 0.02893(17) 0.45588 10) 0.0384 10)
C (18) 0.74437 13) 0.06127(24) 0.42495 13) 0.0448 13)
C (19) 0.74496 14) 0.05047(25) 0.33625 14) 0.0485 14)
C (20) 0.65571 14) 0.04427(23) 0.54390 13) 0.0444 13)
C (21) 0.69855 16) -0 .0699 ( 3) 0.58760 14) 0.0547 15)
C (22) 0.68467 14) -0.06161(24) 0.67511 13) 0.0467 14)
C (23) 0.62916 15) -0.1467 ( 3) 0.71066 16) 0.0561 16)
C (24) 0.61641 17) -0.1396 ( 3) 0.79125 16) 0.0611 17)
C (25) 0.65838 16) -0.0471( 3) 0.83662 15) 0.0567 16)
0(26) 0.65026 14) -0.03072(23) 0.91597 11) 0.0839 15)
C (27) 0.59321 25) -0.1163 ( 4) 0.95448 21) 0.106 ( 3)
C (28) 0.71535 15) 0.04004(25) 0.80120 14) 0.0501 14)
0(29) 0.75471 12) 0.12864(20) 0.85167 11) 0.0728 13)
COO) 0.81660 19) 0.2130 ( 3) 0.82039 20) 0.0804 22)
C (31) 0.72752 14) 0.03372(24) 0 .72140 14) 0.0472 14)
0(32) 0.52564 11) 0.80055(17) 0.42820 12) 0.0683 12)
C (33) 0.58566 15) 0.72211(23) 0.41586 13) 0.0430 13)
0(34) 0.66015 10) 0.75696(16) 0.41640 10) 0.0574 11)
C (35) 0.56603 14) 0.57594(23) 0.39863 15) 0.0481 14)
C (36) 0.47729 16) 0.5280 ( 3) 0.40671 14) 0.0526 15)
0(37) 0.42071 11) 0.61983(20) 0.42093 13) 0.0735 13)
0(38) 0.45923 12) 0.41054(19) 0.40071 12) 0.0757 14)
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Table 2.1(b). Fractional Coordinates of 212-842 Hydrogen Atoms
H (11) 0.3990 0.
H (12) 0.3645 0.
H (13) 0.4546 0.
H (6N) 0.5637 0.
H (91) 0.5620 0.
H (101) 0.6828 0.
H (111) 0.7768 0.
H (121) 0.7771 0.
H(151) 0.5506 0.
H(152) 0.5878 -0.
H (161) 0.5329 0.
H(162) 0.6045 0.
H (171) 0.6475 -0.
H (181) 0.7611 0.
H(182) 0.7897 -0.
H (191) 0.7327 -0.
H(192) 0.8058 0.
H (201) 0.6860 0.
H (202) 0.5907 0.
H (211) 0.7650 -0.
H (212) 0.6736 -0.
H (231) 0.5951 -0.
H (241) 0.5730 -0.
H (271) 0.5957 -0.
H (272) 0.6093 -0.
H (273) 0.5306 -0.
H (301) 0.8406 0.
H(302) 0.7859 0.
H (303) 0.8678 0.
H (311) 0.7703 0.
H (351) 0.6048 0.
H(352) 0.5835 0.






































































Table 2.2(a) . 212-842 bond Lengths(A) with standard deviations
C(l) -H(ll) 1.080 ( 5) C (19) -H (191) 1.080 3)
C (1) -H(12) 1.080 ( 5) C (19) -H (192) 1.080 3)
C (1) -H(13) 1.080 ( 5) C (20) -H (201) 1.080 3)
c<i) - 0(2) 1.448 ( 4) C (20) -H (202) 1.080 3)
0(2) - C (3) 1.326 ( 3) C (20) -C (21) 1.512 3)
C (3) - 0(4) 1.202 ( 4) C (21) -H (211) 1.080 4)
C (3) - C (5) 1.460 ( 4) C (21) -H (212) 1.080 4)
C (5) - N (6) 1.375( 3) C (21) -C (22) 1.509 3)
C (5) - C (9) 1.367 ( 3) C (22) -C (23) 1.377 3)
N(6) -H(6N) 1.080 ( 3) C (22) -C (31) 1.400 3)
N(6) - C (7) 1.372 ( 3) C (23) -H (231) 1.080 4)
C (7) - C (8) 1.416 ( 3) C (23) -C (24) 1.390 4)
C (7) -C(10) 1.396( 4) C (24) -H (241) 1.080 4)
C (8) - C (9) 1.424 ( 3) C (24) -C (25) 1.366 4)
C (8) -C(13) 1.416( 3) C (25) -0(26) 1.366 3)
C (9) -H(91) 1.080 ( 3) C (25) -C(28) 1.403 4)
C(10) —H(101) 1.080( 4) 0(26) -C (2 7) 1.419 5)
C (10) -C(ll) 1.364 ( 4) C (27) -H (271) 1.080 6)
C (11) -H(111) 1.080 ( 4) C (27) -H (272) 1.080 6)
C(ll) -C(12) 1.413 ( 4) C (27) -H (273) 1.080 6)
C (12) -H(121) 1.080 ( 4) C (28) -0(29) 1.371 3)
C (12) -C(13) 1.379 ( 4) C (28) -C (31) 1.375 3)
C (13) -N(14) 1.419( 3) 0(29) -0(30) 1.411 4)
N (14) -C(15) 1.466( 3) C (30) -H (301) 1.080 5)
N (14) -C(19) 1.458 ( 3) 0(30) -H(302) 1.080 5)
C (15) -H(151) 1.080 ( 3) 0(30) -H (303) 1.080 5)
C (15) -H(152) 1.080 ( 3) C(31) -H (311) 1.080 3)
C (15) -C(16) 1.499 ( 3) 0(32) -C(33) 1.258 3)
C (16) -H(161) 1.080 ( 3) C(33) -0(34) 1.238 3)
C (16) -H(162) 1.080 ( 3) C(33) -C(35) 1.517 3)
C (16) -N(17) 1.495 ( 3) C(35) -H(351) 1.080 3)
N (17) -H(171) 1.0800(24) C(35) -H(352) 1.080 3)
N(17) -C(18) 1.498 ( 3) C(35) -C(36) 1.504 4)
N (17) -C(20) 1.505( 3) C(36) -0(37) 1.312 3)
C (18) -H(181) 1.080 ( 3) C(36) -0(38) 1.210 3)
C (18) -H(182) 1.080 ( 3) 0(37) -H (370) 0.997 20)
C (18) -C(19) 1.510 ( 3)
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Table 2.2(b). 212-842 angles(degrees) with standard deviations
H (11) - C (1) -H (12) 109.5( 4)
H(11) - C(l) -H(13) 109.5 ( 4)
H (11) - C (1) - 0(2) 108 . 3 ( 3)
H (12) - C (1) -H (13) 109 . 5 ( 4)
H (12) - C (1) - 0(2) 110.0 ( 3)
H(13) - C(l) - 0(2) 110.1( 3)
C(1) - 0(2) - C(3) 116.00(23)
0(2) - C(3) - 0(4) 122.8( 3)
0(2) - 0(3) - C(5) 112.51(23)
0(4) - C (3) - C (5) 124.7 ( 3)
C(3) - C(5) - N(6) 119.05(22)
C (3) - C (5) - C (9) 130.95(24)
N(6) - C (5) - C (9) 109.97(22)
C(5) - N(6) -H(6N) 125.74(24)
C(5) - N(6) - C (7) 108.52(21)
H(6N) - N(6) - C(7) 125.74(24)
N(6) - C (7) - C (8) 107.88(21)
N(6) - C(7) -C(10) 129.27(24)
C(8) - C(7) -C(10) 122.83(24)
C (7) - C (8) - C (9) 106.61(21)
C (7) - C (8) -C (13) 119.32(21)
C (9) - C(8) -C(13) 134.05(22)
C (5) - C (9) - C (8) 107.00(21)
C (5) - C (9) -H < 91) 126.5( 3)
C (8) - C < 9) -H (91) 126.5( 3)
C(7) -C(10) -H(101) 121.8( 3)
C(7) -C(10) -C(ll) 116.3( 3)
H(101)-C(10) -C(ll) 121.8( 3)
C(10) -C(ll) —H(111) 118.7( 3)
C(10) -C(ll) -C(12) 122.6( 3)
H(111)—C(11) -C(12) 118.7( 3)
C(ll) -0(12) -H(121) 119.3( 3)
0(11) -C (12) -0(13) 121.36(25)
H(121)-C (12) -0(13) 119.3(3)
0(8) -0(13) -0(12) 117.49(22)
0(8) -C(13) -N(14) 118.46(20)
0(12) -C(13) -N(14) 124.04(21)
0(13) -N(14) -0(15) 113.80(18)
0(13) -N(14) -0(19) 116.58(18)
0(15) -N(14) -0(19) 109.15(18)
N(14) -C (15) -H(151) 109.28(23)
N(14) -0(15) -H(152) 109.29(23)
N(14) -C(15) -0(16) 110.23(19)
H(151)-C(15) -H(152) 109.5 ( 3)
H(151)-C(15) -0(16) 109.27(24)
H 152)-C 15) -C 16) 109.28 (24)
C 15) -C 16) -H 161) 109.30 (24)
C 15) -C 16) -H 162) 109.31 (24)
c 15) -C 16) -N 17) 110.12 (19)
H 161)-C 16) -H 162) 109.5( 3)
H 161) -C 16) -N 17) 109.31 (23)
H 162)-C 16) -N 17) 109.32 (23)
C 16) -N 17) -H 171) 109.31 (18)
C 16) -N 17) -C 18) 110.14 (16)
C 16) -N 17) -C 20) 110.76 (16)
H 171)-N 17) -C 18) 107.20 (17)
H 171)-N 17) -C 20) 106.52 (17)
C 18) -N 17) -C 20) 112.74 (16)
N 17) -C 18) -H 181) 109.02 (21)
N 17) -C 18) -H 182) 109.01 (21)
N 17) -C 18) -C 19) 111.26 (18)
H 181) -C 18) -H 182) 109.5( 3)
H 181)-C 18) -C 19) 109.03 (22)
H 182)-C 18) -C 19) 109.03 (22)
N 14) -C 19) -C 18) 110.60 (19)
N 14) -C 19) -H 191) 109.19 (23)
N 14) -C 19) -H 192) 109.19 (23)
C 18) -C 19) -H 191) 109.19 (23)
C 18) -C 19) -H 192) 109.18 (23)
H 191)-C 19) -H 192) 109.5( 3)
N 17) -C 20) -H 201) 108.74 (22)
N 17) -C 20) -H 202) 108.73 (22)
N 17) -C 20) -C 21) 112.40 (18)
H 201)-C 20) -H 202) 109.5( 3)
H 201)-C 20) -C 21) 108.75 (23)
H 202)-C 20) -C 21) 108.73 (23)
C 20) -C 21) -H 211) 108.97 (25)
C 20) -C 21) -H 212) 108.98 (25)
c 20) -C 21) -C 22) 111.46 (20)
H 211)-C 21) -H 212) 109.5( 3)
H 211)-C 21) -C 22) 108.96 (25)
H 212)-C 21) -C 22) 108.98 (25)
C 21) -C 22) -C 23) 120.64 (21)
C 21) -C 22) -C 31) 120.50 (21)
C 23) -C 22) -C 31) 118.86 (22)
C 22) -C 23) -H 231) 119.6( 3)
C 22) -C 23) -C 24) 120.78 (24)
H 231)-C 23) -C 24) 119.6( 3)
C 23) -C 24) -H 241) 119.7( 3)
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Table 2.2(c). 212-842 torsion angles(degrees) with standard deviations
H (11) - C (1) - 0(2) - C(3) 168.6( 3) 0(11) -C 12) -C 13) - 0(8) -1.9( 4)
H (12) - C (1) - 0(2) - C(3) 49.0( 4) C (11) -c 12) -C 13) -N (14) 179.24(24)
H (13) - C (1) - 0(2) - C(3) -71.7< 4) H(121) -c 12) -C 13) - 0(8) 178.1( 3)
C (1) - 0(2) - C (3) - 0(4) -3 .1 ( 4) H (121) -c 12) -0 13) -N 14) -0.8 ( 4)
C (1) - 0(2) - C (3) - C(5) 175.54(23) 0(8) -c 13) -N 14) -C 15) 61.8< 3)
0(2) - C (3) - C (5) - N<6) -171.05 (22) 0(8) -c 13) -N 14) -C 19) -169.73(20)
0(2) - C (3) - C (5) - C (9) 6 . 6( 4) 0(12) -c 13) -N 14) -C 15) -119.3( 3)
0(4) - C (3) - C (5) - N (6) 7 . 6( 4) 0(12) -c 13) -N 14) -C 19) 9.2 ( 3)
0(4) - C (3) - 0(5) - 0(9) -174.8< 3) 0(13) -N 14) -C 15) -H 151) -45.4( 3)
C (3) - C (5) - N(6) -H(6N) -2 . 9( 4) 0(13) -N 14) -C 15) -H 152) 74.4< 3)
C (3) - C (5) - N (6) - C (7) 177.10(23) 0(13) -N 14) -C 15) -C 16) -165.46(19)
C (9) - C (5) - N (6) -H(6N) 179.0( 3) 0(19) -N 14) -C 15) -H 151) -177.50(23)
C (9) - C (5) - N<6) - C (7) -1. 0 ( 3) 0(19) -N 14) -C 15) -H 152) -57.7( 3)
C (3) - C (5) - C (9) - C (8) -177.8( 3) 0(19) -N 14) -C 15) -C 16) 62.40(24)
C (3) - C (5) - C (9) -H (91) 2 .2 ( 5) 0(13) -N 14) -C 19) -C 18) 169.16(19)
N(6) - C (5) - C (9) - C (8) 0 . 0 ( 3) 0(13) -N 14) -C 19) -H 191) -70.7( 3)
N(6) - C (5) - C (9) -H(91) 180.0 ( 3) 0(13) -N 14) -C 19) -H 192) 49.0( 3)
C (5) - N<6) - C (7) - C (8) 1. 6( 3) 0(15) -N 14) -C 19) -C 18) -60.19(23)
C (5) - N (6) - C (7) -C(10) -176.9( 3) 0(15) -N 14) -C 19) -H 191) 60.0< 3)
H(6N) - N (6) - C (7) - C (8) -178.4( 3) 0(15) -N 14) -C 19) -H 192) 179.65(23)
H(6N) - N (6) - C (7) -C(10) 3.1 ( 5) N (14) -C 15) -C 16) -H 161) 179.84(23)
N(6) - C (7) - C (8) - C (9) -1.6( 3) N (14) -C 15) -C 16) -H 162) 60.0( 3)
N(6) - C (7) - C (8) -0(13) -179.92(21) N (14) -c 15) -C 16) -N 17) -60.07(24)
C(10) - C (7) - 0(8) - 0(9) 177.07(25) H(151) -c 15) -C 16) -H 161) 59.7( 3)
C (10) - C (7) - 0(8) -0(13) -1.3 ( 4) H(151) -C 15) -C 16) -H 162) -60.1< 3)
N(6) - C (7) -C(10) -H (101) -2.7( 5) H(151) -C 15) -C 16) -N 17) 179.82(22)
N(6) - C (7) -C(10) -C(ll) 177.3( 3) H(152) -C 15) -0 16) -H 161) -60.0< 3)
C (8) - C (7) -C(10) -H (101) 179.0( 3) H(152) -C 15) -0 16) -H 162) -179.8( 3)
C (8) - C (7) -C(10) -C(ll) -1.0 < 4) H(152) -C 15) -C 16) -N 17) 60.0( 3)
C (7) - C (8) - 0(9) - 0(5) 1 - 0( 3) 0(15) -C 16) -N 17) -H 171) -62.52(24)
C (7) - C (8) - 0(9) -H (91) -179.0( 3) 0(15) -c 16) -N 17) -C 18) 55.02(23)
C (13) - C (8) - 0(9) - 0(5) 179.0( 3) 0(15) -c 16) -N 17) -C 20) -179.59(18)
C (13) - C (8) - 0(9) -H (91) -1.0( 5) H (161) -c 16) -N 17) -H 171) 57.6( 3)
C (7) - C (8) -0(13) -0(12) 2.7 ( 3) H(161) -c 16) -N 17) -C 18) 175.10(22)
C (7) - C (8) -0(13) -N(14) -178.38(21) H(161) -c 16) -N 17) -C 20) -59.5( 3)
C (9) - C (8) -0(13) -0(12) -175.1( 3) H(162) -c 16) -N 17) -H 171) 177.37(23)
C (9) - C (8) -0(13) -N(14) 3. 8( 4) H(162) -c 16) -N 17) -C 18) -65.1( 3)
C (7) -C(10) -C(ll) -H (111) -178.1( 3) H (162) -c 16) -N 17) -C 20) 60.3< 3)
C (7) -C(10) -C(ll) -0(12) 1. 9( 4) 0(16) -N 17) -C 18) -H 181) 66.9( 3)
H(101)-C(10) -C(ll) -H (111) 1. 9( 5) 0(16) -N 17) -C 18) -H 182) -173.61(21)
H(101) -C(10) -C(ll) -0(12) -178.1( 3) 0(16) -N 17) -C 18) -0 19) -53.34(23)
C(10) -C(ll) -0(12) -H(121) 179.6( 3) H(171) -N 17) -C 18) -H 181) -174.23(22)
C(10) -C(ll) -0(12) -0(13) -0.5( 4) H(171) -N 17) -c 18) -H 182) -54.8( 3)
H(lll) -C(ll) -0(12) -H(121) -0.4( 5) H(171) -N 17) -C 18) -C 19) 65.49(23)


































































































































































































































































































































































































































































Table 2.3. 212-842 anisotropic Vibration Parameters with Standard Deviations
Ull U22 U33 U23 U13 U12
c 1) 0.0965 25) 0.0768(22) 0.0882 23) 0.0023(19) -0.0026 19) 0.0392 19)
0 2) 0.0844 13) 0.0671(13) 0.0580 11) 0.0041(10) -0.0082 10) 0.0278 11)
c 3) 0.0731 18) 0.0582(17) 0.0511 16) 0.0051(14) -0.0110 14) 0.0070 14)
0 4) 0.1382 20) 0.0962(17) 0.0550 12) 0.0094(12) -0.0229 12) 0.0509 16)
c 5) 0.0642 16) 0.0477(15) 0.0461 14) 0.0018(12) -0.0082 12) 0.0015 13)
N 6) 0.0816 16) 0.0586(14) 0.0420 12) 0.0055(10) -0.0064 11) 0.0077 12)
c 7) 0.0705 17) 0.0521(16) 0.0474 14) -0.0002(12) -0.0013 13) -0.0015 14)
c 8) 0.0551 14) 0.0421(14) 0.0420 13) 0.0005(11) -0.0028 11) -0.0046 11)
c 9) 0.0554 14) 0.0413(13) 0.0436 13) 0.0003(11) -0.0053 11) -0.0014 11)
c 10) 0.0961 22) 0.0733(20) 0.0450 15) -0.0023(14) 0.0083 15) 0.0077 18)
c 11) 0.0878 22) 0.0721(20) 0.0621 18) -0.0066(16) 0.0185 16) 0.0152 17)
c 12) 0.0688 17) 0.0562(16) 0.0578 16) 0.0007(13) 0.0080 13) 0.0084 14)
c 13) 0.0488 14) 0.0415(13) 0.0497 14) 0.0008(11) 0.0000 11) -0.0043 11)
N 14) 0.0397 10) 0.0430(11) 0.0484 11) 0 .0068 ( 9) -0.0004 8) 0.0006 9)
c 15) 0.0397 13) 0.0518(15) 0.0563 15) 0.0116(12) -0.0046 11) -0.0021 11)
c 16) 0.0363 12) 0.0531(15) 0.0570 15) 0.0121(12) 0.0002 11) 0.0081 11)
N 17) 0.0361 10) 0.0309(10) 0.0479 11) 0.0002 ( 8) -0.0033 8) 0.0000 8)
C 18) 0.0332 12) 0.0466(14) 0.0547 14) 0.0008(11) -0.0009 10) -0.0004 10)
C 19) 0.0405 13) 0.0487(14) 0.0563 15) 0.0037(12) 0.0004 11) 0.0041 11)
C 20) 0.0477 13) 0.0401(13) 0.0454 13) -0.0033(11) -0.0001 10) 0.0057 11)
C 21) 0.0623 16) 0.0529(15) 0.0488 14) -0 .0058(12) -0.0071 12) 0.0200 13)
C 22) 0.0457 13) 0.0459(14) 0.0482 13) -0.0045(11) -0.0071 11) 0.0143 11)
C 23) 0.0516 15) 0.0488(15) 0.0677 17) -0.0069(13) -0.0085 13) -0.0004 12)
C 24) 0.0595 16) 0.0586(17) 0.0653 17) 0.0028(14) 0.0033 13) -0.0067 14)
c 25) 0.0599 16) 0.0597(17) 0.0505 15) -0.0001(13) 0.0031 12) 0.0046 14)
0 26) 0.1032 16) 0.0968(16) 0.0519 11) -0.0029(11) 0.0167 11) -0.0117 13)
c 27) 0.1227 31) 0.1217(33) 0.0748 22) 0.0127(22) 0.0346 22) -0.0091 26)
c 28) 0.0504 14) 0.0489(15) 0.0509 15) -0.0086(12) -0.0054 11) 0.0022 12)
0 29) 0.0807 13) 0.0746(13) 0.0630 12) -0.0210(10) -0.0013 10) -0.0155 11)
c 30) 0.0718 20) 0.0676(20) 0.1014 25) -0.0211(18) -0.0106 18) -0.0108 17)
c 31) 0.0439 13) 0.0449(14) 0.0526 14) -0.0015(12) -0.0009 11) 0.0058 11)
0 32) 0.0617 11) 0.0387(10) 0.1050 15) -0.0065(10) 0.0156 10) 0.0054 9)
c 33) 0.0507 15) 0.0377(13) 0.0404 13) -0.0015(10) 0.0001 10) -0.0043 12)
0 34) 0.0526 11) 0.0451(10) 0.0745 12) -0 .007 6( 9) 0.0009 9) -0.0128 8)
c 35) 0.0450 13) 0.0373(13) 0.0619 15) -0.0090(12) 0.0033 11) -0.0054 11)
c 36) 0.0525 15) 0.0541(17) 0.0509 15) 0.0002(12) -0.0045 12) -0.0104 13)
0 37) 0.0439 10) 0.0644(13) 0.1121 16) 0.0003(12) 0.0080 10) -0.0031 10)




There are 3 strong hydrogen bonds between molecules in the crystal
structure of 212-842. The intermolecular distances of these and the
symmetry operators of the groups involved are shown in table 2.4. The
malonic acid forms an intramolecular hydrogen bond between the
carboxyl oxygen 0(32) and the hydroxyl group 0(37)H. The strongest
hydrogen bond is that between the two charged species, namely 212-842
and the malonic acid. There are two other strong hydrogen bonds, these
are between symmetry related molecules of 212-842. As shown in table
2.4 donor H(6N) is bonded to the acceptor 0(4) of a molecule related
to it by symmetry (1-x, l-y,-z). However the H(6N) of this symmetry
related molecule is also hydrogen bonded to 0(4) of the molecule at
(x,y,z). Therefore there are two identical centrosymmetrically related
hydrogen bonds represented by that particular entry in table 2.4.
2.9.2 Crystal packing.
The crystal packing interactions are of two types, namely hydrogen
bonding and hydrophobic ring stacking. The hydrogen bonding has
already been described above. The majority of van der Waals contacts
are between molecules related by the symmetry operation (3/2-
x,l/2+y,l-z) and occur at both ends of the piperazine ring. Thus the
substituted benzene ring stacks to the indolyl ring of the symmetry
related molecule and vice versa at the other end.
2.9.3 Comparison with related structures.
The crystallographic coordinates of two related structures shown in
figure 2.6 were obtained from the Cambridge Structural Database for
use in the comparison. Initially the structures were superimposed
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Table 2.4 The major hydrogen bonding in 212-842 showing distances (A)
and the symmetry operators of the acceptors involved.
H (171) - 0(34)
H(6N) - 0(4)









QUEST88 REFC = CAGXIR
Tranquiliser, Alpha-adrenoreceptor
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+ - plane 2.
212-842 * - plane 1
+ - plane 2
Figure 2.6 Structure of 212-842 showing the related molecules found
in the database search. The atoms defining the planes used
for the interplanar angle and C.O.G/C.O.G. distances are
indicated.
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manually using FRODO on the Evans & Sutherland PS300. The fragment
used in the database search was used as the basis for superposition.
All structures possessed a chair conformation for the piperazine
ring. The equivalent substituent aromatic groups and the two planes
which define them, for all three molecules, are shown in figure 2.6.
All three structures superimposed particularly well and it was clear
that the equivalent substituent aromatic groups were approximately
coplanar and that these planes were almost at right angles to one
another as shown in plate 2.1. The superposition was carried out more
objectively using CALC. It was found that all the interplanar angles
fell within 12° of each other (Table 2.5). The mean value for the
interplanar angle being 77.86 ± 6°. The centres of gravity of these
planar groups at either end of the piperazine ring were calculated
using CALC, for all the structures and their separations compared
(Table 2.5). The centres of gravity of the planar moieties at either
end of the piperazine ring have a mean separation of 11.15 ± 0.2lA.
Further analysis of similar compounds may prove the interplanar angle
and the C.O.G./C.O.G distance to be important structural features
related to their activity. Additional work may be necessary to show
these structural features are retained when these compounds are in
solution but that is beyond the scope of the work here. It may be that
there are other structural features that are common to this group of
similar compounds that may be understood once the structure of then-
receptors has been elucidated.
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Plate 2.1 Stereo picture of the superposition of 212-842 with two
related molecules. Superposition was performed manually
using FRODO as described in the experimental section.
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Table 2.5
Structural features identified with 212-842 that are shared by two other
molecules of similar biological activity.




CAGXIR ** 78.31 11.16
COKTAX ** 71.81 10.92
*








A necessary requirement for any structural studies on a protein is
that the protein be available to a high level of purity and in
relatively large quantities. Typically from 20 mg up to gram
quantities may be required. Such large quantities are required for
crystallisation trials and for the crystal structure determination
itself. Thus the protein has to be purified on a large scale from some
tissue in which the protein is abundant. More recently, some
genetically engineered organism in which the protein has been cloned
and over expressed can be used.
The non-venom extracellular phospholipase-A2 enzymes (phosphatide
acyl-hydrolase, EC 3.1.1.4), due to their relative abundance and their
stability, have been purified to homogeneity in a number of species.
The extracellular enzyme is synthesised in the pancreas as a pro¬
enzyme which is activated by trypsin in the stomach by removal of the
N-terminal heptapeptide. Pancreatic tissue of ox (Rimon & Shapiro,
1959), man (Magee et al., 1962), horse (van den Bosch et al., 1965)
and rat (Hanahan, 1962) have been used as the enzyme source. The
purification of these extracellular enzymes has been facilitated by
the observation that they are stable at elevated temperatures and
acidic pH. The method described here is based on that used to purify
Bovine P1A-2 (Dutihl et al., 1975) and equine P1A-2 (Zurini, M.
personal communication). Since the amino acid sequences of these
extracellular PlA-2's are very homologous, the general methods used in
their purification are also very similar. Only the chromatographic
properties of the different enzymes require alterations to the
conditions used in the purification. Typically 200-300 mgs of pure
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enzyme can be obtained per kg of pancreas. The aim of the purification
was to obtain sufficient quantities of the zymogen and the active
enzyme from sheep pancreas for structural studies. No crystal
structure has yet been obtained for any of the extracellular pro-
phospholipase A2's, although the mechanism of activation is well
understood.
3.2 Materials and Method.
3.2.1 Materials.
Bovine Trypsin (Type III) and phenylmethylsulphonylfluoride (PMSF)
were obtained from Sigma. All other reagents were of reagent-grade
purity. Diethylaminoethyl cellulose (DE-52) and Carboxymethyl
cellulose (CM-52) were purchased from Whatman and treated according to
the manufacturers instructions. The stirred cell membranes (YM10) were
purchased from Amicon and treated according to the manufacturers
instructions prior to use.
3.2.2 Protein measurement.
Protein concentration was measured either by the Lowry procedure
(Lowry et al., 1951), using crystallised bovine serum albumin (Sigma)
as standard, or spectrophotometrically at 280nm using the molar
absorbance coefficient A^ % jcm = 13 determined previously for the
bovine pro-enzyme (Dutihl et al., 1975).
3.2.3 Gel electrophoresis.
The electrophoretic procedures used were those of Laemmli
(Laemmli, 1970). Standards used were low molecular weight
markers (Sigma) and Bovine phospholipase A2 (Sigma). All gels
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were 12.5% acrylamide unless otherwise specified.
3.2.4 Tissue homogenisation and heat treatment.
Ovine pancreas was harvested from freshly slaughtered animals and
stored over ice during transportation to the laboratory. Subsequent
operations were carried out in a cold room at 4°C. The pancreas were
defatted and connective tissue removed before being cut into small
pieces. The tissue was then homogenised in 3000 ml/kg of ice-cold 150
mM NaCl using a Waring blendor. Homogenisation was carried out in
three bursts of 3mins in duration. A 2 minute period between each
burst was allowed for cooling purposes. The pH of the homogenate was
adjusted to 4.0 using 6M HC1 under efficient stirring. The homogenate
was then heated rapidly under efficient stirring to 70 °C and the
temperature held for 3 minutes. The homogenate was then rapidly cooled
to 4°C using an acetone/dry-ice mixture. This was also performed under
efficient stirring. The homogenate was then centrifiiged for 30 mins at
20 OOOg in an ultracentrifuge at 4°C and the supernatant harvested.
The supernatant was freed from fat by filtration through filter paper
after addition of 5-10 g of Hyflo supercel/1 of supernatant.
3.2.5 Ammonium sulphate fractionation.
The filtrate was brought to pH 7.0 with concentrated ammonia
solution. Solid ammonium sulphate (333.1 g/1 of filtrate, 0.4S, where
S refers to fractional saturation) was slowly added under efficient
stirring. The solution was stirred at 4°C for 2 hours. The subsequent
precipitate was removed by centrifugation in a ultracentrifuge for
30mins at 20 OOOg at 4°C. From the clear supernatant the enzyme was
precipitated by a second addition of solid ammonium sulphate (129 g/1
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of filtrate, 0.65S) which was slowly added under efficient stirring.
The solution was again stirred at 4°C for 2 hours before the
subsequent precipitate was removed by centrifugation for 30 mins at 20
OOOg and the supernatant discarded.
The precipitate was redissolved in a minimal amount of distilled
water using a combination of gentle agitation and sonication. To this
was added 5 vol-% of 0.1M solution of phenylmethylsulphonyl
-fluoride (PMSF), in dry isopropanol. The resulting protein solution
containing PMSF was then dialysed overnight in running water at 4°C.
The small precipitate formed was removed by centrifugation for 20
minutes at 15 900g at 4°C. After further addition of 2 vol-% 0.1M PMSF
solution, the solution (approximately 250mls) was lyophilised.
3.2,6 Ion exchange chromatography.
Two chromatographic steps were used to purify the zymogen. The first
was an anion exchange step and this was followed by a cation exchange
step. The lyophilised material (about 6g) was dissolved in 150 mis of
5mM Tris-HCl buffer pH 8.0 at 4°C. The subsequent chromatographic
steps were carried out at 4°C.
DE-52 Chromatography.
The first step was carried out using an anion exchange column of
dimensions 1.5 cm x 12.5 cm. The matrix was equilibrated in 5mM Tris-
HCl buffer pH 8.0 in the cold room at 4°C. 150mls of protein solution
was applied to the column using a peristaltic pump at a flow rate of
1.5 mls/min. This was followed by 1000 mis of buffer. After the non
absorbed proteins had been eluted, a linear salt gradient of 1.51 of
5mM Tris-HCl buffer from 0 to 0.4M NaCl was used to elute the
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remaining proteins from the column. The samples were collected in 10
ml fractions. The absorbance at 280nm was measured on a Philips PU8700
spectrophotometer. Only fractions containing significant protein as
determined from their A280nm were assayed for enzyme activity. Those
fractions containing enzyme activity after trypsin activation were
pooled and dialysed against 2x5 litres of 5mM acetate/acetic acid
buffer pH 6.0 at 4°C to remove salt and exchange the buffer. The
solution was then concentrated to a final volume of 25 mis using a
stirred cell containing a YM10 membrane (Amicon,) which has a
molecular weight cut-off of ten thousand. This was not necessary since
the next stage was an ion exchange column, but it was done to speed up
the purification as there was such a large volume of dialysed
material.
CM-52 Chromatography.
The secondstep was carried out using a cation exchange column of
dimensions 1.5 x 12.5 cm. The matrix was equilibrated in 5mM sodium
acetate/acetic acid buffer, pH 6.0 at 4°C. A volume of 25 mis of
protein solution (approximately lOmg/ml) was applied to the column
using a peristaltic pump at a flow rate of 1.5 mls/min. After the non-
absorbed proteins had passed through the column, a linear gradient of
200 mis 5mM acetate buffer containing 0 to 0.4M NaCl was used to elute
the remaining proteins from the column. The non absorbed proteins were
collected in fractions of 10 mis whereas the proteins eluted with the
gradient were collected in 5 ml fractions. The protein concentration
of the fractions was determined by the absorbance at 280nm using a Pye
Unicam SP1800 spectrophotometer.
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3.2.7 Trypsinisation of sample for assay.
Trypsinisation was based on the the method of Abita & Lazdunski,
(1972). Samples (0.1ml) were added to the activation buffer (0.9ml)
prior to the addition of trypsin (1/xg). The activation was carried out
at 4°C and pH 8. The activation buffer contained lOmM CaCl2, lOmM
Tris-HCl buffer pH 8. The final concentration of the activating
trypsin was l^g/ml and was added from a stock solution of lmg/ml. The
incubation volume was 1ml. The period of activation was 60 mins.
Tryptic digestion of the enzyme was stopped by dilution (1:600) of
this sample (50fil) in the assay mixture (30mls).
3.2.8 Enzyme Assays.
Phospholipase A2 activity was routinely measured potentiometrically
in a pH-stat Radiometer TTT1C autotitrator equipped with a SBU-la
syringe and a combined glass-calomel electrode at 40°C using 0.1M NaOH
as the titrant. The action of the enzyme on the phospholipids is to
liberate a fatty acid into the medium. This acid is titrated by alkali
and the pH of the medium is maintained at pH 8. The volume of the
autoburette was 2.5mls and the consumption of alkali was automatically
recorded. As substrate, an aqueous emulsion of egg yolk was used,
prepared by homogenizing one egg yolk in 100 ml of water. Per assay,
10 ml of the yolk emulsion was diluted to 30 ml with stock CaCl2 and
sodium deoxycholate solutions, the final concentration of sodium
deoxycholate and CaCl2 in the assay mixture being 2.7x10~3m and
6.0x10"3m, respectively. Nitrogen was bubbled through the assay mix
for 15 minutes and then the pH was adjusted to 8.0 prior to the
addition of enzyme. The enzyme had been activated as described
previously. Basal activity was measured for 31/2 minutes for each assay
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mixture before the addition of enzyme. The volume of activated sample
used in the enzyme assay was 50/xl. The consumption of alkali was
measured over a seven minute period after the addition of the sample.
Activity is expressed as the uptake of alkali in /iequiv/min and was
calculated by measuring the activity and subtracting basal activity.
Thus one unit of activity liberates one micromole of titratable fatty
acid per minute in the egg yolk suspension at pH 8.0 and 37°C under
the specified conditions. Specific activity is given by the number of
fiequiv of alkali consumed per min, per mg of protein. The assay system
was initially tested using known amounts of firstly 0.1 M HC1 and then
bovine phospholipase A2 (Sigma: 48 units/mg protein) and shown to be
over 95% accurate in both cases.
3.2,9 Bulk activation of pro-phospholipase by trypsin.
The typical activation was carried out at pH 8.0 at 4°C, in 50 mM
Tris-HCl, lOmM CaCl2 for one hour. Trypsin solution was freshly made
up at a concentration of 1 mg/ml in the same buffer. The necessary
volume of trypsin solution was added to the protein solution giving a
relative molar ratio of trypsin to pro-phospholipase in the activation
mixture of 1:100. After 30mins of incubation a second quantity of
fresh trypsin was added. The activation was terminated by lowering the
pH of the solution to 6.
3.3 Results.
The results of the initial purification are shown in table 3.1. The
total amount of defatted pancreas used was 1.35kg. This produced
approximately 4.351 of crude homogenate. Subsequently this was reduced
to 3.31 after heat treatment and removal of cell debris and
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Table 3.1. Purification of pro-PLA-2 from Ovine pancreas.
Specific activities were measured after the activation of the
enzyme with trypsin, in the egg yolk assay as described in
the methods, and are expressed in jiequiv. acid released




























105 35 779 5.8 63 6175
4. DE-52
chromatography 60 25 556 54.1 45 472
S. CM-52
chromatography
40 20 445 87 36 235
* Determined as Phospholipase A2 activity after activation of the zymogen with Trypsin.
** 1.35 kilograms of defatted pancreas was homogenised as described in the protocol.
+ No activity could be detected on account of the endogenous Trypsin inhibitors.
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precipitated protein. After rapid cooling there was a large floating
layer of fat. After its removal, the final quantity of the pale
yellowliquid was 3.295 litres. These initial stages of the
purification were also followed by gel electrophoresis using various
samples from the specified stages, Plate 3.1. Approximately 6g of
lyophilised material was obtained after the ammonium sulphate
fractionation. On redissolving, this lyophilised material has a slight
yellow colour to it. The elution profile of ovine prophospholipase
from the DE 52 column is shown in Fig. 3.1, which yielded one peak
containing activity which eluted at approximately 65mM NaCl. The first
and main peak eluted by the NaCl contains this activity, however it is
not clear that this is a single peak and may be a combination of
unresolved peaks. The material containing the yellow colour did not
absorb to the exchanger and was obtained with the flow-through along
with the non absorbed proteins. The flow-through contained no
detectable enzymic activity after tryptic activation. From a protein
estimation of the pooled fractions after dialysis it was estimated
that there was 295mg of prophospholipase A2. This extensively dialysed
material was applied to the CM 52 column. The elution profile from
this is shown in Fig 3.2. The small peak associated with the flow-
through did not contain any detectable activity after tryptic
activation. A single peak was eluted at approximately 240mM NaCl.
These fractions possessed associated activity after activation by
trypsin. Electrophoresis of both a fraction from this peak and the
same fraction after trypsin activation are shown in Plate 3.2, showing
the slight molecular weight shift associated with activation. The two
samples have the apparent molecular weight of Mr 14 400 for the
















SDS-PAGE of samples from the purification of Ovine
pro-PIA-2. Low molecular weight markers (Sigma) are shown
in lanes A and I. The soluble component of the crude
homogenate is shown in B, C is this fraction after heat
treatment at pH 4. Lane D shows the soluble fraction C after
removal of the floating fat layer. Lane E shows the soluble
proteins at 0.4s and F shows the soluble proteins at 0.65s.
Lane G contains purified ovine pro-PIA2 and lane H contains
Bovine PIA2 (Sigma).
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Figure 3.1. Elution profile of ovine pro—phospholipase A2 from a DE52
column (1.5 cm x 50 cm) at pH 8.0. , absorbance at 280nm; ,
enzyme units/ml after activation by Trypsin. The peak associated with




















Figure 3.2. Elution profile of ovine pro-phospholipase A2 from a CM52
column (1.5 cm x 12.5 cm) at pH6.0. , absorbance at 280nm; ,
enzyme units/ml after activation by Trypsin. The gradient applied
















SDS-PAGE of purified ovine pro-PIA-2 before and after
activation by trypsin. The activation was carried out as
described in the methods. Lanes A and H contain low
molecular weight markers (Sigma). Lanes B and G contain
Bovine PIA2 (Sigma). Different loadings of ovine pro-PIA2
are shown in lanes C and F and different loadings of the
activated enzyme are shown in lanes D and E.
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active form of the enzyme (from amino acid analysis Mr « 13 820). The
zymogen fractions were treated with PMSF and freed from salt by
extensive dialysis at 4°C against distilled water. The yield after
lyophilisation was 235 mg (= 79.6 % of column charge). The total
recovery of zymogen was 89 %; however, a few fractions having a
somewhat lower specific activity were discarded. The zymogen
preparation as shown by gel electrophoresis (Plate 3.2) was at least
95% pure.
3.4 Discussion.
The use of freshly slaughtered pancreas for the isolation of the
zymogen is crucially important. It has been shown that even after only
two weeks in the frozen state, enzyme activity can be detected in
porcine pancreas (Rimon and Shapiro, 1959) which has been attributed
to activation of a fraction of the zymogen. Despite the presence of
trypsinogen and trypsin in the pancreas, the need for the addition of
anti-trypsin inhibitors during the initial homogenisation stages was
not required. The pancreas also contains more than adequate supplies
of endogenous trypsin inhibitors (Fritz et al., 1967). However these
are only effective during the initial stages of the purification.
These natural inhibitors are either so effective or so abundant that
no enzymic activity was detected in the crude homogenate after tryptic
activation. All the steps after the ammonium sulphate fractionation
were carried out in the presence of PMSF. This regime proved effective
since none of the samples obtained prior to the salt precipitation
contained a measurable activity before activation by trypsin. It is
clear that the ovine enzyme is stable to heating at 70 °C for 3 minutes
at low pH, since no dramatic loss of activity was seen. Indeed it is
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clear this is quite an effective purification step. Other workers have
noted that the enzyme is stable at these high temperatures, even up to
97 °C for a bacterial source (Hayaishi & Kornberg, 1954). The heat
stability has been attributed to the presence of seven disulphides,
which in such a relatively small protein provides structural
stability. The structural stability conferred to the enzyme can be
more easily understood from the locations of these bonds in the three
dimensional structure itself. This is shown for the bovine enzyme
(figure 1.4) in Chapter 1.
One of the consequences of this heat treatment, which has been
previously identified, is the formation of pyro-glutamic acid at the
N-terminus. This has been shown in the purification of the equine
zymogen (Zurini, M. personal communication) and in the porcine zymogen
(de Haas et al., 1968). It has not been shown that any other residues
of the zymogen have undergone rearrangements at these temperatures.
From the gel, Plate 3.1, it is clear that there is very little loss of
material with the removal of the floating layer of fat. There is
undoubtedly some loss of material but this is not a major problem.
This small loss is due to the association of the zymogen with the
fatty material. Unfortunately this is unavoidable but both the rapid
cooling to a low temperature and the low pH help to minimise this
association. Work on porcine phospholipase A2 has shown that if the pH
is raised to pH 7 before filtration almost all the enzyme was bound to
the insoluble material (de Haas et al., 1968). This material can be
recovered from the insoluble material by treatment with sodium
deoxycholate and solvent extraction with n-butanol to remove the
lipids. This was not necessary in this case, since a substantial
fraction of the zymogen remained soluble.
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Despite being an excellent purification step (Plate 3.1) there is a
quite substantial loss of activity after the ammonium sulphate
fractionation (37% from Table 3.1). This suggests that the
fractionation limits used 0.4s-0.65s (used for bovine and equine
purification) are not optimal for the ovine purification. From the
electrophoresis of these fractions (Plate 3.1) it is clear that a
significant fraction of the enzyme is still soluble at 0.65s. There
are also very few other proteins which are soluble at this
concentration of ammonium sulphate. This upper concentration would
therefore need to be raised for a more optimal purification of the
ovine enzyme. This would not greatly affect the overall purification
of the enzyme but would significantly improve the yield. The
observation that the enzyme is more soluble in ammonium sulphate
solutions than the bovine and equine enzyme might be of relevance when
it comes to crystallisation trials with the enzyme.
The first chromatographic step, anion exchange with DE-52 (Figure
3.1), produced only two main eluted peaks - the largest containing the
activity. This indicates that the initial stages were indeed excellent
purification steps. Indeed this elution profile is very similar to
those obtained for both bovine (Dutihl et al., 1975) and equine
(Zurini, M. personal communication) forms of the zymogen. The presence
of multiple forms of the ovine zymogen were not detected either by the
assay system or during the chromatographic steps. However, the major
peak of the elution profile of the DE 52 column suggests the presence
of other unresolved peaks. Two prophospholipases have been found for
the porcine zymogen (Nieuwenhuizen et al., 1973). The difference
between the two has been shown to be located in the activation
peptide. The major form has the heptapeptide with the pyroglutamic N-
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terminus whereas the minor form (4%) is shorter and contains only the
three amino acids Ser-Ser-Arg. It is thought that this second form
could be generated from the first by cleavage with elastase, since it
can be produced in vitro this way. However, it may be a possibility
that this minor form is also a naturally occuring zymogen. These forms
have slightly different isoelectric points and consequently it would
be expected that they would behave differently on chromatographic
steps. However, from the elution profile of the CM52 chromatographic
step, it is clear that there is only one form, Figure 3.2. The
electrophoresis (Plate 3.2) also indicates a single species, but it is
doubtful that two species differing by three amino acids could be
resolved under the conditions used in the electrophoresis despite it
being possible to detect a molecular weight shift on tryptic
activation where there is a difference of seven amino acids. Also
since ovine PLA-2 runs as a rather broad band it is not possible to
detect multiple forms even if they were present. However, since
trypsin activation yields the same active enzyme regardless of the
sequence of the pro-peptide, the exact sequence of the activation
peptide of the purified zymogen has not been determined. It has been
shown for the porcine enzyme that the tryptic activation kinetics of
these two prophospholipases are very similar (Nieuwenhuizen et al.,
1973). Thus the activity measurements carried out during the ovine
zymogen purification are not affected by the possible existence of two
zymogens. It must also be noted that the activity measurements were
carried out using Ca^+ and deoxycholate concentrations that were
optimal for porcine P1A-2 (Nieuwenhuizen et al., 1974). It is known
that the optimal conditions with respect to Ca^+ and deoxycholate
concentrations for enzymes from different sources can be very
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different (Figarella et al., 1971;Evenherg et al., 1977) in this type
of assay. Every enzyme has its characteristic optimum for these two
components. These concentrations not only affect the rate of
hydrolysis but also affect the linearity of the reaction with time.
Outside the optimal conditions the reaction rapidly slows down with
time, an effect that also has negative influence on proportionality
between enzyme concentration and velocity (Verheij et al., 1981). The
activities measured for the ovine enzyme are of a similar magnitude to
those measured during the purification of the bovine enzyme (Dutilh et
al., 1975). The activity of bovine and the measured activity of the
ovine enzyme are both considerably smaller than those obtained for the
porcine form, which possess an activity an order of magnitude larger
(de Haas et al., 1968). However the ruminant bovine phospholipase has
been shown to be as active as the porcine enzyme in kinetic
experiments with dioctanoyllecithin (Dutilh et al., 1975). The low
activity of the ruminant enzyme in the egg yolk assay system (mixed
micelles of phospholipid + bile salts) was therefore attributed to a
weak interaction between the enzyme and the organised lipid-water
interface. Similar kinetic experiments on the ovine enzyme have not
been carried out using dioctanoyllecithin. It is possible that a weak
interaction between the enzyme and the organised lipid-water interface
may also occur. This would explain the relatively low activity of the
ovine enzyme, another ruminant enzyme, in this assay system. Since
enzyme activity was being used only as a diagnostic of PLA-2 presence,
the relatively low enzymic activity in the egg yolk assay has not
hindered the purification of the enzyme.
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The purpose of this chapter is to give a brief introduction to the
theory of the methods used in the production of protein crystals. Some
of these methods are applied in the attempted crystallisation of
salmon calcitonin (sCT), two derivatives of salmon calcitonin and also
the co-crystallisation of equine phospholipase-A2 with an inhibitory
compound.
The determination of three-dimensional protein structures, as
described for the small molecules in chapter 2, using X-ray
crystallography, is mainly limited by the ability to grow crystals. A
crystal, whether it be of a simple salt or of a complicated protein,
represents an ordered array of molecules extending in three
dimensions. The crystallisation of macromolecules is a relatively
ancient chemical procedure (Osborne, 1892), and has also been used as
a criterion of purity in protein purification. The principles of
crystallisation for any protein are little different to those of
conventional small molecules. The primary differences in protein
crystallisation are due to the nature of the protein molecules
themselves and arise from the size, low symmetry, large solvent
content and small binding energies of proteins in crystals. The latter
causes the protein crystals to be soft and sensitive to small changes
in external conditions. The solution behaviour of macromolecules is
complex and rather unpredictable owing to their varied shapes,
polyvalent surface character and dynamic properties. Macromolecules
can demonstrate a number of distinct solubility minima. These depend
on the nature of the electrolyte, the precipitant, their
concentrations, the concentration of the macromolecule, pH,
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temperature and a variety of other parameters.
The crystallisation of molecules from solution is a reversible
equilibrium phenomenon, the specific parameters required for the
crystallisation depend on the chemical and physical properties of the
solvent and solute involved. However, only under conditions of
supersaturation will this equilibrium be driven towards a state where
the solute will be partitioned between a soluble and solid phase. The
formation of this solid phase obviously results in loss of entropic
energy. This is compensated for by the formation of many new stable
chemical bonds. Thus the driving force in this equilibrium is the
minimisation of the free energy, which can only be achieved by the
ordering of the system in the solid phase - the crystal.
While the crystallisation of small molecules can be scientifically
treated (Strikland-Constable, 1968), macromolecular crystallisation is
more complex, less easily described and poorly understood. In
macromolecular systems the equilibrium often leads to what is called
an "amorphous precipitate". In energy terms this corresponds to one
local minimum and frequently occurs when aggregation occurs too
rapidly. Experience has shown that if supersaturation can be
approached slowly it can afford the molecules sufficient time to
orient themselves into a crystalline lattice. Thus the technique of
macromolecular crystallisation is to bring the system very slowly to a
state of minimum solubility and thus achieve a degree of
supersaturation.
The approach to supersaturation can be achieved in basically two
ways. In the most common case, the precipitant level is gradually
increased until the solubility minimum is reached. A more subtle
technique is to increase the precipitant concentration beyond the
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normal precipitation point of the protein, but at a temperature or pH
at which the protein is still soluble. The temperature or pH are then
allowed to relax slowly to a desired value and produce
supersaturation. There are three main categories of precipitants which
are often used in crystallisation trials: salts, such as ammonium
sulphate; organic solvents, such as ethanol and methylpentanediol; and
the polyethylene glycols. The success of these materials to induce
crystallisation probably reflects the fashion of crystallographers
rather than some innate quality of the materials themselves. There is
also a wide range of methods available to produce the desired
supersaturation. These have been reviewed elsewhere (McPherson, 1982),
but the most common methods include direct addition, interface
diffusion, microdialysis, vapour diffusion and slow cooling. The most
commonly used method is the vapour diffusion or hanging drop
technique. In this technique a small droplet (6 to 40 /xl), containing
the macromolecule, a buffer and a precipitating agent is equilibrated
against a reservoir containing a solution of the precipitant at a
higher concentration than that of the droplet. This is achieved by
placing the droplet on a glass slide which is then inverted over the
well containing the reservoir solution. Equilibration proceeds by
evaporation of volatile species (normally water) until the vapour
pressures are the same in the reservoir and the droplet. As
evaporation progresses from the droplet, supersaturation develops and
can induce crystallisation.
While there are methods and precipitants that have often been proved
to be successful, the crystallisation of a new protein is achieved by
a very much trial-and-error approach. Thus protein crystallisation
remains unpredictable and is still regarded as more of an art than a
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science. Attempts have been made to provide a more scientific approach
to protein crystallisation. Much work has centred on the theory of
protein solubility. The effect of salts on solubility has been
explained in terms of the electrostatic interaction between small ions
and protein charges, or dipoles, by the Debye-Huckel theory (Edsell &
Wyman, 1958). Hydrophobic interactions have also been studied and
shown to be of importance in protein-protein and protein-ligand
interactions (Kauzmann, 1959). More recent work has concentrated on
the study of protein solubility and preferential solvent-protein
interactions at high concentrations of co-solvent (Arakawa &
Timasheff, 1982). Much of this work has been based on the results
obtained for only a handful of abundant proteins such as 15-
lactoglobulin (Treece et al., 1964). The necessary parameters required
for such work having been determined by exhaustive experimentation.
Thus the application of a theoretical approach to the solubility of
new and less abundant proteins is limited.
The process of crystallisation can be reduced to three distinct
phases: (1) nucleation, (2) post-nucleation growth and (3) cessation
of growth. The nucleation stage is a very important step in the
production of crystals and represents the formation of ordered
aggregates. Post-nucleation growth involves various parameters
determining the rate of growth of the crystal. Cessation of growth is
of importance in protein crystallisation because often crystals are
very small. The factors that prevent the growth of crystals are poorly
understood. The nucleation process has been the subject of the work of
Kam et al., (1987), using lysozyme as a model system. This work
produced a theoretical model of the crystallisation process for
understanding nucleation using quasi-elastic light scattering.
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Crystallisation is described as a cooperative step-by-step addition of
monomers, whereas amorphous precipitation is described as a non-
cooperative polymerisation process. According to this theoretical
model, in solutions leading to crystallisation, an abrupt change in
aggregate size is predicted, whereas a nearly linear variation is
expected for precipitating solutions. However, the conclusions of this
model have not been generalised to many other systems (Baldwin et al.,
1986; Carter et al., 1988). Quasi-elastic light scattering has also
been used to study the suitability of solvent conditions
(precipitating agent and buffer) for crystallisation assays (Mikol et
al., 1990). Using concanavalin A and lysosyme it was demonstrated that
the concentration dependence of the translational diffusion
coefficient could be correlated to the ability to crystallise. If the
diffusional coefficient varies in a solvent concentration-dependent
way, then the protein will not crystallise when the solution becomes
supersaturated. In contrast solvents which do not produce variations
in the diffusional coefficient under the same conditions will lead to
crystallisation under supersaturated protein concentrations. The
explanation for this is that under such conditions up to saturation,
the proteins remain essentially monodisperse. This work been applied
to the crystallisation of yeast aspartyl-tRNA synthetase (Mikol et
al., 1990b). Another, less theoretical, approach to improving the
search for crystallisation conditions is the use of incomplete
factorial experiments (Carter & Carter, 1979). The method attempts to
reduce the number of experiments of the more traditional systematic
approach to protein crystallisation. The factorial method utilises
statistical treatment of "individual factors", the permutations of
these are randomly assigned. The problem with this type of study is
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that the results are semi-quantitative and are of little use when only
amorphous precipitates are obtained.
The setting up of crystallisation trials is by no means trivial and
is rather time consuming. A recent technical development for the
hanging drop method has been an automated liquid handling system (Cox
& Weber, 1987). The system is under computer control and consists of a
pipetting station and multiport rotary valve. This can significantly
increase the rate at which experiments are set up and facilitates the
systematic studies of protein crystallisation.
The hanging drop method, which is a vapour diffusion technique, is
the most commonly used method for protein crystallisation. A
theoretical model has been recently proposed to describe the hanging
drop method (Fowlis et al., 1988). One of the main conclusions of this
model was that the rate-limiting step is diffusion of water vapour
across the air space separating the drop and the reservoir. Water
equilibration rates in the hanging drop method have been studied with
different precipitating agents (Mikol et al., 1990). The rate has been
shown to be significantly affected by two parameters namely
temperature and initial drop volume, equilibration rates being slower
at lower temperatures and larger initial drop volumes. This study
indicated that the presence of protein in the drop does not affect the
equilibration rate of the water to any significant extent. The other
parameters which also affect the rate are the water vapour pressure of
the reservoir, the nature of the precipitant and the dilution factor
of the drop relative to the reservoir. The time for water
equilibration has been shown to vary between about 25 hours and 25
days, depending on the experimental conditions.
However, despite these advances in experimentation and understanding
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of the crystallisation process, the complete picture is far from
clear. In the cases where proteins have failed to crystallise no
attempts have been made at an explanation. Undoubtedly, understanding
why a protein resists crystallisation is as important as understanding
why it does.
4.2 Materials and methods
4.2.1 Salmon calcitonin
The salmon Calcitonin (sCT) was prepared by solid-phase chemistry,
purified by preparative HPLC and was the generous gift of Sandoz AG.
The peptide was obtained as a precipitate from tri-fluoroacetate. The
counterion was replaced by acetate using FPLC on a G-25 column
equilibrated in 50% Acetic Acid. The peak was collected and
lyophilised before being used in crystallisation trials. The purity of
the salmon Calcitonin was assessed by amino acid analysis using an LKB
44000 amino acid analyser. The peptide was hydrolysed at 110°C for 24
hours in an evacuated sealed tube containing 6 N HC1.
4.2.2 Salmon calcitonin derivatives
Two derivatives of salmon calcitonin were also used in
crystallisation experiments. Both were prepared by solid phase
chemistry in the same way as salmon calcitonin, purified by
preparative HPLC and were also the generous gift of Sandoz AG. No
further purification was necessary and no amino acid analysis was
carried out on either derivative. The structures of the two
derivatives are shown in Figure 4.1. The Na-isocaproyl-[Ala7]-salmon
calcitonin (5-32)-amide is a derivative that despite the loss of the
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Derivative 1. Molecular weight: 3082.5
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The linear sequence of the two derivatives of salmon calcitonin used in the
n 1
crystallisation trials. These were: Derivative 1 - N -Isocaproyl-[Ala ]-salmon
calcitonin-(5-32)-amide; Derivative 2 - Na-Isocaproyl-[Ala7, TyrO^-I^^-salmon
calcitonin-(5-32)-amide. Also shown are the Molecular Weights and Formulae of both.
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amino terminal region still possesses some activity. The iodinated
derivative Na-isocaproyl-[Ala7,Tyr(3,5-12)22] salmon calcitonin (5-32)
amide was available for use as a potential isomorphous derivative for
the sCT analogue. The location of the iodine atoms in the unit cell
would permit the phasing of the reflections. The iodinated derivative
was kept in the dark and at -40 °C prior to use.
4.2.3 Buffers
The buffers used in all the crystallisation trials and the range of
pH's for which they were used are shown in Table 4.1. All buffers were
lOOmM and contained 0.02% sodium azide. The buffers were filtered
prior to use through Durapore membrane filters, pore size 5/zm
(Millipore).
4.3 Crystallisation by slow cooling
This method was the initial method used for the attempted
crystallisation of calcitonin, since this method has been successfully
applied to the crystallisation of some other small polypeptide
hormones such as glucagon (Sasaki et al., 1975) and avian pancreatic
polypeptide (Wood et al., 1977). This method was applied only to the
native hormone (sCT) and not the two derivatives.
General experimental set up
Buffered protein solutions were produced by addition of buffer at
70°C to lyophilised protein. These were then freed of any particulate
material by centrifugation on a bench centrifuge for 5 minutes at
13000 rpm. A 5/xl volume of this solution was placed in a melting point
tube using a Hamilton syringe. The melting point tubes had been
previously washed with an ethanol/water mixture and oven dried. To
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Table 4.1 Buffers used in all the crystallisation trials showing the pH
range for which they were used.
Buffer pH range used
Glycine - HC1 3.0-3.8
Sodium Acetate - Acetic Acid 4.0 - 5.0
Sodium Cacodylate - HC1 5.2 - 6.8
Imidazole* -HC1 7.0 - 7.8






this was added an equal volume of precipitant at 70 C. The melting
point tube was sealed and placed in a water bath at 70 °C for at least
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2 hours before being suspended in water at 70 C within a Dewar flask.
The flask was sealed and further insulated by surrounding it with
polyurethane foam. The boiling point tubes were left in this
arrangement for five days after which time the water in the flask had
reached room temperature. The tubes were examined under a light
microscope for any signs of crystallisation. Only five pH's were
studied in these experiments namely 4, 5, 6, 7, and 8. An initial
experiment was carried out to determine the maximum peptide
concentration which was not supersaturated in the absence of
precipitating agents, under the experimental conditions. Subsequent
experiments were performed to study the effects of a variety of
different precipitants and effects of pH on the solubility of
calcitonin under the experimental conditions.
4.3.1 Effect of calcitonin concentration
Stock solutions of calcitonin at each pH were produced by dissolving
5 mg of calcitonin in 50 yil of 0.1M buffer at 70°C. These were then
spun for 5 minutes at 13000 rpm on a bench centrifuge. The stock
solutions were thus 100 mg/ml. These were subsequently used to make
further dilutions with buffer at 70 °C to produce calcitonin solutions
approximately 50, 25, 10 and 5 mg/ml. The melting point tubes
containing these solutions were incubated as described previously.
4.3.2 Effect of some divalent metal ions
Calcitonin is known to affect calcium metabolism in osteoclasts
(Maclntyre et al., 1987) and transmembrane zinc transport in Leydig
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cells (Chausmer et al., 1989). Additionally the crystallisation of
some small polypeptides, for example insulin (Adams et al., 1969) and
avian pancreatic polypeptide (Blundell et al., 1981), has required the
presence of a divalent metal ion. The possible requirement of a
divalent ion in the nucleation process leading to crystallisation was
investigated. Calcitonin was dissolved in buffer at 70 °C to a final
concentration of 50 mg/ml. To this was added an equal volume of a
solution of either ZnSC>4 or CaCl2 also at 70 C. The final
concentrations of these salts were 14.6 mM, 29.2 mM, 43.8 and 100 mM.
This represented a molar ratio of calcitonin:divalent ion of 1:1, 1:2,
1:3 and 1:6, the assumption being that calcitonin Mr= 3431.9. The
final calcitonin concentration was 25 mg/ml.
4,3.3 Effect of some organic solvents
A number of organic solvents have been used in the crystallisation of
small polypeptides, for example bovine growth hormone (Bell et al.,
1985). The solvents which were used in these slow cooling trials were
ethanol, dimethyl-sulphoxide (DMSO), dimethyl-formamide (DMF), 2-
methyl-2,4-pentanediol (MPD). Two other solvents used were tri-
fluoroethanol (TFE) and methanol, both of which have been shown from
CD experiments to induce a-helix. All of the solvents were of (AR)
grade. A stock solution of sCT (50mg/ml) was diluted with an equal
volume of the organic solvent within the boiling point tube to produce
an approximately 50% (vol/vol) solution before being heated as
described in the experimental set up. The final protein concentration
was 25 mg/ml. In another set of experiments all the organic solvents,
with one exception, were added directly to lyophilised sCT to produce
an approximately 100% solution. The exception to this was methanol
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which has a boiling point of 64.7°C and was not used. Once again the
final sCT concentration was 25mg/ml. An additional set of experiments
were carried out to study the effect of pH on sCT's solubility in a
range of ethanol concentrations from 10% to 50% under these
experimental conditions.
4.4, Crystallisation bv slow evaporation
This is a method which has often been applied in small molecule
crystallisation to produce supersaturated solutions. Once again this
method was applied only to the native hormone (sCT) and not to the two
derivatives. The polypeptide was shown in small scale trials to be
soluble in a variety of organic solvents. A set of experiments were
set up using the solvents, ethanol, methanol, DMSO, DMF and
trifluoroethanol. A 1ml solution of sCT in each of the 5 solvents was
placed in a small glass test tube. The concentration of sCT was
2mg/ml. The top of the test tubes were sealed with parafilm. A small
puncture in the seal was introduced using a Hamilton syringe to allow
the solvents to evaporate slowly. The test tubes were kept at room
temperature (23 °C) and inspected regularly over a period of one month
or until the solvent had almost completely evaporated.
4.5.Crystallisation by hanging drop
This method was applied to the attempted crystallisation of sCT and
it's two derivatives and also to the co-crystallisation of equine P1A2
with an inhibitor molecule.
Experimental set up
The crystallisation boxes used were Linbro (Flow laboratories, McLean
VA, USA.) 24-well tissue culture plates. The reservoirs contained 1 ml
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of the precipitant solution. The drops were placed on siliconised
coverslips (1cm x 1cm). The drop volume was 10 /d and the drops were
formed by mixing 5/xl of the protein solution with 5/xl of the reservoir
solution. The rims of the wells were lined with a silicone grease and
the coverslip inverted over the reservoir. The concentration of
calcitonin in the drop was 10 mg/ml. The buffers used were 100 mM in
concentration and the pH range for their use is given in Table 4.1.
The experiments were all performed and stored at room temperature,
approximately 23°C. The plates were inspected initially after 4 days
and subsequently every 7 days. The plates were kept for up to 4 weeks
in order to ensure equilibrium had been reached. The plates were
examined using a light microscope. For the more viscous precipitants,
such as the PEG's and MPD the reservoir solutions were made up in
Eppendorf tubes which were mixed thoroughly then centrifuged for 5
minutes at 13 000 rpm on a bench centrifuge to remove debris.
The methodology used in the attempted crystallisation of calcitonin
and it's derivatives was initially to perform broad screen experiments
where the precipitant concentration varied in relatively large steps.
This was carried out over a broad pH range. The initial conditions of
the trials were determined by small scale trials. These were performed
by the direct addition of precipitant using a Hamilton syringe while
viewing the drop under a microscope for precipitation. Results from
the initial broad screening provided well defined boundaries for
precipitation as a function of precipitant concentration and pH.
Further crystallisation experiments involved expanding conditions
between those yielding clear droplets and precipitate. Finally the
effects of additives, such as small amounts of organic solvents and
detergents added to the crystallisation droplets, was studied.
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4.6 Histochemical staining of sCT aggregates with Congo Red.
The peptide precipitates obtained from vapour diffusion experiments
were gently washed from the siliconised coverslips onto a depression
slide using the well solution against which the drop had been
equilibrated. Excess solution was carefully removed using a Hamilton
syringe while viewing under a dissection microscope. Congo Red
staining was carried out as described by the method of Puchtler, Sweat
and Levine (1962). The solution around the aggregates was replaced
with 80% ethanol saturated with NaCl for 20 minutes. This solution was
next replaced by the stock stain solution (80% ethanol saturated with
Congo Red and sodium chloride) and incubated for a further 20 minutes.
Excess stain was removed and the aggregates washed three times in
absolute alcohol. The stained aggregates were subsequently viewed
under a microscope using cross polarised light.
4.7 Transmission electron microscopy of sCT aggregates
A single drop of a lOmg/ml solution of sCT in water was placed on
carbon coated, low viscosity nitrocellulose treated copper grids. This
was allowed to dry at room temperature before being negative stained
with 2% (w/v) aqueous uranyl acetate. The peptide assemblies were
observed in a Philips EM 400 T. E. M.. This same protocol was carried
out for a lOmg/ml solution of melittin, an a-helical peptide from bee
venom (Terwilliger et al., 1982).
4.8 Scanning electron microsocopy of sCT aggregates
Peptide micelles obtained from crystallisation experiments of sCT
were examined using SEM. These micelles were removed from the
siliconised coverslips by rinsing with 0.1 M sodium cacodylate-HCl
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buffer (pH 7.3) onto a depression slide while viewing under a
dissecting microscope. The peptide micelles were fixed with 3%
gluteraldehyde in 0.1 M sodium cacodylate-HCl buffer (pH 7.3). The
samples were then washed three times with excess buffer before being
transferred onto a millipore filter (pore size 2/zM). The filter paper
envelope was then dehydrated through a graded acetone series of 50%,
70%, 90%, 100%. The sample was next critical point dried as described
by the method of Cohen (1979) and then sputter coated with a 20nm film
of a 60/40 gold/palladium mixture as described by the method of Echlin
(1975). The specimens were subsequently viewed in a Philips 505
scanning electron microscope. A similar procedure was applied to
amorphous precipitate specimens. Hanging drops containing amorphous
precipitate of sCT were rinsed directly onto the filter paper with
buffer. The specimen was then dehydrated and coated as described above
before being viewed under the scanning electron microscope.
4,9 Co-crystallisation of an inhibitor with equine PLA-2
The equine PLA-2 and the inhibitor compounds were generous gifts of
Sandoz AG. All were obtained in the form of lyophilised powder. The
hanging drop method as described previously was used in the co-
crystallisation. Six different compounds, which had inhibitory
activity towards PLA-2, were made up as 1.3 M stock solutions in DMSO.
The protein stock solution contained PLA-2 (20mg/ml), 30% ammonium
sulphate, 50 mM imidazole-HCl pH 7, 5mM CaC12. Using a Hamilton
syringe, 1^1 of the stock drug solution was added to 60.5 /ri of the
protein solution, resulting in a 20mM solution of the drug. In the
control experiment 1/zl of DMSO alone was added to the protein
solution. The protein-drug mixture was whirlimixed and allowed to
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stand for 2 hours at room temperature. The solution was then spun on a
bench centrifuge for 2 minutes at 13 000 rpm to clarity the solution.
Before plating out, 3.5/d of a seeding solution was added to the
protein drug mixtures using a Hamilton syringe and the Eppendorfs
gendy agitated. The seeding solution was prepared by crushing several
large crystals of equine PLA-2 in 1ml of their mother liquor, 50mM
Imidazole-HCl pH 7, 2mM CaCl2 and 30% ammonium sulphate. The plates
were prepared as described previously using an automated pipetting
station. The initial trials were performed at pH 7 and the wells
contained 29, 30, 31, 32, 33 and 34% ammonium sulphate. The drop
volume was 10^1 of the protein-drug and seed mixture and the plates
were stored at room temperature. Only the conditions with one drug,
shown in figure 4.2, produced crystals and were expanded. A range of
pH's from 6.8 to 7.2 were studied.
4.10 Results
4.10.1 Purity of salmon calcitonin
The results of the amino acid analysis are shown in table 4.2. The
amino acid composition is identical to that expected for salmon
calcitonin indicating that the peptide is indeed absolutely pure and
chemically identical to salmon calcitonin.
4.10.2 Slow cooling experiments
Effect of calcitonin concentration
With the exception of pH 7, calcitonin was soluble at 70° C up to a
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Phospholipase Inhibitor,





Figure 4.2. The chemical structure of the PLA-2 inhibitory compound
used in the co-crystallisation with equine PLA-2.
137
Table 4.2 Amino Acid Analysis of Salmon Calcitonin.
Hydrolysis with 6 N HCI for 24 hours.

















LKB 4400 with Norleucine internal standard.
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concentration of 100 mg/ml at all pH's. It was observed that
calcitonin dissolved most easily in the more acidic buffers. At pH 7.0
a small fraction of calcitonin did not dissolve and was removed by
spinning. Thus the values of all subsequent dilutions at pH 7 for this
experiment were overestimated. This was not observed at pH 8.0. On
cooling, all the 100 and 50 mg/ml solutions had precipitated at all
pH's. However the nature of the precipitate was significantly
dependent upon pH. All the acidic solutions had formed precipitates
that consisted of small spheres (diameter approximately 0.1mm). These
spheres were soft on crushing and were similar to those obtained later
with the hanging drop experiments as shown later in Plate 4.1 and are
hereafter called peptide micelles. The precipitates at pH 7 and 8 were
floccular in appearance and had sunk to the bottom of the boiling
point tubes. There was no precipitation at 20 mg/ml or below at all
pH's. All subsequent experiments were carried out with calcitonin
concentrations of 25 mg/ml.
Effect of divalent metal ion
No precipitation was detected at any molar ratio of either Ca2+ or
Zn2+ at a peptide concentration of 25 mg/ml. There was therefore no
detectable pH effect. No further experiments were carried out with
divalent metal ions at higher calcitonin concentrations or in the
presence of other precipitants.
Effect of organic solvents
The results of the effects of the different organic solvents on the
solubilty of sCT are summarised in Table 4.3. When the peptide was
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Table 4.3
Solubility of sCT in organic solvents using the slow cooling method for
crystallisation. The method used was as described in the methods
section. The concentration of sCT in these solvents was 25 mg/ml.
Solvent % (vol/vol) Observation












dissolved in neat solvent no precipitates were obtained after cooling.
However, with the exception of MPD and TFE, 50% aqueous solutions of
the solvents produced gelation. Peptide micelles were observed in 50%
ethanol solutions. The effect of pH on the solubility of sCT in
ethanol solutions are summarised in table 4.4. There was no form of
precipitation in the absence of ethanol and at the more acidic pH's
(pH 4 and 5) in the presence of 10% ethanol. However, at pH 6 the
solution had a viscous opaque gel-like appearance and at pH 7 and 8
the solutions contained spherical aggregates that had a familiar gel¬
like appearance. These were found at all pH's at only 50% ethanol.
4.10.3 Slow evaporation experiments
The solvents ethanol, methanol and trifluoroethanol evaporated
completely after about 10 days leaving the sCT as an oily residue at
the base of the test tube. The polypeptide did not appear to come out
of solution until these solvents had almost completely evaporated. The
other two solvents DMSO and DMF had evaporated to about half the
original volume without any signs of precipitation in the period of
one month.
4.10.4 Hanging drop experiments
1. Salts
The solubility profiles of sCT in the hanging drop method in the
presence of various salts as the precipitating agent are shown in
Figures 4.3a-d. They also indicate the different forms of precipitate
obtained. Two forms of precipitate are illustrated in plates 4.1a-b.
The results show a solubility minimum in the pH range between pH 6 - 8
the exact minimum being dependent on the salt used. Amorphous
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Table 4.4
Effect of pH on solubility of sCT in ethanol solutions. The
slow cooling experiment was carried out as described in the
methods section. The peptide concentration was 25 mg/ml.








































Figure 4.3 a-d. pH dependent solubility profiles of sCT with a variety of salts as
precipitant. Vapour diffusion experiments were carried out as
described in the methods section. The peptide concentration in the
drop was lOmg/ml. The salts used were as follows: A
















































Peptide micelles formed by sCT during vapour diffusion
experiments. Magnification x 25.
Plate 4.1b
Surface skins formed by sCT during vapour diffusion
experiments. Magnification x 25.
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precipitates are found in the presence of high levels of all the
precipitants tested. Peptide micelles are obtained at lower levels of
precipitant in three of the four salts investigated; namely ammonium
sulphate, lithium chloride and sodium chloride. In two salts a phase
separation was obtained at low levels of precipitant; namely zinc
acetate at all pH's and lithium chloride between pH 6.2 - 8.2. At no
point along the solubility minima of all the precipitants were
crystalline precipitates obtained.
2. PEG's
The solubility profiles of sCT in the hanging drop method with
various polyethylene glycols as the precipitating agent are shown in
Figures 4.4 a-d. A solubility minimum is observed in all cases around
pH 7. Only amorphous precipitate was observed with this type of
precipitant. No peptide micelles, surface skins or phase separations
were observed, even at the solubility minima. There was no general
correlation between solubility of sCT and the average molecular size
of the PEG used.
3. 2-Methyl-2,4-pentanediol
The solubility profile of sCT in the hanging drop method with MPD as
the precipitating agent is shown in Figure 4.5. The peptide appears to
be particularily soluble in the presence of high levels of MPD. Only
amorphous precipitate was obtained and only a slight pH effect was
observed.
4. Additives
The effects of additives on the solubility profile of sCT with a
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Figure 4.4 a-d. pH dependent solubility profiles of sCT with a variety of different polyethylene
glycols as precipitant Vapour diffusion experiments were carried out as
described in the methods section. The peptide concentration in the drop was
lOmg/ml. The PEG's used were as follows: A - PEG 1 550; B - PEG 4 000; C -
PEG 10 000; PEG 20 000. The numbers refer to the average molecular weight
of the PEG.
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Figure 4.5 pH dependent solubility profile of sCT with methylpentane-
diol (MPD) as precipitant Vapour diffusion experiments were
carried out as described in the methods section. The peptide
concentration in the drop was lOmg/ml.
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variety of precipitants at pH 7.2 are shown in Figure 4.6 a-d. The two
detergents used (octyl-glucoside and SDS) produced opposing results.
Firstly the effect of increasing octyl-glucoside concentration, Figure
4.6a, resulted in a decreased solubility of sCT in PEG 4000. However,
the presence of SDS, even as low as 0.25 % (w/v), increased solubility
of sCT in PEG 4000 at pH 7.2. There was no observed effect of SDS on
the nature of the precipitant at supersaturation. The presence of
octyl-gucoside also promoted the formation of a skin on the surface of
the drop as indicated in Figure 4.6a and shown in plate 4.1b. The
effect of the phospholipid, DMPG, on the solubility of sCT in PEG 4000
was to alter not only the solubility but the form of the precipitate
obtained as shown in figure 4.6 d. The peptide appeared less soluble
at all pH's and also promoted the formation of peptide micelles as
shown in plate 4.1. This is in marked contrast to the effect of the
other a-helix promoting substance SDS, which increased sCT solubility
at all pH's. DMSO appeared to have no effect on the solubilty of sCT
at the concentrations used in the experiment as shown in figure 4.6 c.
5 .Derivatives
The solubility profiles of the two derivatives with a variety of
precipitating agents in the hanging drop method are shown in Figures
4.7 a-f. No peptide micelles or surface skins were observed with
either of these derivatives under any of the conditions tested. The
two derivatives had very similar solubilty profiles in the presence of
a variety of precipitants. However both peptides appeared more soluble
and resistant to precipitation than sCT in the presence of the three
precipitants tested. However, like sCT both the derivatives appeared
to possess a slight solubility minimum around pH 7.
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Figure 4.6 a-d. Solubility profiles of sCT in PEG 4000 at pH 7.2 showing the
concentration dependent effects of a number of additives.
Vapour diffusion experiments were carried out as described in
the methods section. The peptide concentration in the drop was
lOmg/ml. The additives used in these studies were as follows: A
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Figure 4.7 a-c. pH dependent solubility profiles of derivative 1 with a
variety of precipitants. Vapour diffusion experiments
were canied out as described in the methods section. The
peptide concentration in the drop was lOmg/ml. The precipitants














Figure 4.7 d-f. pH dependent solubility profiles of derivative 2 with a
variety of precipitants. Vapour diffusion experiments
were carried out as described in the methods section. The
peptide concentration in the drop was lOmg/ml. The
precipitants used were as follows: D-ammonium sulphate;
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4.10.5 Histochemical staining of sCT aggregates
Due to the fragile nature of both amorphous precipitate and the
surface skins it was not possible to determine their ability to stain
with Congo red. Peptide micelles were shown to retain stain after
washing, these stained aggregates also showed a green birefringence
under cross polarised light as shown in plate 4.2 a-b. Despite the
slight differences of morphology, peptide micelles obtained at a
variety of pH's and with a variety of precipitants were tested and
shown to stain positively. Peptide micelles produced with a variety of
precipitants as indicated in figs 4.3 - 4.6 were tested and shown to
stain a red-pink colour as shown in plate 4.2 a. When these stained
aggregates were crushed and viewed at higher power a fibrous structure
was observed as shown in plate 4.3. This is indicative of amyloid
formation.
4.10.6 Transmission electron microscopy
Fibrils of approximately 60 A in diameter and of maximum length 20000
A were observed after negative staining as shown in plate 4.4. These
are of similar dimensions to the fibrils of 6-protein fragments
(Halverson et al.,1990; Kirschner 1987; Burdick et
1992). These fibrils were single and unbranching but were occasionally
observed to associate along their long axis in ribbon type structures
as shown in plate 4.5 similar to those of 6-protein peptides (Fraser
et al., 1991). There was evidence of twisted fibrils as shown in plate
4.6. No fibrils were obtained for the control peptide, mellittin as
shown in plate 4.7.
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Plate 4.2
a) Peptide micelles after staining with Congo red
under normal illumination. Micelles were shown to
stain a deep red-pink colour. Magnification x315. b)
Peptide micelles after staining under cross-polarised
illumination. A green-blue birefringence is observed
typical of amyloid. Magnification x375.
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Plate 4.3 Congo red stained peptide micelle under cross
polarised illumination. The fibrous sub-structure of
the micelle is apparent. Magnification x375.
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Plate 4.4
Negatively Stained electron-micrographs of sCT fibrils. Staining
with 2% uranyl acetate was performed as described in the methods
section. Magnification X 100 000. Fibril diameter approximately 6
nm and of length upto 2000nm. Scale bar represents lOOnm.
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Plate 4.5
Negatively stained electron-micrographs of sCT fibrils illustrating
the ribbon type aggregations of individual fibrils. Magnification
xlOO 000, scale bar represents lOOnm.
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Plate 4.6
Negatively stained electron-micrograph of sCT fibrils illustrating
the intertwining and twisted nature of pairs of fibrils.
Magnification xlOO 000, scale bar represents lOOnm.
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Plate 4.7
Negatively stained electron-micrograph ofmellitin aggregates.
The peptide (lOmg/ml) was stained in exactly the same manner as
sCT as described in the methods section. No fibrils were
identifed. Magnification xl88 000, scale bar represents lOOnm.
v \-f











4.10.7 Scanning electron microscopy
The peptide micelles produced in the vapour diffusion experiments are
clearly fibrous in nature as shown in plate 4.8. The constituent
fibrils appear to be on average approximately 150 nm in diameter as
shown more clearly in plate 4.9. Thus these fibres must be composed of
at least 25 of the 60 A fibres which were observed in the T.E.M.
across the diameter of the fibrils observed in the S.E.M..
Amorphous precipitate as shown in plate 4.10 is clearly not fibrous in
morphology and does not form large aggregates.
4.10.8 Equine PLA-2 co-crystallisation experiments
In all of the experiments, except for the controls, it was clear that
some fraction of all six of the hydrophobic PLA-2 inhibitors were
dropping out of solution. This occurred even at the lowest ammonium
sulphate concentration. The extent of the precipitate increased
slightly with increasing salt until at higher salt concentrations, the
protein or possibly protein with bound drug also dropped out of
solution. In five cases at the higher salt concentrations only heavy
precipitate was obtained that showed no signs of crystallinity.
However in the case of the inhibitor shown in figure 4.2, a micro-
crystalline precipitate was obtained between 32% and 34% salt which on
expanding the conditions produced single crystals. The effect of DMSO
on the control experiments was not to inhibit crystallisation. However
the crystals were obtained at a slightly higher concentration, 32%
ammonium sulphate, than the established conditions for the equine PLA-
2. Large single crystals suitable for x-ray diffraction studies were
obtained at pH 7.2 and 34% ammonium sulphate after 9 days. These were
of a slightly different morphology to that of the native crystals. It
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Plate 4.8
Scanning electron-micrographs of peptide micelles grown in
vapour diffusion experiments at pH7.2, 30% (w/v) PEG 4000, 6%
(w/v) DMPG. The micelles were prepared for microscopy as




Scanning electron micrograph of peptide micelle fibrils. The
micelles were grown in vapour diffusion crystallisation trials as
previously indicated in legend 4.10. The micelles were prepared for
microscopy as described in the methods section. Magnification
x 10, 300, scale bar represents l|im.
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Plate 4.10
Scanning electron micrograph of amorphous precipitate.
Amorphous precipitate of sCT was obtained during vapour
diffusion experiments as described in the methods section.
The precipitate was prepared for microscopy as described in
the methods section. Magnification xl535, scale bar
represents 10pm.
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was hoped that this slight difference was due to the formation of the
enzyme-inhibitor complex.
4.11 Discussion.
None of the methods applied to the crystallisation of sCT and two
analogues has proved successful. These methods have previously proved
successful in the crystallisation of a wide range of macromolecules;
from whole virus particles (Hogle et al., 1985) to membrane proteins
(Kreusch et al., 1991). The lack of success with salmon calcitonin
cannot therefore be attributed to some flaw in the methods. Rather it
is likely that there are some structural features or solution
properties of sCT which have prevented crystallisation. Only non¬
crystalline material has been obtained which in the case of the
peptide micelle has been shown to be far from amorphous. The
polymorphic nature of these precipitates has made a systematic
approach to the crystallisation of sCT difficult. These unusual
precipitates have been produced both in the slow cooling experiments
and in the vapour diffusion experiments further indicating that some
consistent features of the solution properties are responsible for the
formation of these unusual precipitates. There have been no previous
reports of micellar aggregates with peptides. However, the formation
of 'gels' has been observed in other amphipathic peptides at high
concentrations (Epand et al., 1989) and surface skins have been
observed with peptide fragments of the A4/B amyloid protein of
Alzheimer's disease (Burdick et al., 1992).
The nature of these unusual aggregations was examined by two
independent techniques namely, histochemistry and electron microscopy,
which have both confirmed the existence of amyloid. Amyloid deposits
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are characterised by electron microscopy as consisting of fibres that
are 4-10 nm in diameter (plate 4.4) and histologically as exhibiting
green birefringence under polarised illumination when stained with
congo red (plate 4.2b).
The formation of amyloid fibrils by calcitonin obviously has
important implications for the interpretation of the crystallisation
trials. It provides an explanation as to why calcitonin has resisted
crystallisation. The crystallisation process requires that the monomer
remain as an essentially monodisperse solution up to the point of
superstaturation. Here it is obvious that fibrillogenesis is occurring
before supersaturation since these fibrils can form even in the
absence of precipitate such as during the preparation of the T.E.M.
samples. Although the peptide can exist in solution as a monomer, at
the high concentrations required for crystallisation, it is clear that
peptide-peptide interactions forming the fibre are more favourable
than peptide-hydration interactions, resulting in this specific
aggregation/polymerisation rather than forming a crystal. Aggregation
of calcitonin analogues has been previously observed in CD
experiments, with peptide concentrations in the /jlM range. This has led
to the hypothesis that calcitonin analogues can form trimers (Moe &
Kaiser, 1985) and tetramers (Green et ai, 1987). However the
formation of these fibrous polymers has never before been reported or
proposed. In the crystallisation trials the high concentrations of sCT
have also resulted in the formation of surface skins and gels. The
formation of these unusual precipitates can adequately be explained by
the formation of amyloid fibrils with subsequent further aggregations
of these fibrils into the skins and gels. While the peptide micelles
are clearly composed of fibrous material as seen in plate 4.8, the
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fibrous nature of the other types of precipitate have not been
determined. It has been shown that amorphous precipitate is not
fibrous as shown in plate 4.10. Therefore, alternative possibilities
for the origin of these other precipitates cannot be ruled out.
It is possible that the surface skins (plate 4.1b) occur as a result
of the surface active properties of amphipathic peptides. Model
peptide studies have shown that an amphipathic a-helix can be formed
by an air-water interface (Kaiser & Kezdy, 1983). It has also been
shown that amphipathic a-helices can form stable monolayers at the
air-water interface (de Grado et al., 1981). Thus these skins could be
formed by the aggregation of these a-helices at the air-water
interface. The formation of such skins could affect the water
equilibration in the hanging drop experiments if they occurred before
supersaturation. The fibrils of the peptide micelle are by their size,
clearly composed of many of the single fibrils seen with the negative
staining technique plate 4.4 & 4.5. From the S.E.M. micrographs the
diameter of these larger fibrils must represent at least 25 of the
individual fibres (as shown in plate 4.4) across the diameter. The
nature of the interaction of the individual fibres is unknown, but the
aggregation of amyloid fibrils into 'ribbons' has been previously
observed (Fraser et al., 1991). These are very similar to those
observed in plate 4.5 but are not composed of anywhere near 25
individual fibres.
Despite providing some useful information on the solubility of sCT,
the slow cooling method has not proved a good method for the
screening of a wide range of crystallisation conditions. It has been
difficult to set up and the rate of cooling has been difficult to
control. Interpretation of the results has also not been
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straightforward, but duplication of conditions in vapour diffusion
experiments have helped assess the effect of individual parameters on
the solubility of the peptide. There appears to be no specific effect
of temperature other than increasing the rate of formation of these
aggregates, while having no effect on their morphology. The slow
cooling experiments have indicated a pH optimum for the formation of
the fibrils around pH 6-7. Also at high concentrations (8-15 mM)
aggregation occurs in the absence of precipitating agents. There also
appears to be no specific role for divalent metal ions such as Ca^+
and Zn2+ in the aggregation process indicating no role for divalent
metal ions in the formation of the fibrils themselves. The polypeptide
has been shown to be particularily soluble in a variety of organic
solvents (Table 4.3) which even at high peptide concentrations does
not result in the formation of any aggregates. Solubility in this two
component system could indicate that hydrophobic interactions are of
importance in the solubility of this peptide, excluding any pH
effects. This could be of particular relevance to the peptide's
ability to bind and solubilise phospholipid micelles. In the three
component system (the buffer is neglected due to it's low
concentration) where the third component was water, peptide micelles
were frequently formed. Quite why the presence of water should induce
aggregation is unclear. It is known that when exposed hydrophobic
sidechains are placed in aqueous solution, a structure will collapse
to a state which shields the hydrophobic groups from solvent. As in
protein folding, this leads to the formation of an hydrophobic core.
With such a small peptide it could not be envisaged that the molecule
itself forms such a core. Rather it is likely that hydrophobic
sidechain interactions could occur as a consequence of aggregation.
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Model compound studies have suggested that pairwise hydrophobic
interactions can even occur when non polar sidechains are separated by
a layer of water (Wood & Thompson, 1990). Thus the hydrophobic
interactions of the sidechains, even if partly solvated, could promote
fibrillogenesis.
Another effect of hydration, identified in an NMR study (Meyer et
al., 1991), is the induction of cis-trans isomerisation in the
peptide. It was observed that the addition of water to sCT in TFE
induced cis-trans isomerism at Pro-23. While the structure in TFE is
an amphipathic a-helix, cis-trans isomerism at this residue has been
observed in an amphipathic 6-sheet structure (Motta et al., 1989). In
this NMR study, carried out in cryoprotective DMSO-water mixtures, an
amphipathic sheet structure from Leu-12 to Lys-18 was also observed.
It was proposed that this structure was responsible for the initial
interaction with lipids in the same way that signal sequences are
thought to interact with bilayers (Briggs et al., 1986). The existence
of cis peptides has been identified in bombolittin (Bairakarti et al.,
1990), a bee venom peptide which can form an amphipathic helix in the
presence of SDS. Cis-peptide conformation has also been identified by
solid state NMR in the amyloid deposits of Alzheimer's disease
(Spencer et al., 1991) in which the peptide was also shown to exist in
a single conformation. In both cases the stabilisation of the
energetically unfavorable conformation (free energy difference of ca.
3kcal/mol at 298 K) has been proposed to occur as a consequence of the
resulting newly formed interactions providing the necessary energy. In
the case of bombolittin this is a peptide-micelle interaction, in the
amyloid deposits of AD it is believed the cis bond is stabilised by
the intermolecular interaction energy as it aggregates in the
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formation of fibrils. However, the lack of formation of either peptide
micelles or gels in the slow cooling experiment with sCT in a 50/50
mixture of TFE and water does not support the possible role of cis-
trans isomerism in the formation of these amyloid fibrils. The
hydrophobic and the cis-trans isomerisation effects are two of many
possible consequences of hydration. While it is possible that both
effects occur, it cannot be ruled out that there are other as yet
undetermined hydration effects which have a role in the formation of
these amyloid fibrils.
The hanging drop experiments have indicated an increased solubility at
acidic pH's at calcitonin concentrations up to 7.5mM, with a
solubility minimum around 6.5-7.2. The estimated isoelectric point for
sCT is 10.4 (Maier et al., 1977). Thus at a pH of 7 the peptide should
carry an overall charge of approximately +3. These overtly positively
charged molecules would tend to repel each other rather than
aggregate. The formation of fibrils by synthetic peptides of A4/6
protein of AD have been shown to be similarity pH dependent (Fraser et
al., 1991). It was suggested that this process might be an isoelectric
phenomenon since at the pH's at which fibrils were obtained (pH 3-8)
the peptide had no charge. If sCT forms fibrils in a similar way to
A4/6, the process cannot be isoelectric.
The alternative explanation proposed for the pH dependence of A4/J3
fibrillogenesis was that it was dependent on one or more His-Asp/Glu
salt bridges (Spencer et al., 1991). Although the pH dependence of
fibrillogenesis for sCT is different, it would indicate that certain
charged residues have a role in fibrillogenesis. It is also possible
that the ring structure of the amino terminus plays some role. No
micellar aggregates were obtained with either of the two derivatives.
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It has been proposed from NMR work (Meadows et al., 1991) that this
ring structure may act as a template upon which secondary structures
may develop. That the vapour diffusion experiments with the
polyethylene glycols and MPD did not lead to the formation of these
amyloid aggregates, again indicates the importance of hydrophobic
interactions. Peptide-solvent interactions in this case are presumably
of similar magnitude to peptide-peptide interactions associated with
fibrillogenesis. However in the presence of the helix inducing
phospholipid DMPG, amyloid precipitate was obtained in PEG 4000 which
had previously produced only amorphous precipitate. Since the use of
additives in crystallisation trials is to improve crystal quality, the
lack of success with the four additives could be expected. Octyl-
glucoside and DMPG both affect the form of the precipitate with
peptide micelles being obtained in PEG 4000 with only DMPG. It is
highly likely that the surface skins obtained with octyl-glucoside are
also fibrous since similar skins have been observed with peptide
fragments of A4/B amyloid protein of Alzheimer's disease (Burdick et
al., 1992) and shown to stain with Congo Red. Unfortunately it has not
been possible to stain histochemically the skins obtained with sCT due
to their physical fragility. In contrast to DMPG and octyl-glucoside,
SDS which like DMPG induces helicity in sCT, actually increases the
solubilty of sCT and leads only to amorphous precipitate. Quite why
such opposing results have been obtained with these additives cannot
be explained.
Since fibrillogenesis has been observed only in aqueous solutions,
where sCT has been shown to possess no secondary structural features
(Wuthrich, 1976), the necessary structure required for fibrillogenesis
must be induced at the fibril itself. This would not therefore be
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expected to be a rapid process. Rather it would be similar to the
formation of a crystal where the slow approach to supersaturation
allows molecules sufficient time to orient themselves for specific
contacts to be made. This could explain why at high precipitant levels
only non-specifc aggregates occur. Here, the rapid loss of solvation
results only in amorphous precipitation. The induction of a structure
at the fibre is further supported by the fact that fibrillogenesis can
occur in the presence of helix promoting solvents such as DMPG. There
has been no evidence that amyloid fibrils possess helical structure,
rather all the structural studies indicate some form of B-structure as
proposed by Glenner (1980). Some structural rearrangement must
therefore occurr during the fibrillogenesis. Unfortunately the
techniques which have been used to characterise amyloid have provided
no detailed structural information on the plaque itself. Only
speculative models similar to Pauling's cross 8-structure have been
proposed as shown in figure 4.8. Since amyloid forming protein
sequences are so diverse it could not be imagined that one single
model of the fibril could be applied to all of them. Thus it has been
proposed (Lansbury, 1992) that the defining properties of amyloid
characterise a class of related structures, of which the cross-B
fibril (Marsh et al., 1955) is one member rather than the definitive
structure. It is possible that the B-sheet structure identified by NMR
in DMSO-water mixtures (Motta et al., 1989) could resemble the
conformation in the fibre.
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Figure 4.8 Schematic illustration of Pauling's cross-P fibril model (Marsh et
al., 1955). This model is generally accepted to represent all
amyloid. The anti-parallel arrangement of the peptide chains and








This chapter explains how two methods of crystallographic refinement
were successfully applied to equine phospholipase A2 and the putative
co-crystal of equine PLA-2 with an inhibitor compound crystallised as
described in Chapter 4.
5.2 Crystallographic refinement using XPLOR
As previously explained in chapter 2, the purpose of any refinement
process is to produce a model which agrees as closely as possible to
the observed data but still has sensible geometry. Thus any refinement
must produce the best fit between the observed structure factors F0
and those calculated from some model Fc. Thus Fc is a function of the
x, y, z coordinate positions and B (temperature factor) for each atom
of the model. However unlike small molecule crystallography,
constraints or restraints are needed for proteins in order that the
number of observations remains greater than the number of parameters
of the model which is being refined. A variety of methods have been
developed for protein crystallography which can do this. The relative
merits of these methods make some more applicable in certain
situations. The majority of the methods are least squares in essence,
one of which will be discussed later. A relatively recent addition to
the methods available is the use of molecular dynamic simulations.
These are used to search conformational space, while at the same time
trying to minimise the difference between the observed and calculated
structure factors. This technique has proved to be a particularly
powerful technique in the crystallographic refinement of protein
structures (Brunger et al., 1987, Brunger, 1988a). This has
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subsequently been developed by Brunger into a refinement package
called XPLOR (Brunger, 1988b).
The package incorporates simulated annealing (SA) (Kirkpatrick et
al., 1983), which allows exploration of the phase space of a
complicated multi-parameter target function. In the crystallographic
refinement this target function can be described
etotal = Eempirical + Ex-ray
where EempiRTCAe is the empirical energy of the model and Ex-RAY *s
the squared difference between F0 and Fc summed over all the
reflections. The reason this method proves so powerful over
conventional least squares methods is that energetically unfavorable
'uphill steps' can be taken across barriers between energy minima,
with a probability e~Etotal/kgT^ using an effective temperature as a
control parameter (kg is the Boltzmann constant). Conventional least
squares can only take energetically 'downhill' steps and as a result
can end up trapped in local minima. This is due to the limited radius
of convergence, as restrained least squares refinement does not
usually correct atoms whose positions are more than 1 A in error. This
necessitates frequent manual inspection and refitting using
interactive computer graphics which is a time consuming process. The
larger radius of convergence of xplor reduces the need for manual
corrections. The name of the method is derived from the physical
analogy of changing an amorphous glass (high energy, only local order)
to a crystalline solid (low energy, long range order): the glass must
first be liquefied, then slowly cooled or 'annealed' into the
crystalline state. Slow cooling is required to prevent the system from
becoming trapped in a metastable solid state with only local order.
The restrained molecular dynamic simulation does not correspond to any
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physical reality; it is simply a tool for carrying out a search of
configuration space.
5.2.1 The XPLOR energy function
As mentioned earlier there are two components of the energy
function (when performing crystallographic refinement) and these
are:
Etotal = Eempirical + Ex-ray
The first term EemPIRICAL describing the energy of the molecule can be
broken down further. Since it describes the interactions that
stabilise the protein structure, the term can be replaced by a series
of expressions that give the potential energy of the molecule as a
function of its atomic positions. In XPLOR, the empirical energy
function has the from:
Eempirical=Ebonds+eangles+edihedral+
elmprops +enonbonded+esBOUNDS
Each bond is treated as a simple spring obeying Hooke's law with a
characteristic force constant and equilibrium bond length:
Ebonds = kb(r - ro)2
the second term accounts for the deformation energy of angles between
the covalent bonds to a given atom:
EANGLE = k0(0 " 0o)2
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The next two terms represent the intrinsic deformation energy for
twisting about an axis through covalently bonded atoms:
eDIHEDRAL = EimPROPER = k(l + cos(n<£+<5)) if n>0
k(<£ - 8?) if n=0
[n=periodicity 8=phase shift angle]
The reader is directed to Levitt (1982) for a fuller explanation of
these two angular terms and an explanation of the difference in their
definition. Because a harmonic approximation (Jack & Levitt, 1978) is
used for the deformations in bond lengths and angles, the number of
times the direct computation of structure factors and their
derivatives have to be calculated is reduced.
The nonbonded energy term has the form:
ENONBONDED = evdW + EELEc + Epvdw + EPELEC
These correspond to the van der Waals and Coulombic interactions of
the atoms and those related through symmetry operations. No explicit
hydrogen bonding term is included since the hydrogen bonding energy
can be accounted for satisfactorily by electrostatic and van der Waals
terms. The parameters for all these terms have been taken from CHARMM
(Brooks et al., 1983) and have been previously modified to avoid
artefacts of the high temperatures encountered during simulated
annealing.
5.2,2 Crystallographic refinement
The second term Ex-RAY is described thus:
Ex-ray = eax-ray + epx-ray
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The second term, Epx-RAY> describes phase information if present. No
phase information was used in the refinement of equine PLA-2 since the
initial model was obtained from the direct method of molecular
replacement. The first term, E^x-RAY consists of the weighted
differences between observed and calculated structure factor
amplitudes,
FAX-RAY = WA/NA E(hkl) W(hkl)[ | Fobs (hkl) | -
k I Fc (hkl) | ]2
where (hkl) are indices referring to the reciprocal lattice points of
the crystal and extends over all observed and selected reflections
with indices (hkl).The overall weight WA relates the crystallographic
term to the empirical energy function. The normalisation factor NA
allows the weight WA to be approximately independent of the resolution
range used during SA-refinement. NA has been set to:
NA = E(hkl) W(hkl) I Fobs (hkl) I 2
The necessary constants used to approximate the atomic scattering
factor are from the International Tables for Crystallography Volume 4
(1974). The structure factors are computed using the Fast Fourier
Transformation (FFT) method (Agarwal, 1978). In order to minimise the
computational requirements of SA-refinement an approximation is
included. At every dynamics or minimisation step the Fcajc(hkl) and
it's first derivative are only recalculated if the coordinates of the
model have changed by a specified amount, for example 0.2 A during
molecular dynamics and 0 - 0.05 for minimisation.
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5.2.3 Molecular dynamics
Having a knowledge of the energy of the system as a function of
atomic coordinates, allows one to perform molecular dynamic
simulations. There are forces acting on the atoms of the system. These
forces, are derived from the empirical potential energy that describes
the stereochemical and nonbonded interactions. These can be used to
calculate the dynamic behaviour of the system by solving Newton's
equations of motion for the atoms as a function of time. The atoms are
assigned initial velocities with a Maxwellian distribution at some
given temperature. The temperature can be measured by the mean kinetic
velocity of the atoms
lA E mj<vi 2> = 3/2 NkBT
where N is the number of atoms in the system, < vi 2 > is the average
velocity squared of the ith atom and kg is the Boltzmann constant. A
simulation is performed by finding the acceleration aj of atom i from
Newton's law Fi =mjaj. From the acceleration of the atom it is possible
to calculate it's new position q after a time interval t+<5t, given rj
at time t:
ri(t+5)=rj(t)+vi<5t+l4ai(5t)2 +..
The quantity 5t must be very small so that the potential energy does
not change too much during each time step; in XPLOR this is about
one femtosecond (10~15s). The desired temperature is maintained by
coupling the dynamics to an external heat bath via ffictional
dampening as described by Berendsen et al., (1984). This method is
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a mathematical abstraction and has no physical reality, but the
algorithm is particularly suited to the simulated annealing technique.
5.2,4 XPLOR refinement of equine PLA-2.
Simulated annealing has been applied to the refinement of equine
PLA-2. The relevant crystallographic details are described in table
5.1. The initial data set was collected by Dr. M. Walkinshaw on a
CAD-4 in Delft, Holland and a second data set was collected on a FAST
area detector in Basle. The CAD-4 data set was used in the initial
'solving' of the structure. Molecular replacement was used by Dr.
Walkinshaw using the program MERLOT (Fitzgerald, 1988) to locate the
structure within the unit cell.
During a crystallographic experiment only the relative intensities of
reflections can be measured and not their phases. This phase
information is lost during the experiment. However, once the
approximate positions and identities of all the atoms in the unit cell
are known, the amplitudes and the phases of the structure factors can
be readily calculated. The method of molecular replacement involves
finding these approximate positions by the use of an already
determined structure which is believed to be sufficiently similar to
the new structure. It is generally the case that proteins whose
sequences are similar tend to have a similar overall fold. In this
case, the crystal structure of Bovine PLA-2 of Dijkstra et al., (1981)
was used. The bovine sequence shares a high sequence homology with
that of the equine (76.8% identity). This bovine structure was
determined at 1.7 A resolution and has been refined to a
crystallographic residual of 0.171 (Dijkstra et al., 1981) making it
the ideal candidate for a search molecule. The necessary changes to
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Table 5.1 Crystallographic details for the refinement of equine
PLA-2.
Crystallised in: 30% Ammonium sulphate/6mM
CaCh/100mM Imidazole-HCl,
pH 7.2.
Structure solution: Molecular replacement
Space group: C2 2 molecules/asymmetric
unit each of 125 residues.
Unit cell parameters: a=83.2, b=45.44, c=65.13 A
a=^90.0,° P=101.98 °
Table 5.2 Analysis of the CAD-4 data as a junction of
resolution between 8.0 and 2.45 A.
Resolution Range
(A)
Number of reflections R-factor
2.45 2.56 266 0.5127
2.56 2.69 476 0.5173
2.69 2.85 498 0.4061
2.85 3.06 723 0.3540
3.06 3.34 1072 0.3145
3.34 3.78 1096 0.2865
3.78 4.61 1086 0.2578
4.61 8.00 1107 0.2681
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the bovine structure, in compliance with the equine sequence, were
carried out by Dr. Walkinshaw using the molecular modelling program
SYBYL (Tripos associates, 1991) prior to the molecular replacement.
5.2.5 Simulated annealing refinement of equine PLA-2
The initial data set used for the refinement extended to 2.45 A
resolution. The resolution range used in the initial refinement was
from 8 - 2.7 A. This data set contained 5537 unique reflections. An
analysis of the data as a function of resolution is shown between 8.0
and 2.45 A in table 5.2.
The first step in the refinement was the determination of the ideal
weight Wa between the structure factor information and the empirical
energy function. This was calculated by performing a brief molecular
dynamics calculation without the structure factor information and then
comparing the norm of the gradient of the empirical energy function
and the norm of the gradient of the structure factor information. This
weight was used in all subsequent parts of the refinement carried out
with this data. The initial R-factor was 45.0%. Since the initial
structure was essentially that of an already highly refined crystal
structure only 40 cycles of energy minimisation were carried out. No
harmonic constraints on the Ca positions were used and the R-Factor
after this stage was 44.8%. Next an overall B-Factor refinement was
carried out using an 8 step least squares optimisation. An overall B-
Factor of 25.87 was calculated for all non-hydrogen atoms. This
structure was then run through a simulated annealing refinement "slow
cooling" protocol as shown in figure 5.1. The starting temperature was
3000K and the system was coupled to a heat bath. The temperature was
cooled by 50K every 50 steps of the dynamic simulation with a 0.0005
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Figure 5.1 Slow cooling protocol for equine PLA-2 using XPLOR.
Methodology
1. Prepare: 40 cycles of Energy Minimisation
2. B-overall refinement of all non-H atoms.
3. Slow cooling from 3000 K to 300 K in 50 K steps, Timestep 0.0005ps
50 integration steps.
Simulated Annealing Schedule
remark 3000 K to 300 K in 50 K steps
resolution-limits= 8.0 2.7
tolerance= 0.2 {Use linear approximation until}
{any atom has moved by more }
{than 0.2 A }
wa=50000 {These are the weights from }
wp=0.0 {weights.inp }
vector do (vx=maxwell (3000.0)) (all)
vector do (vy=maxwell (3000.0)) (all)
vector do (vz=maxwell (3000.0)) (all)
vector do (fbeta=100) (all)
evaluate ($1=3000.0)




{Small timestep since the}








{Number of integration steps}
{Berendsen method, heatbath}
{Output Control }
Results: Initial R Factor= 45.0
Final R Factor= 28.8
After B-overall refinement=35.6
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picosecond timestep. The final temperature was 300K. The R-Factor
after this stage was 28.8. Figure 5.2 outlines the comparison of the
Cqj's of the initial (EPLA1) and final structures (EPLASAl) for both
the molecules A and B which form the asymmetric unit. The rms
difference between the starting (EPLA1) and final (EPLA SAl) structure
was 0.903 A for the main chain atoms and 1.722 A for the sidechain
atoms. Figure 5.3 outlines the difference in Ca positions between both
molecules of the asymmetric unit cell after optimal superposition of A
and B using SYBYL (Tripos Associates, 1991). The rms difference
between the main chains of molecule A and B was 0.804 A. Table 5.3
shows the stereochemical analysis of EPLA SAl indicating the larger
movements of both the backbone and the sidechains. Both a 2F0-FC map
and omit maps with coefficients 2F0-FC were used to remodel atoms back
into density. Less than 10% of the structure was omitted in any one
omit map. Remodelling was carried out using FRODO (Jones, 1982). The
main areas that required remodelling were around residues 63 - 67 and
around the C-terminus in both molecules. There were also breaks in
main chain density in a number of the loop regions. This structure
(EPLA2) was then used as the starting model with the same protocol as
before in a second "slow cooling" refinement again using the data
between 8-2.7A. The R factor after this annealing run was R=28.0% for
EPLA SA2. Once again remodelling using 2F0-FC and omit maps were
carried out to produce EPLA3. At this stage a higher resolution data
set (here called FASTI) was collected by Dr. M. Walkinshaw on a FAST
area detector in Sandoz, Basle. This data set extended to 2.0 A and
had a low Rmerge (6%). However, after analysis of the higher
resolution reflections a resolution cut off was applied and the
resolution range used in the refinement was 15 - 2.5 A which contained
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Figure 5.2
Distance (in Angstroms) between the CA
positions of EPLA1 and EPLA1_SA1. The solid line
represents molecule A and the dotted line molecule





Distance (in Angstroms) between the CA
positions of molecule A and molecule B of EPLA1_SA1.
These distances were calculated after optimal
superposition using SYBYL.
10 20 30 40 50 60 70 80 90 100110120*30
Residue Number
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Table 5.3 Stereochemistry of EPLA1_SA1 illustrating deviations from ideality.
Also shown are the largest sidechain and backbone movements (B elements)
which occurred during the "slow cooling" refinement. These distances or




12 bonds (sidechain) in A





10 (main) 20 (sidechain) in A





atoms B element > 2.0
largest B element
0.9
10 atoms (5 residues) in A
15 atoms (11 residues) in B
Lys124 CA in A (2.8 A)
Sidechain (not Hydrogen)
rms 1.72
atoms B element > 5.0
largest B element
4 atoms (3 residues) in A
7 atoms (5 residues) in B
Tyr 19 OH in A (7.07 A)
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7069 unique reflections. This data set was used with the EPLA3
structure. A new ideal weight was calculated for this data set and
found to be 0.1132x106. This structure was then used with the same
"slow cooling" protocol used previously to produce EPLA-SA3. The final
R-factor at this stage was 29.8%. The electron density maps with this
new data were significantly better and more featured. However the C-
terminus was still badly defined and some of the loop regions still
had breaks in the main chain density. The most notable of which was
around residue 65 in both molecules. The omit maps did not indicate
alternative chain tracing either in this region or in the C-terminus.
Another round of remodelling produced EPLA4 which was used in an
altered annealing protocol. As before the starting temperature was
3000K and the system was coupled to a heat bath. However, the
temperature was now cooled by 25K every 50 steps of the dynamic
simulation with a 0.0005 picosecond timestep. The final temperature
was 300K. The final R-factor dropped only to 29.7% to produce
EPLA SA4. Since very little improvement in the structure was occurring
with subsequent computationally expensive XPLOR runs, the refinement
using XPLOR was halted at this stage.
5.2.6 Generation of electron density maps
The electron density maps were not calculated using XPLOR but from
the CCP4 suite of programs as outlined in figure 5.4. These maps were
normally 2F0-FC maps but often "omit" maps were produced. Parts of the
model were omitted (by setting the occupancy of the omitted atoms to
zero) in the calculation of structure factors. The linear length of
the structure omitted was never more than 10%. This has been suggested
to provide a less model-biased electron density map and was thought to
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Figure 5.4 Method of generating electron density maps




















extends map over molecule






help with the manual refitting of the structure into the electron
density.
5.2.7 Discussion
XPLOR has proved very successful in the initial stages of refinement.
The slow cooling methodology on it's own seems sufficient in producing
a reasonable final model. No equilibration stage was used and the
final structure had reasonable stereochemistry indicating that a final
minimisation stage would not be necessary. It was noticed that some
lysine sidechains, in particular Lys 124 adopted peculiar
conformations and formed hydrogen bonds with the backbone carbonyl
oxygens. However, the electron density of the 2F0-FC and "omit" maps
allowed these to be easily remodelled into density with sensible
geometry. In subsequent refinements charged sidechains had their
charges switched off. The successful progress of the initial
refinement indicated both that the structure was successfully located
within the unit cell and that the starting model was adequate. From
table 5.3 it is clear that the largest movements in the starting
structure EPLA were obtained in the side chain atoms. The largest of
these movements occurred in residues which had been substituted from
the sequence of bovine PLA-2 to comply with the equine sequence. A
good example of this is Tyr 19B OH which moved over 7 A during the
refinement. In the bovine sequence this residue is a Leucine. A
movement of this scale would only be possible, manually, with
molecular graphics. However, not all of these large movements are by
substituted side chains. A good example of this is provided by the CD1
atom of Leu 3IB which has shifted 5.5 A. These provided early
indications that the equine structure and the bovine structure were
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slightly different in overall conformation and quite different at
certain areas within the sequence. Comparison of the Ca's of the
starting and final structures in figure 5.2 indicates four major areas
in the sequence where large rms differences occur. These areas are
located particularly in the loop region between helix A (1-14) and
helix B (17-22) and the calcium binding loop (25-37). The worst two
areas occur between helix D (54-58) and helix E (89-108) and the area
of the last 6 residues at the C-terminus. These areas are consistent
in both molecules although it appears that molecule B is slightly
further from the starting structure than molecule A.
5.3 Crystallographic refinement using TNT
It has become clear that while refinement methods incorporating
molecular dynamics simulations are very powerful, they are most
productively used at the early stages of structure refinement (Jhoti,
1989). Subsequent refinement steps are completed with the more
conventional least-squares type refinement methods.
Further progress in the refinement process requires the use of a
least squares refinement program. This method is less computationally
intensive than methods which incorporate dynamical simulations. Least
squares methods can only take steps that are energetically favourable
as the function is minimised. Since the method has a small radius of
convergence the structure can easily be refined into local minima.
This is then overcome by manual inspection and remodelling using
molecular graphics.
TNT is such a restrained least squares refinement package (Tronrud et
al., 1987) and has been applied to the refinement of equine
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phospholipase A2. The function to be minimised in TNT is
M = E(hkl) W(hkl) [F0(hkl) - Fc(hkl,p)]2
where F0(hkl) is the experimental value for observation hkl,
Fc(hkl,p) is a corresponding value calculated from the coordinate and
thermal parameters p that specify the structural model and W(hkl) is
the desired weighting function. This is performed by summation over
all the independent reflections. To obtain the best fit the parameters
p are considered as variables which may be adjusted to minimise M.
This is done by setting the derivatives of M with respect to each of
these parameters p equal to zero. This leads to p independent
simultaneous equations. These equations are not linear in the
parameters, since they involve trigonometric and exponential functions
and so cannot be treated directly by least squares methods since the
method requires linear equations. However, if a reasonable starting
set of parameters is known, then it is possible to derive a set of
linear equations in which the variables are the shifts from the
starting parameters, rather than the parameters themselves. This is
done by expanding in a Taylor's series about the trial parameters,
retaining only the first-derivative terms on the assumption that the
shifts needed are sufficiently small that the terms involving second
derivative and higher order derivatives are negligible. Thus the
process starts with some initial set of parameters which are used to
produce small shifts in these parameters and a new set is produced.
This new set of parameters is used again in a new cycle of refinement.
In TNT the function to be minimised is further separated into the sum
of two terms based on the crystallographic observations s and the
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stereochemical observations b.
M = £s W(s)[F0(s) - Fc(s,p)]2 + Lh W(b)[F0(b) - Fc(b,p)]2
The gradient of M can also be separated into these terms. The
stereochemical observations take the form of restraints and are
specified as bond lengths, bond angles and so on. There are six
classes of stereochemical information with which the structural model
can be restrained: bond lengths, bond angles, torsion angles, trigonal
planarity, general planarity and contact between non-bonded atoms.
These restraints can be individually weighted during the process of
refinement or modified to suit the desired requirements.
The crystallographic term which is minimised is
M = EsW(s)[k|F0(s)| - |Fc(s,p)|]2
At the beginning of each cycle of refinement the scale factor k is
determined by minimising
M(k,B) = Es W(s)[k | F0(s) | -exp(-BS2/4) | Fc(s,p) | f
where s = sin0/\ and Fc(s) is treated as a constant. The thermal
factor B allows for the initial overall discrepancy between the F0 and
Fc's. As the refinement proceeds this B is absorbed within the thermal
factors of the atoms and during successive cycles rapidly approaches
zero. The structure factors are calculated by a space-group-specific
fast Fourier transform (FFT) (Ten Eyck, 1977). The gradients are
calculated using a modified version of the method of Agarwal (1978).
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The modifications are described more comprehensively in Tronrud et al
(1987). Essentially the gradients are calculated by first producing an
(F0-Fc) map for the molecular volume. For each parameter in the model
a convolution, evaluated at the atomic position, is calculated between
this F0-Fc map and the derivative of the calculated atomic electron
density function for the atom involved. Having determined the gradient
for each parameter a shift is applied in the opposite direction. The
size of the shift then has to be determined by a line search along the
gradient vector. An overview of the TNT refinement process is shown in
figure 5.5.
5.3.1 TNT refinement of equine PLA-2
The last model from the XPLOR runs EPLA SA4 was remodelled on the
graphics using FRODO to produce the starting model in the TNT
refinement PLATNT1. At this stage another FAST data set was available
(here called FAST2) and attempts were made to scale the two FAST data
sets (FASTI and FAST2) using the CCP4 program ANISOSC. Regardless of
which data set was treated as the derivative, the two sets of data
scaled together poorly (RScale= 18% using F^). Analysis of the scaling
as a function of sin0/\2 could not provide an obvious explanation for
this. It was noted that of the three data sets available, the two FAST
data sets scaled together the best, with the FASTI and the CAD4 data,
not surprisingly, scaling together the worst (39%). Rather than used
badly scaled data the refinement was continued with this new FAST2
data set since it also had a very low RSyram[l] value of 4.1 % and also
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Figure 5.5 Flow diagram of a TNT refinement cycle.
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extended to 2.0 A. The data set used contained 13454 reflections of
which 7969 were unique reflections and the resolution range for the
refinement was 15-2.4 A. This data was 82.6% complete to 2.4 A. The
diffraction data had to be first sorted with the index 1 varying the
fastest and also h,k,l had to be transposed to -h,k,-l (in this space
group these reflections are equivalent) for use in TNT. The refinement
of phospholipase A2 was carried out in two stages. The first stage
consisted of weighting up the crystallographic term. This resulted in
the R-factor improving (getting smaller) at the expense of the
geometry. Obtaining a suitable weighting scheme for this stage
involved a mainly trial-and-error process. The refinement method used
was the conjugate gradient (CG) method (Fletcher & Reeves, 1964). This
method has a better rate of convergence than the steepest descent (SD)
method. For good results with the CG method it was necessary firstly
to run one cycle of SD and then at least three cycles of CG. The
weights could not be adjusted between these cycles. Refinement cycles
were followed up with temperature factor refinement before the
structure was remodelled on the graphics and the whole process
repeated. Temperature factors were refined between the range 0-100 A^.
Modelling of the structure was accomplished using the program FRODO
(Jones, 1982) on an Evans and Sutherland PS300 graphics machine. The
geometry was not allowed to deteriorate too badly, however because
there were no chiral restraints in this program three residues had
adopted the wrong hand, residues Asp 66A, Glu 21B and Asp 66B. These
were subsequently corrected using FRODO before further refinement
cycles. The course of this initial stage of refinement is indicated in
figure 5.6. The initial R-factor was 30.9% and after fifty cycles of
CG refinement and four rounds of remodelling on the graphics, each
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Figure 5.6 The course of the first stage
of refinement using TNT.
Refinement Cycle
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followed by two cycles of temperature factor refinement, this had
dropped to 23.1%. The second stage involved decreasing the
crystallographic weight to restore the geometry of the model while
trying to maintain the R-factor value. A round of refinement was
started by carrying out one cycle of SD refinement followed by ten
cycles of CG refinement. The round of refinement was completed with
two cycles of temperature factor refinement, before the model was
inspected on the graphics. At this stage water molecules were added
where there was clear evidence of density both in 2F0-FC (contoured at
la) and F0-Fc (contoured at 2a) with acceptable hydrogen bonding
geometry. Water molecules with thermal factors greater than 50 A^ were
deleted. The progress of this second stage of refinement is outlined
in table 5.4.
5.3.2 Discussion
With the refinement of the structure completed, the final model
contained a total of 1936 protein atoms, and 112 water positions had
been included that made chemically reasonable contacts. The Ca^+ ions
were refined with partial occupancies in the latter stages of the
refinement. This was done because the quality of the electron density
in this region, when contoured at 2a, did not suggest a fully occupied
site. Refinement of equine phospholipase A2 structure resulted in the
reduction of the R-factor from 30.9% to 21.7% for data in the
resolution range 15-2.4 A, excluding reflections for which Ijjj < 1
a(I). The rms shift of the atomic parameters in the last cycle of
refinement was 0.008A. The observed deviations in the geometric
parameters of the final model are outlined in table 5.5. The
stereochemistry of the final model is shown in figure 5.7 a-b and 5.8
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Table 5.4 Summary of the latter stages of refinement of equine PLA-2.
Cycle R-value Comments
51-55 23.1—> 22.9 Structure after 50 cycles contained 3
residues out of hand A:66, B:21 and B:66.
These were corrected on graphics
before cycle 51.
56-65 24.1—>-22.6 Geometry weights increased (x10) for







141-168 21.2 —> 20.9
18 water positions added, 11
sidechains repositioned.
One water removed, 6 moved back
into density. 27 new water positions
added, 3 sidechains moved.
Two waters removed 11 moved back
onto density.
35 new water positions added. 3
waters moved back on to density.
40 new water positions added, 5
sidechains moved.
9 waters removed 10 new water
positions added.
7 waters moved back onto density
169-187 20.9 —> 21.4
188-201 21.4—>21.7
8 waters removed, 13 new water
positions added. Calcium ions
refined with partial occupancies.
Geometric terms upweighted.
7 waters moved back on to density.
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Table 5.5 Weighted deviations from 'ideal' geometry of the final
model in the refinement of equine PLA-2.
Parameter rms deviation sigma
Bond length (A) 0.014 0.02
Bond angle (o) 2.894 3.0




Planar groups (A) 0.014 0.02
Bad contacts (A) 0.20 0.10
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Figure 5.7 a. Ramachandran plot for A chain of final
model from TNT. The glycine conformations












































Figure 5.7 b. Ramachandran plot for B chain of final
model from TNT. The glycine conformations
are highlighted and Ser 34 Asp 66, Gin 67,
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Figure 5.8 a. Omega plot for the A chain of the final
model obtained from TNT.
-1 80 (feA
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Figure 5.8 b. Omega plot for the B chain of the final
model obtained from TNT.
residue number
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a-b. The average B-factors for the main chains of the final model are
shown in figure 5.9 and those of the sidechains in figure 5.10. The
average B-factor of the solvent molecules is 48.3 A^.
While it is clear the structure has adequate geometry as indicated in
table 5.5, figures 5.7a and 5.7b show the unusual geometry adopted by
the glycine residues required for the Ca?+ binding loops of both
molecules. Also figure 5.7b shows unfavorable conformations adopted by
the region 66-67 in molecule B. Analysis of the thermal factors of
these residues, figure 5.9 and 5.10 indicates that this region also
has high thermal factors for both the main chain atoms and the
sidechain atoms. This region of molecule B has poorly defined electron
density which can explain these high values. Other areas of the
structure where electron density is poor are also indicated by high
thermal factors. There are three regions in particular that are
obvious from figures 5.9 and 5.10. The regions, common to both
molecules are between residues 28-35, 64-68 and 118-125. These are all
loop regions in the structure. In molecule A there is an additional
area with high thermal factors between 15-16 which is also a loop
region immediately after the first helix. Both Ca^+ ions were refined
with partial occupancies with values of 0.77 for the ion associated
with molecule A and 0.92 for the ion associated with molecule B. The
partial occupancies of these ions may explain why the binding loop is
so badly defined. This flexible loop region being disordered in the
absence of the Ca^+ ions. The binding constant for Ca^+ in the bovine
enzyme is 4mM at pH 6 (Dutihl et al., 1975) and it was assumed that
the K(ya for the equine enzyme would be similar. This work would
suggest that in order to saturate all the sites in the enzyme a higher
Ca2+ concentration be used in the crystallisation trials. Despite
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Figure 5.9 average B-factor for mam chain atoms of
final model from TNT. Molecule A and
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Figure 5.10 average B-factor for sidechain atoms of
final model from TNT. Molecule A and
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these badly defined loop regions the quality of the electron density
map is good.
5.4 Refinement of putative PLA-2 - inhibitor complex
Crystals of the proposed complex were grown as outlined in Chapter 4.
The data set obtained from a crystal of the proposed enzyme inhibitor
complex from 15.25 - 2.07 A contained 18 262 reflections of which 8669
were unique. The unit cell information of the proposed PLA2-drug
complex is shown in table 5.6 together with the differences which
relate this unit cell to that of the native unit cell. Attempts were
made to scale this data with that used in the refinement of the native
structure using the CCP4 program ANISOSC. The two data sets did not
scale together well (Rscale=30% using F^) and consequently the data
used in the refinement was unsealed to the native. It is possible that
the difference in the unit cell could account for the poor scaling.
Although these two cells are similar, a difference map with
coefficients F0-Fc using the native structure in its unit cell with
the data for the proposed complex did not show any signs of continuous
density either in the active site or elsewhere in the asymmetric unit.
It was possible that this lack of success was due to the differences
in the unit cell dimensions. It was also possible that the two
molecules which formed the asymmetric unit of the native structure may
have been in different orientations relative to each other and the
cell axes in the proposed complex. It was therefore necessary to
perform a rigid-body refinement of the model within the unit cell of
the complex. This was initially attempted using TNT by treating both
molecules as separate independent rigid groups using the COMBINE
option in the control program. Positional parameters are treated as
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Table 5.6
Unit cell information for proposed PLA-2-drug complex. Also shown are the
differences between the proposed PLA-2-drug unit cell and the unit cell of
the native. Unit cell lengths are given in Angstroms, angles in degrees.
a b C a P Y
Proposed PlA2-drug complex 84.53 45.83 65.39 90.0 102.62 90.0
Native 83.20 45.44 65.13 90.0 101.98 90.0
Difference
(Complex-native)
1.33 0.39 0.26 0 0.64 0
% Difference 1.6 0.85 0.4 0 0.6 0
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though the groups are a rigid body. The control program fits an
overall rotation and translation to the individual shifts of the atoms
by a least squares fitting procedure. This was performed initially
using all the data from 15 - 8 A with fixed occupancies and
temperature factors. The model used in this refinement contained no
water molecules. Ten cycles of CG refinement were performed and the
final structure analysed. No overall improvement in the R-factor was
achieved and the rms movement after the tenth cycle was 0.001 A.
Analysis of the mean movements of the rigid group indicated that there
was no net movement, but that both the rigid groups were making very
small movements, like vibrations or oscillations, where they would be
moved in one cycle and then be moved back again the next. This was not
improved when higher resolution data from 15 - 2.4 A was used.
It was then decided to try a different approach using XPLOR. Rather
than perform a rigid body refinement using XPLOR, the native structure
was used with the new cell parameters and the data of the drug complex
in a simulated annealing refinement. An ideal weight Wa was calculated
and the complete refinement was carried out as outlined in figure 5.11
for the data between 10 - 3.0 A. Both a 2F0-FC and an F0-Fc were
calculated for this structure and inspected using FRODO. While the
density around the structure was quite good there was no continuous
density in the F0-Fc map, even when contoured at 0.5a, in the active
site of both molecules. The majority of the density was around the
outside of the molecules in the asymmetric unit, with very little
density within the molecule itself. Attempts were made to locate the
bromine atom of the inhibitor by contouring at 2 and 3a, but the
positions of these electron dense regions bore no relation to the
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The initial signs that a complex of enzyme and inhibitor had been
crystallised - a slightly different crystal morphology and a slightly
bigger unit cell, unfortunately have not stood up to further
investigation. No traces of density were observed in the active sites
of either molecule in the asymmetric unit or elsewhere in the crystal
structure. Since no density could be assigned to the inhibitor
molecule it must be assumed that there was no inhibitor bound at the
active site or at any other location in the crystal. Consequently
during the crystallisation experiments the hydrophobic inhibitor must
have precipitated. Phospholipid like inhibitors such as the one used
here are not sufficiently tight binding to be regarded as binding
irreversibly. It is probable that on release from the active site
during the crystallisation trial the inhibitor precipitated. This is
further substantiated by the inability to locate the relatively
electron dense bromine atom which forms part of the inhibitor
molecule. Thus it would appear that the crystal structure from this
data is very similar to the TNT structure refined from the so called
"native" data despite the unit cell differences. Superposition of the
Cq,'s of the TNT structure onto this structure (rms deviation for the
two molecules of 0.419 A) supports this idea.
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The purpose of this chapter is to analyse the structure of equine
phospholipase A2 (PLA-2) which has been refined from x-ray data as
outlined in Chapter 5. The structure is interpreted in relation to its
biological activity and compared and contrasted to the structure of
bovine PLA-2 (Dijkstra et al., 1981).
6.1.1 Symmetry
Equine PLA-2 crystallises in the monoclinic space group C2. The
asymmetric unit is a dimer and there are four symmetry related dimers
in the unit cell. Plate 6.1 shows a stereo view down the b-axis. The
two molecules A and B are coloured pink and white respectively, the
other molecules, related by symmetry, are coloured as yellow dimers.
Plate 6.1 Stereo picture of the unit cell of equine PLA-2.
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6.2 Folding of the polypeptide chain and secondary structure.
From the ribbon structure shown in plate 6.2 three long helices A, C
and E (using the same notation as for the bovine enzyme), and two
shorter ones B and D can be seen. Helix A runs from residue 1 to 13.
Helix C is 19 residues long and begins at residue 40. Helix E is of a
similar length (20 residues, from 89 to 108). Helix B (residues 19 to
23) and helix D (residues 59 to 64) are both short a-helices of about
one turn. There are two antiparallel B-strands, running from residues
74 to 78 and 81 to 85 respectively. The structure was analysed for the
occurrence of 6-turns using the DSSP program of Kabsch and Sander
(1983). The criteria adopted for the definition of the turn were from
Chou and Fasman (1977). Table 6.1 lists the B-turns in both molecules
of equine PLA-2.
Since the equine sequence is 78.6% identical with that of the bovine
enzyme it is not surprising that the structure of equine phospholipase
is very similar to that of the bovine enzyme. Plate 6.3 shows a stereo
picture of the backbones of the two molecules A and B, after optimal
superposition to the backbone atoms (1 to 121) of the bovine enzyme
using SYBYL. A comparison of the Ca's in molecule A with those of the
bovine enzyme gives a root mean square difference of 0.951 A,
similarly for molecule B this is 0.868 A. We have already seen that
this rms distance between A and B is 0.789 A.
There were four major areas where there appeared to be a significant
difference to the bovine structure. This was the case for both
molecule A and B. It was also noticed that these four areas coincided
with the areas of difference between molecule A and B. All of these
areas were to be found in certain loop regions and not in any of the
secondary structural elements. On analysis, it was seen that three out
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Plate 6.2 Stereo picture of the ribbon structure of equine PLA-2. The
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Table 6.1 p - turns in equine PLA-2.
Segment Residues <t>2 ^2 <j>3 ^3 Type
55A-58A Ala.Lys.Glu.Leu -51.7 -21.0 -64.2 -34.8 III
67A-70A Asn.Pro.Tyr.Thr -36.4 -27.5 -85.6 -7.7 I
78A-81A Ser.Gly.Thr.Glu 79.5 -119.5 -84.2 -17.5 II'
85A-88A Ser.Asp.Lys.Asn -49.7 -39.0 -68.2 -18.0 III
113A-116A Pro.Glu.Asn.Lys -68.5 -34.9 -78.3 -33.4 III
13B-16B Ile.Pro.Asn.Ser -63.2 -24.5 -96.8 7.2 I
58B-61B Leu.Ser.Ser.Cys -53.1 -46.1 -69.9 -22.9 III
78B-81B Ser.Gly.Thr.Glu 61.7 -129.6 -99.7 10.7 II'
85B-88B Ser.Asp.Lys.Asn -67.3 -15.7 -66.2 -18.3 III
112B-115B Asn.Pro.Glu.Asn -65.4 -17.5 -58.8 -37.9 III
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Plate 6.3 Stereo picture of the backbone fit of equine PLA-2 with
bovine PLA-2. Molecule A is shown in red, molecule B in
green. The bovine backbone is coloured by atom type. The
superposition and picture were produced from SYBYL.
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of the four could be explained by different crystal packing
interactions.
The first region of difference was between residues 15 and 22. It was
observed that in molecule A the Asn 15 sidechain formed a strong
hydrogen bond to the sidechain of Arg 122 of molecule B related to it
by the symmetry operator Vi-x,y-lh, 1-z. The sidechain of Asn 15A also
formed a second hydrogen bond to the sidechain of Asn 115A. In
molecule B there was no such hydrogen bonding of Asn 15B since there
were no packing interactions in this region. Additionally Tyr 19B OH
formed a strong hydrogen bond with Glu 114B related by the symmetry
operator l/i-x,Vi+y ,\-z.The second region of difference was between
residues 56 and 65. Here three hydrogen bonds were formed between
molecule A and molecule B of two independent symmetry related
molecules. These were between the sidechains of Arg 62A and Glu 89B,
Asn 67A and the mainchain carbonyl of Ser 59B related by the symmetry
operator 1A-x,1A +y,l Z the mainchain carbonyl of Phe 63A and the
sidechain of Lys 74B related by the symmetry operator . These
hydrogen bonds were not possible in molecule B and there were no
crystal contacts for this area. The third region of difference was
between residues 114 and 120. In molecule A it was noted that the
sidechain of Glu 114A formed a strong hydrogen bond to the sidechain
of Asn 46B related to it by the symmetry operator
Similarly the sidechain Gin 115A formed a strong hydrogen bond with
Gin 112A. However in molecule B Glu 114B formed no hydrogen bonds to
any symmetry related molecules and the sidechain of Gin 115B formed
two hydrogen bonds. The first of which is to the sidechain of Asp 39B
and the second is to the sidechain of Gin 15A related to it by the
symmetry operator Vi+x,xA+y,z.This is the same hydrogen bond as
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described for the first region. The fourth region of difference
between 30 and 35 could not be explained by different crystal
contacts. A possible explanation for the differences will be discussed
in section 6.5.
6.3 The disulphide bridges.
Plate 6.4 shows the location of the seven disulphide bridges in the
equine structure. These clearly help to stabilise the enzyme structure
and are responsible for its ability to survive the high temperatures
involved in the purification steps outlined in Chapter 3. These
disulphides are also important for the enzyme's biological activity by
providing the necessary structural stability to work at the micelle
interface. The geometry of the disulphides are shown in table 6.2. The
X3 angle is defined according to the IUPAC-IUB (1970) convention. In
agreement with the findings of Thornton (1981), the X3 angles are
distributed around X%= +90°(right handed) and ^"3=-90°(left handed).
Similarly local disulphides (half-cystine separation < 45 residues)
were right handed (6 out of 6). For non-local disulphides (half-
cystine separation > 45 residues), these were equally likely to be
left handed (4 out of 8). The geometry of the disulphide bond 27-124
is particularly variable and this is possibly due to the differences
in the main chain conformation at the C-terminal region between
molecule A and B and the mobility of this region. Analysis of the
thermal factors of both the main and sidechains of residues 120 - 124
(figure 5.9 and 5.10) and the different conformations found between A
and B would indicate that these five residues at the C-terminus are
mobile. The mobility of these residues has been noted in the 2.1 A
structure of an engineered porcine PLA-2 (Thunissen al., 1990),
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Plate 6.4 Stereo picture of the ribbon structure of equine PLA-2
showing the location of the disulphide bridges.





Hand molecule B Hand
Cys 29 - Cys 45 92 R 92 R
Cys 44 - Cys 105 -82 L -88 L
Cys 51 - Cys 98 -83 L 112 R
Cys 61 - Cys 91 100 R 98 R
Cys 77 - Cys 11 94 R 92 R
Cys 84 - Cys 96 89 R 93 R
Cys 124 - Cys 27 -77 L 110 R
*% angles are defined according to IUPAC-IUB (1970) convention.
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where the two molecules that formed the asymmetric unit also possessed
differing conformations in this region.
6.4 The dimer interface.
The interaction between the two molecules of the asymmetric unit
occurs through a number of hydrogen bonds. Two secondary structural
elements of the enzyme are involved. Plate 6.5 illustrates the nature
of the dimer interface and also how the two molecules are positioned
relative to each other in the unit cell. There is a number of
hydrogen bonding interactions which involve residues from the helix A
(Ala 1 - lie 13) of both molecules. These helices are adjacent and in
an antiparallel arrangement. As a consequence of this there are four
hydrogen bonds formed between the two chains as listed in table 6.3.
Two of these occur in the middle of the helix between Ser 7 A and B.
The third and fourth hydrogen bonds are identical with respect to the
donor and acceptor groups involved but have slightly different
geometries. At both ends of the helices the sidechain NE1 of Trp 3
hydrogen bonds to the mainchain carbonyl of Gly 79 of the other
molecule. Gly 79 is at the middle of the 6-turn of the antiparallel fi¬
shed. Thus the helix of molecule A is not only hydrogen bonded to the
helix of molecule B but also the 6-sheet structure of molecule B.
The second structural element involved in the dimer interface is the
6-sheet. The 6-sheets of both molecules are adjacent along one edge
and run in an antiparallel manner forming an extensive hydrogen
bonding network as shown in plate 6.6. The hydrogen bonds and their
geometries are listed in table 6.4. Additionally these sheet
structures have an amphipathic distribution of amino acids. The
hydrophilic residues Lys 74, Ser 76, Ser 78, Glu 81 and Thr 83 lie
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Plate 6.5 Stereo picture showing the dimer interface and location of the
two molecules in the asymmetric unit. Molecule A is shown
in blue, molecule B in red and the unit cell in purple.
Plate 6.6
The antiparallel (3-sheet/sheet interaction at the dimer interface. Both
the ribbon pattern and the atoms are shown. Molecule A is shown in
white, molecule B in blue. The hydrogen bonds are illustrated by the
broken lines. In this orientation the hydrophobic residues are behind
the plane of the sheet. The electron density map (2Fo-Fc) was
contoured at la.
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Table 6.3 Hydrogen bonding geometries of the groups involved in




Distance (A) Angle (°)
OG 7B—OC 7A 3.2 (O-O) 130
OG 7A—OG7B 2.7 (0-0) 116
NE1 3B—OC 79A 2.6 (N-0) 171
NE1 3A---OC 79B 3.4 (N-0) 107
Table 6.4 Hydrogen bonding geometries of the groups involved in the




Distance (A) Angle (°)
NH 75A—OC 77B 3.0 (N-0) 162
NH77B-OC75A 2.8 (N-0) 148
NH 77A--OC 75B 2.9 (N-0) 130
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above the sheet exposed to solvent. The hydrophobic residues Phe 75,
Cys 77, Val 82 and Cys 84 lie below the sheet structure. The
hydrophobic residues below the sheet provide additional van der Waals
contacts. The amphipathic partitioning of these residues must also
contribute further to the stability of the dimer. As a combination of
these three interactions, the dimer of the asymmetric unit is tightly
associated.
6.5 The active site.
The active site of the equine enzyme is located in a cavity at the
molecular surface with His 48 located at the bottom. The imidazole
ring of His 48 forms a hydrogen bond with the carboxyl group of Asp
99, similar to the serine protease enzymes. The wall of the active
site is covered by hydrophobic residues: Phe 5, lie 9, Phe 22, Ala 102
and 103, Phe 106 and the disulphide bond between Cys 29 and 45. Plate
6.7 shows a stereo picture of the position of the active site,
including the calcium ion, the liganding oxygens, and the His 48 - Asp
99 couple. The refinement of equine PLA-2, as described in Chapter 5,
was completed with only partial occupancies for both calcium ions. As
already mentioned the quality of the electron density of both the loop
itself and that of the calcium ion merited this. In particular the
electron density of residues 30 and 31 was poor and did not improve
when the calcium ions were given partial occupancies. It has been
noted that Leu 31, can adopt different conformations (Dijkstra
1983, Thunissen et al.,1990)which has been attributed to
conformational freedom in this region. The geometry of the oxygen
ligands to the active site calcium ion are shown in table 6.5 a-b. The
different geometries could not be attributed to sequence variations
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Plate 6.7 Stereo picture of the Ca trace of equine PLA-2 showing the
location of the calcium ion of the active site. Also shown
are the mainchain atoms from 28-32 which form the
calcium binding loop.The His 48 - Asp 99 couple of the
active site is also shown. The two main helices C and E are
running vertically
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Table 6.5a Ligand to calcium distances in the active site of equine




Molecule A Molecule B Bovine *
OD1 49 1.90 2.40 2.48
OD2 49 2.39 2.88 2.69
032 2.55 2.28 2.30
030 5.46 3.08 2.47
028 3.23 3.09 2.29
*from Dijkstra et al., (1981).
Table 6.5b Ligand to calcium angles in the active site of equine PLA-2
and a comparison to bovine PLA-2.
Description Angle (°)
Molecule A Molecule B Bovine *
OD1 49 - Ca++ - OC 32 111 92 88
OD1 49 - Ca++ - OC 30 147 148 164
OD1 49 - Ca++ - OC 28 134 116 97
OD2 49 - Ca++ - OC 32 158 134 135
OD2 49 - Ca++ - OC 30 92 100 141
OD2 49 - Ca++ - OC 28 96 98 109
* from Dijkstra et al., (1981).
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between the enzymes, since the active site residues are highly
conserved. While it is clear that the geometry is similar there is a
significant discrepancy in some of the liganding distances. This is
possibly as a consequence of disorder caused by the partial occupancy
of the calcium ion. Disordered atoms (or atoms with partially occupied
sites) may be separated by distances less than the minimum hydrogen
bond length (Karle & Duesler, 1977). The same phenomenon has been
observed for the ligand to calcium distances in trypsinogen, where the
calcium site was only half occupied and the average calcium to ligand
distance was 2.1 A instead of the expected 2.4 A (Fehlhammer
1977). Thus the rather short liganding distances of the Asp 49
carboxylate group can be explained by the partial occupancies of the
calcium ion. The geometry of the carbonyl of Gly 30 is considerably
different from that of the bovine enzyme. No water ligands for the
calcium ions were found around the calcium of either molecule although
a water molecule was located in the active site of each molecule. Each
formed a single hydrogen bond to an active site sidechain as indicated
in table 6.6. It is clear these are not similar to those identified in
the bovine structure and are not in the correct geometry for the
catalytic mechanism.
The other residues of the calcium binding loop were well defined and
the loop was seen to be stabilised by a number of interactions with
other residues or mainchain atoms as listed in table 6.7. It is
noticeable that residues Tyr 25, Tyr 28, Asp39 and Asp42 which are
involved in stabilizing the calcium binding loop are invariant in all
the known pancreatic and snake venom phospholipases (Heinrikson
al., 1977). The loop is further stabilised by the disulphide linking
Cys 27 to Cys 124 and the disulphide bond between Cys 29 and Cys 45.
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Table 6.6 Geometry and hydrogen bonds of active site waters in equine
PLA-2 and their comparison to bovine PLA-2 (Dijkstra et al.,
1981).
0
Hydrogen bond distance (A) Angle measured Angle (°)
48A ND1--OH2 4D 2.2
49B OD2--OH2 5D 2.8
032A, Ca++, OH2 4D
OD1 49A, Ca++, OH2 4D
OD1 49B, Ca++, OH2 5D










Molecule A Molecule B
NH 28 - OD1 42 2.8 2.9
NH 24 - OC 29 2.7 3.2
NH 29 -- OC 25 3.4 2.9
OH 28 - OC 35 2.3 2.3
NH 27 — OD142 2.6 2.8
NH 38 -- OD 42 3.4 3.0
SG 27 -- SG 124 2.0 2.1
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It can be concluded that these invariant residues have the important
function of stabilising the calcium binding loop and, together with
Asp 49, they guarantee a precise three dimensional geometry of the
calcium ion with respect to the active site residues. Thus the
majority of the loop, in the absence of the calcium ion, does not have
the ability to adopt multiple or different conformations. However,
analysis of the thermal factors of the residues in the active site
(figure 5.9 and 5.10) would also indicate that there was mobility in
the part of the calcium loop and that this mobility was due to the
partial occupancy of the calcium ion. The porcine active site
(Dijkstra et al.,1983) was found to be almost identical to that of
the bovine enzyme. Additionally the active site residues possessed
thermal factors that were 60% lower than the average temperature
factor for all the protein atoms which would indicate that the bound
ion heavily reduces the mobility of the active site residues.
6.6 The amino terminus.
The N-terminal region and, in particular, the a-NH3+ group of Ala 1
play an important role in the activity of the enzyme on aggregated
substrates (Pieterson et al.,1974a; van Dam-Mieras et al., 1975). Ala
1 has its amino group buried in the interior of the enzyme, and this
amino group has various hydrogen bonding interactions. In the bovine
and porcine enzymes, a similar hydrogen bonding network is present
around an internal water, but they differ in their finer details as
shown in figure 6.1. In the porcine enzyme, the N-terminus is somewhat
more open to the solvent than the bovine enzyme (Dijkstra et al.,
1983). The N-terminal region of equine phospholipase is depicted in
plate 6.8. Plate 6.9 shows the quality of the electron density around
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Figure 6.1 Hydrogen bonding network around the amino terminus of
bovine (upper) and porcine (lower) phospholipase A2. Adapted
from Dijkstra et al., (1983).
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Plate 6.8 Stereo picture of the amino-terminal region of equine PLA-2.
The hydrogen bonding network in the amino terminal region
of molecule B is illustrated by the broken lines.
Plate 6.9 Stereo picture showing the integrity of the electron
density around the water at the amino terminus in
equine PLA-2. This is shown for molecule A and the
electron density map (2Fo-Fc) has been contoured at
l.Oo.
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Molecule A Molecule B
Alal N 4 OE1 - 2.8
Alal N 71 0 2.7 2.9
Alal N Water 2.3 3.1
Water 52 OH 2.6 3.1
Water 68 0 3.1 3.2
Tyr52 OH 99 0D2 2.8 3.0
His48 NE2 99 0D2 3.1 2.6
Tyr 73 OH 99 0D1 2.6 3.1
- no hydrogen bond was found.
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the water molecule which is bound in this region. In table 6.8 the
hydrogen bonds in the N-terminal region are listed. The hydrogen
bonding network is very similar to that of the bovine enzyme as
illustrated in figure 6.1. However there is a slight difference
between both molecules of the asymmetric unit cell. In molecule A the
sidechain of Gin 4 is not involved in hydrogen bonding to the NH3 +
group, rather it is involved in hydrogen bonding to two mainchain
atoms. This is not the case for molecule B, here the sidechain
hydrogen bonds in the same manner as the bovine structure depicted in
figure 6.1.
6.7 The '65' loop.
This is the name given to the loop region between Ser 60 and Thr 70.
It has been suggested (Drenth et al., 1987) that this region might be
involved in the interaction of the enzyme with micelles. This loop
region forms part of what has been called the interface recognition
site (IRS). The IRS was initially described as a result of kinetic and
amino acid modification experiments (Volwerk & de Haas, 1982) and this
was subsequently completed when the X-ray structure became available.
Plate 6.10 shows a stereo picture of the backbone atoms of A and B
after optimal superposition of the bovine and equine structures. It is
clear that while the conformation of the equine enzyme is slightly
different, the loop has a similar overall fold to the bovine. Also
this loop is slightly different between molecule A and B. The presence
of different crystal contacts has been already given as a possible
reason for this (Chapter 6.2). Further evidence that this loop is more
like that of the bovine enzyme was seen in chapter 6.6 where the
mainchain carbonyl of Pro 68 is involved in the hydrogen bonding
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Plate 6.10 Stereo picture of the '65' loop backbone of equine
PLA-2 after optimal superpositon with the bovine
PLA-2. The region between 60-70 is shown for
molecule A in green and molecule B in red, the bovine
loop is coloured by atom type.
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network at the amino terminus. As seen in figure 6.1 Pro 68 is not
involved in hydrogen bonding at the amino terminus in the porcine
enzyme. The fact that equine PLA-2 adopts the bovine conformation
calls into question the explanation given as to why the porcine is
different to the bovine (Dijkstra 1983). Here a single
substitution in this loop region (bovine Val 63 - > porcine Phe 63) was
suggested to be responsible for the differences in the conformation of
the bovine and porcine structures. This was suggested to explain the
different affinities of bovine and porcine PLA-2's for micelles
(Dijkstra et al.,1983). In the equine enzyme there is this similar
single substitution but no dramatic conformational change is observed.
However it is possible that crystal contacts are responsible for
preventing the equine structure adopting the porcine conformation. It
is more likely, however, that crystal packing interactions are
responsible for producing the slight differences between the two
molecules in the asymmetric unit and also to the bovine conformation.
6.8 The second calcium binding site.
In addition to the catalytically essential calcium ion, it has been
demonstrated that porcine and equine PLA-2's contain a second calcium
binding site. Compared with the calcium ion at the active site, the
second ion binds with almost tenfold lower affinity. The importance of
this site became clear from the observation that binding of a second
ion is essential for effective interaction of PLA-2 with organised
lipid/water interfaces, at alkaline pH (van Dam-Mieras et al., 1975,
Slotbloom et al., 1978). Site directed mutagenesis experiments with
porcine PLA-2 (van den Bergh et al., 1989) have shown that two
carboxylates, Glu 71 and, to a lesser extent, Asp 66, were both
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directly involved in the low affinity calcium binding. However the
crystal structure of porcine (Dijkstra 1983) has Asp 66 and
Glu 71 too far apart to be both involved in ion binding. Athough in
the bovine sequence residue 71 is Asn (which is presumably the reason
it does not bind a second calcium), it is close to Asp 66 in the '65'
loop of the bovine structure. Plate 6.11 shows this area for molecule
A. It is clear that in the equine enzyme there are three carboxylates
in close proximity, these are Asp 66, Glu 71 and Glu 92. Additionally
there are a number of water residues around this site in both molecule
A and B but no calcium could be identified at these sites. It is not
surprising that calcium ions were not identified at these sites since
the affinity of this second site is tenfold lower than that of the
active site. Since the active site was only partially occupied the
second site could not be expected to be filled, even partially.
6.9 Description of hydrogen bonding.
The hydrogen bond is an electrostatic interaction between a proton,
carrying a partial positive charge, on a donor group, with the
electron density of an acceptor atom. In proteins these normally
involve amide groups, carbonyl oxygens, and water molecules. The
limits used for the geometry of hydrogen bonds are those of Baker
al., (1984). For example, the commonest hydrogen bond NH--0:
1.3A < O-H < 2.5A
90° < 0--H--N < 180°
90° < C= =0—H < 180°
However it must be noted that the relative strength of a particular
hydrogen bond is highly dependent on it's precise geometry.
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Plate 6.11 Stereo picture showing the proposed second calcium binding
site of equine PLA-2. The enzyme is represented by the
ribbon structure. Some potential liganding sidechains are
shown along with their van der Waals surfaces. The picture
also shows the location of two crystallographically
determined waters around this site in molecule A.
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6.9.1 Main chain interactions.
The 2.4A structure has revealed the high content of secondary
structure in the phospholipase A2 molecule. A great number of hydrogen
bonds occur between mainchain and sidechain atoms and between
sidechains. In this case, a hydrogen bond is assigned if the donor to
acceptor distance is between 2.2 and 3.4A. Table 6.9 lists hydrogen
bonds between peptide nitrogens and sidechains. Table 6.10 lists
hydrogen bonds between peptide oxygens and sidechains. Table 6.11
lists hydrogen bonds between sidechains.
6.9.2 Helix geometry.
In the alpha helix, the polypeptide chain is normally coiled into a
helix with 3.6 residues per turn, and hydrogen bonds between the C=0
of residue n and the N-H group of residue n+4. This is the most common
type of a-helix in globular proteins with l->5 hydrogen bonds along
the helix. Other types of helix are possible, notably the 3io-helix,
with 3 residues per turn, and l->4 hydrogen bonds, and the 7r-helix,
with 4.4 residues per turn, and 1- > 6 hydrogen bonds.
Essentially the helical geometry of both equine PLA-2 and bovine PLA-
2 is identical. Helix A is a regular a-helix with l-> 5 contacts
ending at residue 13. Helix B is rather irregular, with a mix of l->5
and l->4 contacts. Helix C is one of the longest helices in the
structure and again is mainly a regular a-helix with l->5 contacts,
but at residue 52 there is a smooth transition to the 3 jo-helix (from
residue 52-58). This is identical to the situation found in the bovine
enzyme (Dijkstra et al., 1981). Helix D is also an a-helix, although
at the beginning of the helix there is a l->4 contact. Helix E is
approximately the same length as helix C but runs in an anti-parallel
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Molecule A Molecule B
27 NH--OD2 42 2.6 2.8
28 NH--OD1 42 2.8 2.9
73 NH--OE1 4 3.0 2.3
74 NH--OD1 88 2.8 2.9
89 NH--OE2 92 3.0 3.2
92 NH--OD1 89 2.8 2.7
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Table 6.10 Hydrogen bonds between peptide carbonyls and





6 CO--NE2 10 3.1
9 CO--OG 12 2.8
21 CO—OH 111 2.9
35 CO-OH 28 2.3
48 CO-ND1 48 2.8
112 CO-OH 25 2.7
124 CO-NZ 123 3.0
B
13 CO-OG 16 2.7
35 CO-OH 28 2.3
67 CO-ND2 67 2.4
85 CO—ND2 88 3.2
112 CO-OH 25 3.4
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39 OD1--ND2 112 3.1
48 NE2--OD2 99 3.1
73 OH--OD1 99 2.6
52 OH--OD2 99 2.8
89 ND2--OE2 92 3.1
112 ND2--OD1 115 2.9
B
21 OE1--NZ 116 3.2
39 OD1--ND2 112 2.4
48 NE2--OD2 99 2.6
52 OH—OD2 99 3.0
73 OH--OD1 99 3.1
115 ND2--OD1 39 2.3
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direction. It also has similar geometry to helix C, it being mainly a-
helix, but towards the end (from residue 103) the a-helix is distorted
and the last residues (104 to 108) form a 3 io-helix. This is indicated
in plate 6.12 for the Helix E of molecule B.
6.9.3 Protein-solvent contacts.
Hydrogen bonding between the protein and the water molecules is
summarised in table 6.12 and 6.13. Hydrogen bonds between solvent
molecules are shown in table 6.14. It is clear that most of the water
molecules make contacts < 3.5 A with the protein. The waters at the
amino terminus which have more than one hydrogen bond have a
distinctly reduced freedom of mobility, as measured by their B values.
However, most of the solvent forms only single hydrogen bonds to the
protein. The majority of these are to the main chain carbonyls with
very few being identified for sidechains.
6.10 Conclusions
It would appear that the three-dimensional structure of equine
phospholipase is very similar to the high resolution structure of the
bovine enzyme (Dijkstra et al., 1981). Due to differences in crystal
contacts the conformations around three areas in the two monomers are
slightly different. It is proposed that the differences in the calcium
binding loop between the two monomers are due to the partial occupancy
of the calcium ion in the active site. The majority of the calcium
loop is similar to the bovine enzyme and this has been attributed to a
number of interactions of the loop with other parts of the structure.
Waters have been located in the active site, but they are in a
different arrangement to those in the bovine structure and have not
241
Plate 6.12 Stereo picture of the mainchain structure of helix E of
equine PLA-2, showing the hydrogen bonding pattern. This
picture shows the a-helix becoming a 3io-helix at residue
103. Hydrogen bonds are illustrated by the broken lines.
242
Table 6.12 Hydrogen bonds between protein and solvent.
Description
O
Distance (A) Angle (°)
A 1 NH3+--OH2 ID 2.3 144
68 CO--OH2 ID 3.1 156
20 CO--OH2 17D 2.6 157
44 CO--OH2 11D 2.8 117
66 NH--OH2 52 D 3.0 133
72 NH--OH2 20 D 3.2 160
76 CO--OH2 78 D 3.0 110
78 NH--OH2 78D 2.9 120
78 CO--OH2 55D 2.8 141
82 CO--OH2 70D 3.2 120
88 CO--OH2 56 D 3.0 123
107 CO--OH2 26 D 2.4 110
111 NH--OH2 27D 2.6 167
113 CO--OH2 58D 3.2 123
120 NH--OH2 8ID 3.2 147
B
1 NH3+-OH2 2D 3.1 124
68 CO--OH2 2D 3.2 129
31 CO--OH2 6D 2.6 120
35 CO--OH2 91D 2.5 146
37 CO--OH2 96D 3.2 105
39 CO--OH2 96D 3.3 114
40 CO--OH2 32D 2.5 118
84 NH--OH2 16D 2.3 151
84 CO--OH2 99D 2.7 161
84 CO--OH2 98 D 3.3 109
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Table 6.13 Hydrogen bonds between protein sidechains and solvent.
Description
0
Distance (A) Angle (°)
A
34 OG--OH2 5ID 2.9 123
48 ND1--OH2 4D 2.3 99
50 ND2--OH2 46D 3.0 137
53 OG1-OH2 51D 2.6 124
56 NZ--OH2 75D 2.7 158
71 OE1--OH2 8D 3.1 137
71 OE2--OH2 80D 2.6 128
83 OG1--OH2 70D 2.9 167
87 NZ--OH2 44D 3.0 112
88 OD1--OH2 54D 2.8 153
B
40 OE1--OH2 70D 2.3 144
49 OD1--OH2 5D 2.8 134
108 NZ--OH2 73D 2.9 118
120 OG1--OH2 105D 2.4 107
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21D OH2--OH2 70D 2.9
10D OH2-OH2 38D 3.3
52D OH2--OH2 76D 3.1
87D OH2-OH2 88D 2.9
61D OH2--OH2 86D 2.9
30D OH2-OH2 104D 3.3
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been assigned as the waters which take part in the catalytic
mechanism. The hydrogen bonding network which involves another water
molecule is identical to that found in the bovine enzyme. This network
is slightly different to that found in the porcine enzyme (Dijkstra et
al., 1983). In the equine and bovine structures Pro 68 is involved in
the hydrogen bonding of the water at the amino terminus. This may be
responsible for the so called '65' loop of the equine enzyme adopting
the bovine structure. It was expected that this loop, which has a
phenylalanine at position 63 similar to the porcine sequence, would
adopt the porcine conformation. In the present structure Asp 66 is now
in the correct geometry to be involved in the proposed second calcium
binding site along with other sidechains. No calcium ion was found at






During the work of this thesis the crystal structures of two molecules
have been determined. The first of these is a small molecule which is
an adrenoreceptor antagonist. Certain structural features of this
molecule have been proposed as being important in the interaction of
this compound with its receptor. This has been proposed on the basis
of a number of other molecules with similar biological activity
sharing these structural features. Unfortunately these features refer
more to the shape of the molecule than to it's specific interaction
with the adrenoreceptor. Nonetheless, simple features such as shape
are of particular importance in biological interactions. The
structural studies on the these small molecules on their own do not
provide very much new information to the understanding of their
binding to the receptors. It is the hydrogen bonding interactions
which are responsible for the specific and tight binding of this
molecule to the adrenoreceptor. It is not particularly sensible with
so few structures at hand, to attempt to suggest the disposition of
donors and acceptors in the binding site of the receptor. However, if
there had been some quantitative information available concerning the
binding affinities of these related molecules then the study of this
structure and the related molecules could have provided better
information on the binding. This information is used to produce what
is called a quantitative structure-activity relationship (QSAR).
Unfortunately this was not available and the only likely solution to
the understanding of the interaction of these molecules with their
receptor awaits the solution of the receptor structure itself.
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It is often not appreciated what a wide range of techniques are
required in the production of a crystal structure. These techniques
are often nothing in comparison to the beauty of the structure itself
and are consequently not given much comment. This is unfortunate but
does not mean they were unimportant. Two particular aspects of the
work involved in this thesis deserve further mention. The first of
which was the purification of the protein in large quantities.
Crystallographic investigations require large quantities of absolutely
pure protein. This very fact makes the crystallographic investigation
of the less abundant proteins either more complicated or unlikely.
Chapter 3 described the bulk purification of ovine prophospholipase A2
from pancreas, an abundant source of the enzyme. The purification was
made simpler by the protein's ability to survive high temperatures in
acidic conditions. It is hoped that the pro-PLA-2 and the activated
PLA-2 will be crystallised and the structure of the both forms of the
ovine enzyme obtained in the future.
The second technique which lies closer to the solution of the crystal
structure itself, is protein crystallisation. This is one of the major
stumbling blocks in the process of protein crystallography. So it was
with salmon calcitonin (sCT) and its two derivatives, which, despite
much effort failed to crystallise. A possible explanation as to the
lack of success has been obtained with the discovery that sCT can form
amyloid fibres. These fibres are of clinical relevance in that a
number of amyloid forming proteins are involved in a whole manner of
clinical situations such as Alzheimers' disease. It is highly likely
in light of these results, that the gene-related peptide CGRP, also
has the ability to form these amyloid fibrils. As mentioned in Chapter
1 CGRP has a high sequence identity with amylin a polypeptide hormone
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which has been shown to form amyloid deposits in vivo. CGRP as the
name suggests has sequence similarities to calcitonin which has been
shown in this thesis to also have the potential to form amyloid
deposits. Although it could be expected that CGRP could form these
fibrous aggregates there has been no clinical evidence to suggest they
occur in vivo. It is now clear a wide variety of quite diverse
proteins have been linked with amyloidosis. Since amyloid forming
protein sequences are so diverse, it could not be imagined that one
single model of the fibril could be applied to all of them. Thus it
has been proposed (Lansbury, 1992) that the defining properties of
amyloid characterise a class of related structures, of which the
cross-B fibril (Marsh et al., 1955) is one member rather than the
definitive structure. It is possible that the B-sheet structure
identified by NMR in DMSO-water mixtures (Motta et al., 1989) could
resemble the conformation in the fibre.
The existing understanding of the action of calcitonin at its
receptor is that the active conformation is an a-helix. Thus the
formation of these fibres, while explaining the failure of sCT to
crystallise, can shed no light on the interaction of sCT with it's
receptor. It is evident though, both in light of these results and
from various NMR studies, that sCT can adopt a number of quite
different conformations depending on the nature of it's environment.
Thus the active conformation of sCT can only be determined within some
complex. This complex would preferably be with the receptor itself or
some soluble extracellular fragment of this receptor. Alternatively
the complex could be with a monoclonal antibody which blocks sCT
activity - ie. is a mimic of the receptor binding site. Not only would
this be easier to crystallise but it would also provide the most
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valuable information for the rational design of more active
calcitonins.
Even when crystals have been obtained there is the whole process of
data collection and processing. This has only been discussed for the
crystal structure of the small molecule in Chapter 2. In the crystal
structure of equine PLA-2 this work was carried by Dr M. Walkinshaw in
Basle. Similarly the process of producing an initial model for a
crystal structure, which involves overcoming the phase problem was
only mentioned in chapter 2 in relation to small molecules. For
protein structures this is much more complicated and has not been
discussed in this thesis. Once again this work was carried out for the
equine PLA-2 by Dr. M. Walkinshaw. The final stage of the process is
the refinement of the initial model. In chapter 5 the procedure of
crystallographic refinement was applied in the production of the
crystal structure of equine PLA-2. Two methods were successfully
applied and the final model possessed a crystallographic residual of
21.7% with data used between 15 and 2.4A. The refinement of the data
obtained from the putative inhibitor-PLA-2 complex failed to indicate
the presence of the inhibitor at the active site. This highlights two
of the existing problems with inhibitors of PLA-2 which are mimics of
the natural substrate. Firstly these types of molecule are very
hydrophobic and cannot exist at high concentrations in aqueous
environments. Secondly they do not possess sufficient binding affinity
to inhibit the enzyme in the presence of the natural substrate which
in vivo is in vast excess. Both of these problems must be overcome if
an effective clinically useful inhibitor of PLA-2 is to be found. The
structure of equine PLA-2 has been shown to be very similar to the
bovine structure of Dijkstra et al., (1981). A number of slight
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differences in the structure were observed, some of which have been
explained by the packing interactions in the crystal. However one of
the differences has been attributed to the partial occupancy of the
active site calcium ion. Since the crystal structure of the equine
enzyme has indicated only partial occupancy of the calcium ion in the
active site it is not of much use in the drug design process, but it
is hoped that further work with this enzyme will lead to novel
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